Regulation of Membrane Traffic at the Golgi Apparatus by Rab GTPases and their GAPs by Fuchs, Evelyn
  
 
 
 
 
 
 
 
Regulation of Membrane Traffic 
at the Golgi Apparatus by 
Rab GTPases and their GAPs 
 
 
 
Dissertation 
zur Erlangung des 
Doktorgrades der Naturwissenschaften 
(Dr. rer. nat.) 
der Fakultät für Biologie der 
Ludwigs-Maximilians-Universität München 
 
 
 
vorgelegt von 
 
Evelyn Fuchs 
 
München 2007 
 
 
 
 Dissertation eingereicht am: 30. August 2007 
Tag der mündlichen Prüfung: 22. Februar 2008 
 
Erstgutachter:  Prof. Dr. Erich Nigg 
Zweitgutachterin: PD Dr. Angelika Böttger 
 Ehrenwörtliche Versicherung und Erklärung über frühere 
Promotionsversuche 
 
 
Hiermit versichere ich, Evelyn Fuchs, ehrenwörtlich, dass die vorgelegte 
Dissertation von mir selbständig und ohne unerlaubte Hilfe angefertigt ist. 
Desweiteren erkläre ich, dass die vorgelegte Dissertation weder ganz noch in 
wesentlichen Teilen einer anderen Prüfungskomission vorgelegt wurde. Ich habe 
mich anderweitig keiner Doktorprüfung unterzogen. 
 
 
 
München, 19. August 2007 
 
 
 
Evelyn Fuchs 
 
Table of contents 
 
I 
Table of contents 
Summary ..................................................................................5 
1 Introduction ........................................................................6 
1.1 The Golgi apparatus: Processing and sorting station along 
intracellular transport routes.................................................................6 
1.1.1 The Golgi apparatus in a cell biological view....................................... 6 
1.1.2 Structure and function of the Golgi apparatus ..................................... 6 
1.1.3 Molecular mechanisms of intracellular transport ................................. 8 
1.1.4 Anterograde transport and Exocytosis .............................................. 10 
1.2 Endocytosis and retrograde transport .....................................11 
1.2.1 Endocytic vesicle formation at the plasma membrane....................... 11 
1.2.2 Endocytic sorting pathways............................................................... 13 
1.2.3 Retrograde transport of Shiga toxin .................................................. 15 
1.3 Rab GTPases: Molecular switches regulating membrane 
traffic.......................................................................................................18 
1.3.1 The Rab family of small GTPases..................................................... 18 
1.3.2 The Rab GTPase cycle ..................................................................... 20 
1.3.3 Catalytic mechanism and members of the human Rab GAP family... 22 
1.4 Rab6: Role of a Golgi localised Rab..........................................25 
1.4.1 Isoforms and features of Rab6.......................................................... 25 
1.4.2 Rab6 function in membrane transport ............................................... 26 
1.4.3 Rab6 effector proteins....................................................................... 27 
2 Identification and Characterisation of PIST as a novel 
Rab6 effector protein ............................................................29 
2.1 Aim of the work ............................................................................29 
2.2 Results ..........................................................................................29 
2.2.1 Identification of PIST as a putative Rab6 effector.............................. 29 
2.2.2 Generation and validation of a PIST specific antibody ...................... 31 
2.2.3 PIST binds Rab6 in a GTP-dependent fashion.................................. 32 
2.2.4 PIST is a specific binding partner of Rab6 and not of TC10 .............. 33 
2.2.5 PIST is a Golgi localised protein ....................................................... 36 
Table of contents 
 
II 
2.2.6 Domain specific Rab6 binding and Golgi localisation of PIST ........... 37 
2.2.7 Interfering with Rab6 levels does not affect PIST at the Golgi........... 41 
2.2.8 Golgin160 is a binding partner of PIST.............................................. 45 
2.2.9 PIST is unaltered in Golgin160 depleted cells ................................... 47 
2.2.10 Depletion of PIST does not have an effect on Golgi structure ........... 49 
2.3 Conclusions .................................................................................51 
3 Rab GTPase-activating proteins defining Shiga toxin 
and epidermal growth factor uptake pathways..................52 
3.1 Aim of the work ............................................................................52 
3.2 Results ..........................................................................................52 
3.2.1 Establishment of the Shiga toxin and EGF retrograde transport assay .
 ......................................................................................................... 52 
3.2.2 Shiga toxin transport but not EGF uptake is Rab6 dependent........... 56 
3.2.3 TBC1D11/GAPCenA acts on Rab4 and does not block Shiga toxin 
transport ......................................................................................................... 59 
3.2.4 A subset of human RabGAPs influences Shiga toxin transport ......... 62 
3.2.5 Only RabGAP-5 is able to block EGF uptake .................................... 69 
3.2.6 Different RabGAPs define Shiga toxin and EGF uptake pathways.... 71 
3.2.7 Biochemical identification of target Rabs........................................... 74 
3.2.8 Functional verification of target Rabs for RN-tre and RabGAP-5....... 76 
3.3 Conclusion....................................................................................78 
4 Discussion ........................................................................80 
4.1 The novel Rab6 binding protein PIST .......................................80 
4.1.1 PIST binds Rab6 with high affinity and specificity ............................. 80 
4.1.2 PIST does not bind the Rho GTPase TC10 ...................................... 81 
4.1.3 How is PIST localised to Golgi membranes?..................................... 82 
4.1.4 What is the function of PIST in complex with Rab6? ......................... 84 
4.2 Rab GTPase activating proteins defining Shiga toxin and 
epidermal growth factor uptake ..........................................................86 
4.2.1 A subset of human Rab GAPs influences Shiga toxin transport ........ 86 
4.2.2 The role of Rab6 in the Shiga toxin trafficking pathway..................... 89 
4.2.3 Only RabGAP5 is able to block EGF uptake ..................................... 90 
4.2.4 What are the target Rabs for the GAPs blocking Shiga toxin transport 
or EGF endocytosis?....................................................................................... 91 
Table of contents 
 
III 
5 Material and Methods ......................................................93 
5.1 Material..........................................................................................93 
5.1.1 Reagents .......................................................................................... 93 
5.1.2 Equipment ........................................................................................ 93 
5.1.3 Solutions........................................................................................... 94 
5.1.4 Plasmids ........................................................................................... 95 
5.1.5 siRNA oligonucleotides ................................................................... 101 
5.1.6 Antibodies ....................................................................................... 102 
5.2 Bacterial Methods......................................................................103 
5.2.1 Growth and maintenance of E. coli ................................................. 103 
5.2.2 Bacterial strains .............................................................................. 103 
5.2.3 Preparation and transformation of chemically competent bacteria .. 104 
5.2.4 Preparation and transformation of electrocompetent bacteria ......... 105 
5.2.5 Plasmid DNA preparation from bacteria .......................................... 105 
5.2.6 Purification of 6xHis- and 6xHisGST-tagged proteins from bacteria 105 
5.2.7 Purification of MBP-tagged proteins from bacteria .......................... 106 
5.3 DNA methods .............................................................................107 
5.3.1 "Shortway" cloning strategy ............................................................ 107 
5.3.2 Restriction digests and agarose gel electrophoresis of DNA........... 107 
5.3.3 Cloning digested DNA fragments .................................................... 108 
5.3.4 mRNA isolation and cDNA synthesis .............................................. 108 
5.3.5 PCR and cloning of PCR products .................................................. 108 
5.3.6 Site-directed mutagenesis............................................................... 109 
5.3.7 DNA sequencing............................................................................. 109 
5.4 Protein methods.........................................................................109 
5.4.1 SDS-PAGE and Coomassie staining .............................................. 109 
5.4.2 Tryptic digest for mass-spectrometry .............................................. 110 
5.4.3 Western blotting.............................................................................. 110 
5.4.4 Determination of protein concentration............................................ 111 
5.4.5 Protein precipitation with TCA......................................................... 111 
5.4.6 GST-Rab binding and pulldown assays .......................................... 111 
5.4.7 Antibody generation and purification ............................................... 112 
5.5 Yeast methods ...........................................................................112 
5.5.1 Strains, media and growth .............................................................. 112 
5.5.2 Yeast transformation (frozen cell method)....................................... 113 
5.5.3 Plasmid DNA minipreps from yeast cells......................................... 113 
Table of contents 
 
IV 
5.6 Mammalian cell methods ..........................................................114 
5.6.1 Cell culture...................................................................................... 114 
5.6.2 Immunofluorescence....................................................................... 114 
5.6.3 Cell extracts and immunoprecipitation ............................................ 115 
5.6.4 Transient transfection of mammalian cells ...................................... 115 
5.6.5 RNA interference ............................................................................ 116 
5.7 Functional assays......................................................................116 
5.7.1 STxB purification and endocytosis .................................................. 116 
5.7.2 Shiga-like toxin 1 cytotoxicity assay ................................................ 117 
5.7.3 EGF uptake assay .......................................................................... 118 
5.7.4 GTP-hydrolysis assay ..................................................................... 118 
Abbreviations.......................................................................120 
References ...........................................................................121 
Publications .........................................................................132 
Acknowledgements.............................................................133 
Curriculum Vitae..................................................................135 
 
 
Summary 
 
5 
Summary 
Rab family GTPases together with their regulators define specific pathways of 
membrane traffic within eukaryotic cells. Dependent on the bound nucleotide, they 
exist in an inactive (GDP) and active (GTP) state. In their active state, Rab 
GTPases are able to recruit specific effector proteins required for vesicle motility 
and membrane fusion. Guanine nucleotide exchange factors (GEFs) and GTPase-
activating proteins (GAPs) control the activation state of the Rab GTPase and 
therefore the functional relationship with effector proteins.  
The first part of this work focuses on the Golgi localised GTPase Rab6. Rab6 
interacts with the dynein-dynactin microtubule motor complex, through the p150glued 
subunit and the coiled-coil proteins Bic-D1 and Bic-D2 (Matanis et al., 2002; Short et 
al., 2002). In this way, Rab6 facilitates the minus-end-directed transport of vesicles 
along microtubules. However, many details of this Rab6 pathway remain unclear. 
Therefore, a screen for novel Rab6 effector proteins was carried out. This led to the 
identification of PIST as a Rab6 binding protein. Biochemical and cell biological 
analysis showed that PIST is a strong and specific binding partner of Rab6 in vitro 
and in vivo. However, PIST localised to Golgi membranes independently of Rab6 
and was not affected in cells with altered Rab6 protein levels. Thus, the function of 
PIST as a Rab6 binding protein remains unclear. 
In the second part of this work the family of Rab GTPase-activating proteins 
(GAPs) was investigated. The 39 predicted human GAPs were tested for their ability 
to interfere with the trafficking of Shiga toxin from the cell surface to the Golgi 
apparatus, and with the transport of the epidermal growth factor (EGF) from the cell 
surface to endosomes. The screen identified 6 GAPs (EVI5, RN-tre, TBC1D10A-C, 
and TBC1D17) as specific regulators of Shiga toxin, but not EGF uptake. 
Biochemical assays showed that Rab43 is the target of RN-tre, and is required for 
Shiga toxin uptake. In contrast, RabGAP-5, a Rab5 GAP, was unique amongst the 
GAPs tested and reduced uptake of EGF but not Shiga toxin. These results suggest 
that Shiga toxin trafficking to the Golgi is a multi-step process controlled by a 
number of Rab GAPs and their target Rabs, and that this process is discrete from 
ligand-induced EGF-receptor trafficking. 
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1 Introduction 
1.1 The Golgi apparatus: Processing and sorting station along 
intracellular transport routes 
1.1.1 The Golgi apparatus in a cell biological view 
A defining characteristic of eukaryotic cells is their compartmentalisation into 
physically separated and functionally distinct organelles. This is reflected in the 
specific subset of proteins and lipids present in the lumen or in the enclosing lipid 
bilayer of each organelle. Therefore, the maintenance of the structural and 
functional organisation of a eukaryotic cell requires an efficient transport system for 
newly synthesised proteins and lipids from their site of production to their final 
destination within or outside the cell. 
At the centre of this intracellular transport system is the Golgi apparatus, 
linking the endoplasmic reticulum (ER) with endosomes and the plasma membrane. 
First described by Camillo Golgi in the year 1898 as an “internal reticular apparatus” 
in neurons (Bentivoglio and Mazzarello, 1998; Golgi, 1898), we now know that the 
Golgi apparatus is a ubiquitous organelle present in every cell type except for red 
blood cells and conserved from yeast to mammals. Dependent on the organism and 
on the particular needs of specialised cells, the Golgi apparatus can vary in shape 
and size. A common feature, however, is the modification and sorting of protein and 
lipid cargo within the Golgi membrane system. A general overview of the 
mammalian Golgi apparatus structure and function, as well as mechanisms and 
routes determining intracellular transport will be provided in the next chapters. 
1.1.2 Structure and function of the Golgi apparatus 
The mammalian Golgi apparatus consists of a series of overlapping flattened 
membrane-enclosed cisternal structures. Several cisternae are arranged in layers 
and build a so-called stack. Golgi stacks can be interconnected by membrane 
tubules and associated with vesicular structures (Farquhar and Palade, 1981). How 
the cisternae are hold together in stacks without fusing with one another is not yet 
fully understood. It has been proposed that a proteinaceous matrix shapes and 
organises Golgi cisternae, by linking membranes to each other and to the 
cytoskeleton. Key components of this Golgi matrix are long coiled-coil proteins 
termed Golgins, regulated by the Rab family of small GTPases. Together with actin 
filaments or microtubules and associated motor proteins, these proteins may play a 
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role in maintaining Golgi architecture and in directing membrane trafficking 
(Gillingham and Munro, 2003; Short et al., 2005). 
Within the cell the Golgi apparatus is located in the perinuclear region close 
to the centrosome. This positioning is microtubule dependent. Upon 
depolymerisation of microtubules using the drug nocodazole, the ribbon-like 
structure of the Golgi apparatus breaks apart into smaller individual stacks 
distributed throughout the cytoplasm (Robbins and Gonatas, 1964; Rogalski et al., 
1984). Thus, the complex Golgi membrane system is not randomly oriented in the 
cytoplasm but closely linked to the cytoskeleton. This is important for regulated 
secretion in polarised cells, e.g. at the leading edge of migrating cells. Stimulated by 
intracellular signalling processes involving kinases of the Ste20 family, PAK4 and 
protein kinase D family members (Preisinger and Barr, 2005), the Golgi apparatus 
polarises together with the centrosome towards the site of membrane protrusion and 
delivers membrane cargo to the outgrowing side of the cell (Corthesy-Theulaz et al., 
1992; Kupfer et al., 1982; Preisinger et al., 2004). 
At the onset of mitosis the Golgi stack breaks down into small vesicles 
(mitotic haze), which become partitioned between the forming daughter cells. This 
process is also linked to intracellular signalling cascades. Phosphorylation of Golgi 
structural proteins by Cdk1-cyclin B, polo-like and mitogen-activated kinases, 
induces the reorganisation of Golgi stacks during mitosis (Acharya et al., 1998; 
Lowe et al., 1998; Preisinger and Barr, 2005; Sutterlin et al., 2001). Whether the 
Golgi apparatus keeps its own identity and remains discrete in vesicular shape, or 
whether Golgi components redistribute to the ER and are inherited as a merged 
compartment before Golgi stacks reform from newly established ER exit sites in 
telophase, is currently debated (Altan-Bonnet et al., 2006; Axelsson and Warren, 
2004; Pecot and Malhotra, 2004; Pecot and Malhotra, 2006). 
As the central organelle of the secretory pathway the Golgi apparatus 
exhibits a defined polarity. The cis side of the stacks faces the ER and defines the 
site of lipid and protein cargo input arriving from ER exit sites. The opposite side of 
the Golgi apparatus, where lipid and protein sorting to other organelles or to the 
plasma membrane occurs, is referred to as trans Golgi, flanked by a tubular-
vesicular network called trans Golgi network (TGN). 
Besides cargo sorting and secretion the main function of the Golgi apparatus is to 
catalyse complex lipid and protein modifications, like N- and O-linked glycosylation 
or sulfation. This is accomplished by a variety of enzymes residing in discrete Golgi 
cisternae, dependent on their order of action more towards the cis or trans face of 
the Golgi apparatus. As lipids and proteins become modified in a serial manner the 
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temporal and spatial organisation of these enzymes is crucial for the correct pattern 
of modification (Spiro, 2002). Like all post-translational modifications, glycosylation 
is an important means of creating functional diversity in lipids and proteins. Errors in 
the glycosylation pattern can result in severe diseases such as the congenital 
disorders of N-glycosylation caused by mutations in genes required for glycosylation 
and Golgi function (Aridor and Hannan, 2002; Olkkonen and Ikonen, 2006). 
All trafficking steps to, from and within the Golgi apparatus and thus the Golgi 
cisternae themselves are highly dynamic and need to be regulated in a complex 
way. The full details of membrane trafficking through the Golgi apparatus are not yet 
known but the importance of the Golgi apparatus as central sorting and modifying 
station along intracellular and secretory transport routes can be seen clearly in the 
long list of diseases linked to Golgi dysfunction (Aridor and Hannan, 2000; Aridor 
and Hannan, 2002). 
1.1.3 Molecular mechanisms of intracellular transport 
Intracellular traffic between compartments occurs through membrane vesicles or 
tubules budding off from a donor membrane and fusing with an acceptor membrane 
downstream of the transport process (Figure 1.1). These vesicle fission and fusion 
processes are facilitated by a number of molecules, which are either integral 
transmembrane proteins or peripheral membrane proteins recruited from the 
cytoplasm. 
 
Figure 1.1 The four main steps of vesicular transport, which involve budding of the vesicle 
from the donor membrane, movement along microtubule or actin filaments, tethering to the 
acceptor membrane and fusion of vesicular and acceptor membrane. Proteins that facilitate 
these processes are either integral membrane proteins (e.g. cargo receptors, SNAREs), or 
recruited from the cytoplasm (e.g. coat proteins, motor proteins, tethering factors). Figure 
adapted from (Behnia and Munro, 2005). 
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Coat proteins play a vital role in vesicle budding. Together with adaptor proteins and 
transmembrane cargo receptors, they associate with the donor membrane. The 
coated membrane region gets curved and adapts a ball-like structure, which finally 
pinches off as a free vesicle. Three different coat machineries are known so far: 
Clathrin coated vesicles budding from the plasma membrane, endocytic structures 
and trans Golgi regions, COPI coated vesicles in intra Golgi and retrograde 
transport and COPII coated vesicles carrying cargo from ER exit sites to the cis 
Golgi network (Bonifacino and Glick, 2004). Also GTPases, like dynamin, Arf or 
Sar1 are involved in coat formation and vesicle fission (Bonifacino and Glick, 2004). 
One class of proteins, the CtBP/BARs, was just recently discovered to convey 
membrane curvature and induce the formation of membrane tubules, which can be 
important for vesicle formation and abscission (Corda et al., 2006). It is hard to 
imagine that only three different coat machineries accomplish the full variety of 
vesicular transport steps. Despite the fact that the COPI and COPII machinery can 
adjust its exact composition of protein components according to the kind of sorting 
process within the vesicle, one speculates that there are more, so far unknown 
coats and also uncoated mechanisms of vesicle budding (Bonifacino and Glick, 
2004). 
Once the vesicle has budded off the donor compartment, the coat proteins 
dissociate and the vesicle gets transported to the acceptor compartment. Interaction 
with motor proteins facilitates transport along microtubules or actin filaments 
(Matanis et al., 2002; Seabra and Coudrier, 2004; Short et al., 2002). At the 
acceptor membrane tethering factors, usually long coiled-coil proteins, can help to 
bring vesicles close to the target membrane. Tethering factors are recruited from the 
cytosol by small GTPases of the Rab family, which are anchored in the membrane 
through a C-terminal lipid  modification (Pfeffer, 2001; Zerial and McBride, 2001). 
The actual fusion reaction is driven by the interaction of SNARE proteins. A specific 
v-SNARE on the vesicle interacts with the t-SNAREs of the target membrane, 
inducing a conformational shift in these proteins, which generates the force 
necessary to merge two membranes (Chen and Scheller, 2001; Pelham, 2001). 
The variety of compartments and the high number of different forward and 
retrograde transport routes within the cell require that both, donor and acceptor 
membrane are well defined and can be specifically recognised by the respective 
transport machinery. Many of the proteins that mediate transport between 
organelles are cytosolic proteins and need to be recruited to the cytosolic face of the 
membrane. The unique identity of a membrane domain is conferred, on the one 
hand by transmembrane proteins, like cargo receptors or SNAREs, and on the other 
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hand by activated Rab GTPases and specific lipids, such as phosphoinositides. 
Four forms of phosphatidylinositol are known to localise to different organelles. 
PI(4)P is generated in Golgi membranes and in the plasma membrane, whereas 
PI(4.5)P2 is found only in the plasma membrane. PI(3)P is predominantly found in 
early endosomes, PI(3,5)P2 in late endosomes and lysosomes (Behnia and Munro, 
2005). Specific lipid kinases and phosphatases regulate the transformation of 
phosphatidylinositol forms and are therefore important players in organelle identity 
and intracellular transport (Choudhury et al., 2005). Out of 60 human Rabs only a 
handful have been shown to localise to distinct membrane compartments and to be 
involved in specific transport routes. The best characterized is Rab5 which is 
involved in the homotypic fusion of early endosomes. Less is known about the Rab 
co-factors for nucleotide exchange and GTP-hydrolysis, the GEFs and GAPs (see 
1.3). So, the puzzle of membrane identity and specificity in intracellular transport is 
far away from being solved. 
1.1.4 Anterograde transport and Exocytosis 
Anterograde transport is the transport of lipids and proteins from their site of 
production in or at the ER to various destinations within the cell or secretion outside 
of the cell. Cargo to be sorted or secreted leaves the ER at so called ER exit sites in 
COPII coated vesicular or tubular structures (Duden, 2003; Klumperman, 2000). ER 
exit sites are marked by the absence of ribosomes and the presence of the ER 
integral membrane protein Sec12p, which acts as an exchange factor for the 
GTPase Sar1. Thereby, Sar1 is locally activated and initiates COPII coat formation 
at ER exit sites (Pfeffer, 2003). Transmembrane proteins to be transported are 
enclosed directly into a COPII vesicle whereas soluble cargo binds transmembrane 
cargo receptors such as ERGIC53 to be enriched in the lumen of the forming vesicle 
(Appenzeller-Herzog and Hauri, 2006). In general, only proteins, which have passed 
the ER quality control for correct folding, can be transported. For that reason 
chaperones like BiP or Calnexin can be found in ER exit sites. Vesicles or tubular 
structures leaving ER exit sites are believed to fuse shortly after to form vesicular-
tubular clusters (VTCs) or the ER-to-Golgi intermediate compartment (ERGIC) 
(Appenzeller-Herzog and Hauri, 2006). VTCs are the first stations for lipid and 
protein sorting in the anterograde pathway. ER resident proteins are recycled back 
to the ER in COPI coated vesicles. Many of them carry signal sequences, which 
make them visible for retrograde sorting receptors, like the KDEL sequence is 
recognised by the KDEL-receptor. ER resident transmembrane proteins carry a C-
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terminal basic sequence (KKXX) which is recognised by the COPI machinery for 
retrograde sorting (Pelham, 1996). 
Cargo proteins destined for forward transport or secretion are transported 
further in COPII vesicles, which fuse then with the cis face of the Golgi apparatus. 
Subsequently cargo gets transported within the Golgi apparatus and modifications 
(glycosylation, sulfation) are carried out along this pathway. There is a debate going 
on whether cargo transport within the Golgi is facilitated via vesicles budding from 
one cisterna and fusing with the anterograde cisterna of the Golgi stack (vesicular 
transport model) or whether the Golgi cisternae themselves mature while enzymes 
along the biosynthetic pathway of carbohydrate and other modifications get recycled 
back in a retrograde fashion (cisternal maturation model) (Pelham, 2000). In reality it 
could be well true that a mixture of both pathways exists and that the vesicular 
transport is the fast track for small cargo whereas larger cargo has to take the 
slower route of cisternal maturation. 
Finally, after cargo has got the full set of modifications, it reaches the trans 
Golgi region and the TGN. The TGN is primarily sorting station for arriving cargo. 
Vesicles are budding from the TGN as clathrin coated vesicles and are either 
destined for the endocytic membrane system or for the plasma membrane, where 
transmembrane proteins and lipids get incorporated into the plasma membrane and 
soluble cargo secreted to the extracellular space. Clathrin assembly at the TGN is 
regulated by Arf GTPases, activated locally by their GEFs, and by GGA-proteins, 
which are able to bind to the cytosolic side of cargo receptors. Some proteins carry 
a molecular tag for sorting. The N-linked oligosaccharide mannose-6-phosphate for 
example is an identification tag for lysosomal proteins and is recognised by a 
specific transmembrane receptor (mannose 6-phosphate receptor, MPR) shuttling 
between TGN and late endosomes/ lysosomes (Ghosh and Kornfeld, 2004). Other 
sorting signals for soluble and transmembrane proteins are less well understood 
(Rodriguez-Boulan and Musch, 2005). 
1.2 Endocytosis and retrograde transport 
1.2.1 Endocytic vesicle formation at the plasma membrane 
Endocytosis is the process by which a cell takes up membrane components, 
receptor-associated ligands and soluble molecules from outside to various 
destinations within the cell. Endocytic trafficking is closely linked to signalling 
processes and is therefore necessary for cell growth and communication. In 
principle endocytosis is the opposite process to secretion and is also mediated by 
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vesicular membrane transport. Endocytic vesicles invaginate and pinch off from 
specific domains at the plasma membrane. Based on the requirement for coats and 
other proteins and lipids, different types of endocytic vesicle formation can be 
discriminated (Figure 1.2) (Nichols, 2003). 
 
 
Figure 1.2 Endocytic vesicle formation at the plasma membrane. Both, clathrin-mediated and 
caveolar endocytosis require the GTPase dynamin for vesicle abscission, whereas other 
types of endocytosis don’t. Due to its cage-like structure clathrin coated vesicle formation is 
well characterised. In contrast, it is not clear how many mechanisms of clathrin-independent 
endocytosis besides caveolar endocytosis exist. Figure taken from (Nichols, 2003). 
Due to their unique cage-like structure in electron micrographs, clathrin coated pits 
were observed very early in cell biological research and belong to the best-studied 
processes in endocytosis (Roth, 2006). Clathrin is recruited to the plasma 
membrane by the multisubunit adaptor complex AP2 in cooperation with several 
other adaptor proteins, like Epsin or Eps15. Epsin is able to bind PI(4,5)P2, a 
phosphoinositide generated mainly in the plasma membrane and in the TGN. By 
interaction with Eps15, Epsin recruits AP2 and clathrin subunits and additionally 
acts in curving the membrane for vesicle formation. AP2 and probably other adaptor 
proteins mediate the assembly of the clathrin cage around the forming vesicle 
(Mousavi et al., 2004). It should be noted that PI(4,5)P2 alone is not sufficient to 
determine the site for clathrin coat formation on the plasma membrane. In order to 
be recruited to the membrane, AP2 seems to require also specific integral 
membrane proteins like synaptotagmin or cell surface receptors, which define 
membrane microdomains in clathrin coated pit formation (Mousavi et al., 2004). For 
the abscission of the coated vesicle the action of dynamin, a high-molecular-weight 
GTPase, is needed. Dynamin forms ring-like oligomers around the neck of the 
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budding vesicle, which constrict the membranes by conformational change upon 
GTP-hydrolysis. Because dynamin is also able to bind actin-modifying proteins, it 
may be involved in regulating actin polymerisation at the site of vesicle fission 
(Mousavi et al., 2004). 
Clathrin-independent vesicle formation is less well understood. One example 
is caveolae-mediated endocytosis, characterised by the protein caveolin and a lipid 
compositon different from the surrounding membrane region, called lipid rafts. Lipid 
rafts are membrane microdomains enriched in cholesterol, glycosphingolipids, 
phospholipids, GPI-anchored proteins and integral membrane proteins. Caveolin 
binds cholesterol and is extremely resistant to detergent extraction (Nichols, 2003). 
Like clathrin-mediated endocytosis, caveolar endocytosis requires the activity of the 
GTPase dynamin. Yet, other clathrin-independent, mainly uncharacterised pathways 
exist that are dynamin-independent (Glebov et al., 2006; Nichols, 2003). 
1.2.2 Endocytic sorting pathways 
After budding endocytic vesicles fuse with each other to form the early endosomal 
compartment. This homotypic fusion process is regulated by the small GTPase 
Rab5 and its effector protein EEA1 (early endosomal antigen 1). EEA1 is a coiled-
coil protein that dimerises and acts as a tethering factor to bring two membranes in 
close contact. EEA1 is recruited to the endosomal membrane by both, PI(3)P and 
active Rab5. Additionally EEA1 interacts with the SNARE Syntaxin13, which is 
important for the actual membrane fusion step (Woodman, 2000). The early 
endosome is the first sorting station within endocytic routes and is therefore also 
called sorting endosome. The entire endosomal system is extremely complex, 
therefore only the main endocytic routes are depicted in Figure 1.3 and will be 
described below. 
The major determinant in early sorting steps is whether cargo is meant to be 
recycled back to the plasma membrane or to be further transported to intracellular 
destinations. One assumes that, by default, membrane and components like integral 
membrane proteins take the recycling pathway, whereas solute cargo is destined for 
the intracellular route. This is achieved by “geometry-based sorting”, where 
membrane components are enriched in narrow endosome tubules from which 
vesicles bud off towards the plasma membrane, and solute cargo is left behind in 
the main lumen of the endosome (Maxfield and McGraw, 2004). 
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Figure 1.3 Main endocytic routes. Endocytic vesicles fuse to form the sorting endosome, from 
which cargo gets either recycled back to the plasma membrane or transported further to the 
late endosome/ early MVB (multivesicular body). In specialised cells, like antigen presenting 
cells, the early MVB can mature to form exosomes. In general, early MVBs are in exchange 
with the Golgi apparatus and can mature to form late MVBs and lysosomes, where protein 
degradation takes place. Clathrin is indicated in red and is involved in vesicle formation at the 
plasma membrane, in endocytic compartments and in the TGN. Figure adapted from (Raiborg 
et al., 2003). 
An example for the recycling pathway is transferrin receptor (TfR), which transports 
iron bound to the carrier protein transferrin and shuttles between plasma membrane 
and sorting endosome. While the standard recycling route is taken by many nutrient 
receptors, activated mitogenic receptors, like the epidermal growth factor (EGF) 
receptor are marked for degradation by monoubiquitination and actively sorted into 
the internal vesicles of multivesicular bodies (see below) (Mukhopadhyay and 
Riezman, 2007; Urbe, 2005). Ligands are usually released in the sorting endosome 
due to the low pH (approx. pH6) and the receptor becomes free for another round of 
ligand uptake or for degradation in the lysosome. This first sorting step involving 
budding tubules and vesicles for recycling goes along with maturation of the core 
sorting endosome to form the late endosome. The maturation is accompanied by 
the exchange of key regulatory proteins, Rab7 is replacing Rab5, and by the 
transport towards the cell center along microtubules. The latter is mediated by the 
minus-end directed motor protein dynein (Bananis et al., 2004; Driskell et al., 2007; 
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Valetti et al., 1999). Late endosomal membranes can invaginate and create 
intralumenal vesicles. These multivesicular bodies (MVBs) can serve as storage 
intermediates for secretory lysosomes, like the MHCII compartment in antigen-
presenting cells or function in receptor down-regulation (Raiborg et al., 2003). By 
sequestering the cytosolic signalling domain of transmembrane receptors to the 
luminal side of MVBs, any signalling cascade gets terminated prior to degradation of 
the receptor in the lysosome. In the past few years the molecular details of the MVB 
sorting machineries have elucidated. Networks of the multisubunit ESCRT 
(endosomal sorting complex required for transport) complexes recognise 
ubiquinated transmembrane receptors and drive their internalisation into lumenal 
vesicles of MVBs (Hurley and Emr, 2006; Williams and Urbe, 2007). Receptor-
downregulation is a very important intracellular process to terminate extracellular 
signalling events. In the case of EGF receptor, whose activation leads to a 
stimulation of cell proliferation, MVB formation can even be referred to as a tumor 
suppressor pathway (Alexander, 1998; Dikic, 2003). 
The endocytic system is in cross talk with other membrane systems like the 
Golgi apparatus. Late endosomes and MVBs can fuse with Golgi-derived vesicles 
carrying newly synthesised lysosomal hydrolases to build lysosomes for lipid and 
protein degradation. Apart from the exchange of lysosomal enzymes and the 
transport of their receptors (MPRs) back to the Golgi (see 1.1.4), other retrograde 
recycling pathways between endosomes and the Golgi apparatus exist, yet they are 
not well characterised. Most data on this subject were obtained from work with 
Shiga toxin and other bacterial toxins, which exploit existing cellular pathways in 
order to intoxicate the cell. 
1.2.3 Retrograde transport of Shiga toxin 
Shiga toxins and Shiga-like toxins are produced by Shigella dysenteria and some 
enterohaemorrhagic E. coli strains (EHEC). Infection with these bacteria occurs in 
most cases through poisoned food or water and causes severe diarrhoea and fatal 
complications like haemorrhagic uremic syndrome (HUS). Shiga toxin producing 
bacteria colonise and associate with the large intestinal mucosa, which causes 
severe inflammation and intestinal damage leading to diarrhoea and dehydration. 
Active toxin is secreted into the lumen of the gut and is able to enter the systemic 
circulation by translocation through the epithelial layer of the gut from the apical to 
the basolateral sides of the cells. Once circulating Shiga toxin intoxicates endothelial 
cells leading to microvascular thrombosis and organ damage mainly in the 
gastrointestinal tract, brain and kidney (O'Loughlin and Robins-Browne, 2001). 
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Similar to the bacterial Cholera toxin or the plant toxin ricin, Shiga toxin is a two 
subunit protein containing an enzymatically active A-subunit (32 kDa) and a 
pentameric B-subunit (7.7 kDa per monomer) that is important for binding and 
transport of the toxin into target cells (Figure 1.4 A). Both subunits are non-
covalently linked to form the AB holotoxin. The five identical B-monomers build a 
doughnut-shaped structure that binds to the membrane glycolipid globotriasoyl 
ceramide (Gb3) on the cell surface of Shiga toxin sensitive cells (Sandvig et al., 
2002). Cells deficient of the Shiga toxin receptor Gb3 are resistant to Shiga toxin. 
However, non-Gb3 mediated transport of the toxin seems to exist as human colon 
cancer cell lines devoid of Gb3 were shown to internalise Shiga toxin. The purpose 
of such a pathway could be the entry of the toxin into the systemic circulation 
without destroying the epithelial cell layer of the gut (O'Loughlin and Robins-
Browne, 2001). 
 
 
Figure 1.4 Structure and transport pathway of Shiga toxin. The full toxin comprises an 
enzymatically active A-subunit and a pentameric B-subunit, which is important for binding the 
toxin to the glycolipid Gb3 on the cell surface. In early endosomes, the A-subunit is cleaved 
into A1 and A2 but remains linked by a disulfide bond (A). After binding to the surface of Gb3 
positive cells, Shiga toxin is endocytosed by clathrin-dependent and –independent 
mechanisms and transported to the Golgi apparatus. From there Shiga toxin is transported in 
a retrograde fashion to the ER, where the A-subunit is translocated to the cytosol (B). Figure 
adapted from (Sandvig and van Deurs, 2002). 
After binding to Gb3 through its B-subunit Shiga toxin becomes endocytosed by 
clathrin-dependent and clathrin-independent (e.g. caveolae) pathways (Figure 1.4 
B) (Sandvig and van Deurs, 2002). In early and recycling endosomes the 
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endopeptidase furin cleaves the A-subunit of Shiga toxin into disulphide linked A1 
(29 kDa) and A2 (3 kDa) chains. This proteolytic cleavage transforms the non-toxic 
pro form of Shiga toxin into an active form, which is able to inhibit protein synthesis 
in target cells. From early and recycling endosomal compartments the toxin is 
transported to the trans Golgi network (TGN). This pathway depends on the function 
of clathrin and dynamin (Lauvrak et al., 2004), on the SNAREs Syntaxin5 and 
Syntaxin16 (Amessou et al., 2007), on the small GTPase Arl1 and its effector 
protein Golgin-97 (Lu et al., 2004), on the lipid phosphatase OCRL1 (Choudhury et 
al., 2005) and on Rab6 and its effector proteins (White et al., 1999). From the TGN 
the toxin is transported in a retrograde fashion through the Golgi apparatus to the 
ER. Unlike other bacterial toxins (e.g. Pseudomonas exotoxin A) Shiga toxin does 
not contain a KDEL sequence for efficient retrieval to the ER. It was shown that 
retrograde trafficking of Shiga toxin is COPI-independent (Girod et al., 1999) and 
relies on an alternative mechanism involving Rab6 (White et al., 1999). After arrival 
in the ER, the toxin A-subunit enters the cytosol by retro-translocation, probably 
subverting the ER-associated degradation pathway (ERAD) (Spooner et al., 2006; 
Yu and Haslam, 2005). Usually, retro-translocation is a quality control mechanism 
by which misfolded proteins are transported from the ER lumen to the cytosol where 
they are degraded by the ubiquitin-proteasome system (Tsai et al., 2002). Having 
arrived in the cytosol the toxin A-subunit is not degraded but refolds and inhibits 
protein synthesis by inactivating the ribosome. In detail, Shiga toxin A-subunit 
cleaves a specific N-glycosidic bond within the 28S rRNA, which leads to the 
release of a conserved adenine base in the position of the aminoacyl-tRNA acceptor 
site and consequently to a block in peptide chain elongation (O'Loughlin and 
Robins-Browne, 2001). 
Although the basic steps of Shiga toxin transport and the mechanism of 
toxicity are known, the full molecular details of retrograde toxin trafficking remain 
obscure. Elucidation of intracellular processes required for efficient transport of 
Shiga toxin is not only of great medical interest but would also answer many cell 
biological questions concerning endogenous routes within the endocytic and 
secretory membrane system. 
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1.3 Rab GTPases: Molecular switches regulating membrane traffic 
1.3.1 The Rab family of small GTPases 
The human Ras superfamily of small GTPases comprises more than 150 human 
members and is divided in 5 family branches according to sequence and functional 
similarities: Ras, Rho, Rab, Ran and Arf. With 63 known members, the family of 
human Rab GTPases represents the biggest branch in the Ras superfamily of 
monomeric G proteins (Wennerberg et al., 2005). Like all small GTPases Rab 
proteins function as GDP/GTP-regulated molecular switches. While some Rabs are 
cell type or tissue specific, many are ubiquitously expressed (Pereira-Leal and 
Seabra, 2001). For instance, in melanocytes Rab27a regulates the trafficking of the 
pigment-containing melanosomes (Bahadoran et al., 2001; Hume et al., 2001; Wu et 
al., 2001), whereas Rab1 is a ubiquitous Rab defining ER to Golgi transport (Allan et 
al., 2000; Moyer et al., 2001). 
Rab GTPases are localised to distinct membrane compartments and are regulators 
of secretory and endocytic intracellular transport pathways. They play a role in 
vesicle docking and fusion with target membranes and in vesicle motility through the 
recruitment of motor proteins, and some have also been implicated in receptor 
cargo selection and vesicle formation (Pfeffer, 2005a; Zerial and McBride, 2001). 
However, only a handful of Rabs and their effector proteins are characterised in 
detail and the impact of the majority of Rabs is largely unknown. Examples for well-
established Rab functions are Rab1, which recruits the p115 tethering factor to ER-
derived vesicles to mediate targeting and fusion to cis Golgi membranes (Allan et 
al., 2000; Moyer et al., 2001; Weide et al., 2001) or Rab9 and its effector protein 
TIP47, which is important for the selection of the mannose 6-phosphate receptor 
(MPR) to late endosomal vesicles for recycling of MPR to Golgi membranes 
(Aivazian et al., 2006; Carroll et al., 2001). 
Rab GTPases are conserved from yeast to human. While the human genome 
contains more than 60 Rab genes, the fission yeast Schizosaccharomyces pombe 
possesses only seven and the budding yeast Saccharomyces cerevisiae only 12 
Rab (or Ypt) genes (see Figure 1.5). In yeast, gene disruptions of either Rab results 
in lethality or in a severe phenotype concerning membrane trafficking (Pereira-Leal 
and Seabra, 2001). The yeast Rabs have homologues within the human Rab family 
and the members of this group are considered the “ancestral” Rabs, such as 
scYpt1/ hsRab1 regulating ER to Golgi trafficking. The increased number of Rab 
genes in humans might correspond to the functional diversification and cellular 
specialisation in a multicellular organism. 
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Figure 1.5 Phylogenetic tree of 60 human and 
12 yeast Rabs/ Ypts. The Ypts from 
Saccharomyces cerevisiae are shown in 
italics. 
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All Rabs share a 20 kDa globular GTPase domain with conserved structure and 
biochemical properties. The G-domain is folded into a six-stranded β-sheet (β1 - β6) 
surrounded by five α-helices (α1 − α 5). Within the G-domain there are two regions 
that change their conformation dependent on the bound nucleotide GDP or GTP. 
They are located between α1 and β 2 and between β3 and β 4 and are called switch 
I and switch II regions (Ostermeier and Brunger, 1999; Pfeffer, 2005b). In and 
around these switch regions there are five Rab family specific motifs (RabF1 − 
RabF5) that determine the identity of a Rab and most likely the interface of effector 
and regulator binding. In addition, within clusters of related Rabs, there are 
sequence motifs that show higher identity than other regions. They are termed Rab 
subfamily motifs (RabSF1 − RabSF4) and define Rab isoforms, which share more 
than 70 % overall sequence identity, such as Rab1a and Rab1b (Pereira-Leal and 
Seabra, 2000). 
Outside of the globular G-domain Rab GTPases exhibit a C-terminal hyper-
variable region, which is unstructured and variable in length (approx. 30 – 40 amino 
acids). This sequence stretch together with other domain determinants is thought to 
be essential for Rab localisation in the target membrane (Pfeffer, 2005b). At the very 
C-terminus there are usually two cysteines, which are geranylgeranylated by 
geranylgeranyltransferase II. This post-translational lipid modification is needed to 
anchor the Rab in the membrane. In the cytosol a protein called GDI chaperones 
the double prenylated Rab in its GDP bound conformation. Structural studies show 
that the Rab GTPase sits on the side of GDI whereas the prenyl groups lie at the 
bottom of GDI, the first one deep inside a binding pocket, the second prenyl group 
more towards the surface of GDI (Pylypenko et al., 2006). The C-terminal hypervari-
able region stretches over the surface of GDI and represents a polypeptide linker 
between the globular GTPase domain and prenylation site. This extension could 
also be important for Rab function within the membrane, by positioning the active G-
domain in distance to the lipid bilayer and therefore holding it available for cytosolic 
effector proteins. 
1.3.2 The Rab GTPase cycle 
Rab GTPases bind both, GDP and GTP with high affinities and usually exhibit low 
intrinsic GDP/GTP exchange rates. However, to act as molecular switches, the 
spatial and temporal control of GDP-bound, inactive and GTP-bound, active Rab 
conformation is necessary. So, the Rab GTPase itself is not sufficient to fulfil its role 
as a membrane organiser, and a whole set of other proteins is needed to initiate and 
control the Rab GTPase cycle (Figure 1.6). 
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Figure 1.6 The Rab GTPase cycle. GDP bound prenylated Rab (red rhombus) is chaperoned in 
the cytosol by GDI. Upon membrane delivery, GDI is displaced by GDF and the Rab is inserted 
into the membrane by both prenyl groups at the C-terminus. A GEF catalyses the exchange of 
GTP for GDP and the Rab switches to its active state (red circle). Only in its active state a Rab 
can bind effector proteins, which can fulfill various functions within intracellular transport. 
Effector binding is terminated when the Rab switches back to its inactive, GDP-bound state. 
GTP-hydrolysis and the release of free phosphate is catalysed by GAP proteins.  
In the cytoplasm, inactive Rab proteins in their GDP conformation are chaperoned 
by GDI (see above). Rab-GDI complexes were shown to contain all of the 
information needed to deliver the Rab to its target membrane. Within the membrane 
so-called GDI displacement factors (GDFs) can bind the Rab-GDI complex (Sivars 
et al., 2003). Upon this binding, conformational changes sequentially release both 
prenyl groups of the Rab from the GDI binding site and allow them to insert into the 
membrane. Once anchored in the membrane, the Rab protein is released from GDI 
and can start its functional cycle (Pylypenko et al., 2006). While GDI is a general 
factor and recognises all Rabs in their prenylated, GDP-bound state, there seem to 
exist several GDFs with distinct membrane localisation and selectivity for certain 
Rabs. The Golgi/ endosome localised transmembrane protein Yip3 has been shown 
to have GDI displacement factor activity for endosomal Rabs. According to BLAST 
searches and expression profiles there are 12 ubiquitously expressed members of 
the human Yip family, but only two have been shown to act as GDFs (Pfeffer and 
Aivazian, 2004). 
In order to be activated, GDP must be exchanged for GTP in the Rab G-
domain. A class of proteins called GEFs (guanine nucleotide exchange factors) 
catalyse this reaction by complex formation with the GDP-bound Rab. A subsequent 
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structural rearrangement in Switch I and Switch II within the Rab G-domain disrupts 
the interaction of Switch I with GDP and facilitates the release of GDP (Delprato et 
al., 2004; Dong et al., 2007; Sato et al., 2007). Because the concentration of GTP in 
the cytoplasm is far higher than that of GDP, nucleotide free Rab proteins are 
loaded preferentially with GTP. In their GTP-bound state Rabs change to their active 
conformation, which can be recognised and bound by effector proteins with high 
affinity. Rab effector proteins can have a variety of functions. They can be tethering 
factors for vesicle fusion or linkers to motor protein function (Grosshans et al., 2006; 
Zerial and McBride, 2001). Initially, Rab effectors were considered independent 
proteins recruited by a specific Rab in order to fulfil their function, but it turned out 
that some Rab effectors can even influence the stability and localisation of a Rab 
such as TIP47 stabilises Rab9 on late endosomal membranes (Ganley et al., 2004). 
Thus, effector proteins can play a role in recruitment of specific Rabs to specialised 
membrane micro-domains and therefore in defining membrane identity. The active 
state of Rab GTPases is turned off by hydrolysis of the bound GTP to GDP with 
release of free phosphate. Most Rabs exhibit a very slow intrinsic GTP-hydrolysis 
rate and need GTPase activating proteins (GAPs) for efficient enzymatic cleavage 
of the γ-phosphate group. Once in the inactive GDP-bound form the Rab protein 
gets either activated again by the GEF for another round of activity or retrieved to 
the cytosol through the interaction with GDI. 
While GEFs for Rho or Ras GTPases are well characterised, relatively little is 
known about GEFs acting on Rab GTPases. So far, only a few GEFs for Rabs and 
their yeast homologues Ypts were identified. The best understood are Vps9/Rabex-
5 which acts on Rab5, and the Sec2p GEF for the Sec4p GTPase in yeast (Dong et 
al., 2007) which belongs to the class of coiled-coil GEFs. In general, Rab GEFs are 
structurally unrelated and can be part of larger protein complexes, like the yeast 
TRAPP complex, regulating transport from the ER to the Golgi (Jones et al., 2000; 
Kim et al., 2006; Kim et al., 2005). Therefore, the systematic identification of 
putative GEFs by homology search is rather difficult. In contrast, Rab GAPs share a 
conserved domain, defining a family of about 40 human Rab GAP candidates. 
1.3.3 Catalytic mechanism and members of the human Rab GAP family 
Human Rab GAPs were identified through a conserved domain which was first 
defined in yeast GAPs for Ypts (Gyps). Because of its homology to regions in the 
Tre-2 oncogene and in the yeast mitotic regulators Bub2 and Cdc16 the domain was 
called TBC (Tre-2/Bub2/Cdc16) domain (Richardson and Zon, 1995). The TBC 
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domain is between 200 and 400 amino acids long and consists of six conserved 
sequence motifs (A-F) (Figure 1.7). 
 
 
Figure 1.7 The TBC domain. The conserved sequence motifs IxxDxxR with the catalytic 
arginine (red R) and YxQ with the catalytic glutamine (red Q) for the dual-finger mechanism 
are given below the six conserved sequence motifs A-F. 
Crystal structural analysis of the yeast Gyp1 in complex with human Rab33 showed 
that Rab GAPs act by a dual-finger mechanism (Pan et al., 2006). Similar to the 
“arginine finger” in Ras or Rho family GAPs a conserved arginine residue of the 
TBC domain inserts into the GTP binding pocket of the G-domain and mediates 
hydrogen-bonding with oxygen of the γ- and β-phosphate group of GTP. This 
interaction compensates the accumulation of negative charge at the β-phosphate 
group during the hydrolysis reaction. Concomitantly the TBC domain provides a 
conserved glutamine residue to coordinate the water molecule for the nucleophilic 
attack of the γ-phosphate (Pan et al., 2006). Before, it has been assumed that the 
coordination of the water molecule was mediated by a conserved glutamine (DxxGQ 
motif) of the Rab GTPase itself. This was the basis for constitutively active Rab QL 
mutants where GTP cannot be hydrolysed. From the structural study of (Pan et al., 
2006) we now know that the conserved glutamine of the Rab instead mediates the 
interaction with a tyrosine residue and the amino group of the glutamine of the 
active site of the GAP. The motifs for the arginine and glutamine fingers in the TBC 
domain of the GAP are IxxDxxR (in motif B) and YxQ (in motif C) respectively. As 
both motifs are conserved throughout all yeast Gyps and in about 70 % of all known 
human Rab GAPs the dual-finger mechanisms seems to be the general principle of 
GTP hydrolysis catalysed by Rab GAPs. Based on the B and C active site motifs of 
the characterised yeast Gyps a database search for human homologues identified 
39 potential human RabGAPs (Figure 1.8) (Francis Barr and Alexander Haas, 
unpublished results). Whereas some candidates comprise more or less only the 
TBC domain, many other contain other functional domains (RUN, GRAM, PH, PTB, 
SH3) that may regulate their activity or localisation. 
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Figure 1.8 Alignment of the core B-motif 
of human TBC domain proteins with the 
yeast protein Bub2. Stars at the top 
indicate the conserved residues within 
the catalytic motif. At the bottom the 
consensus sequence containing the 
IxxDxxR arginine finger motif is depicted. 
Human TBC domain proteins are either 
shown with their full name according to 
the TBC nomenclature, or with their 
protein database accession number. 
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1.4 Rab6: Role of a Golgi localised Rab 
1.4.1 Isoforms and features of Rab6 
Rab6 is a Golgi localised GTPase (Goud et al., 1990) and was one of the first 
human Rabs to be cloned (Zahraoui et al., 1989). There are three isoforms of Rab6, 
named Rab6a, Rab6b and Rab6c. Rab6a was found to exist in two isoforms Rab6a 
and Rab6a’, which are generated by alternative splicing of a duplicated exon within 
the Rab6 gene. Both, Rab6a and Rab6a’ are ubiquitously expressed and differ only 
in three amino acids (Echard et al., 2000). Rab6b is encoded by a different gene 
and exhibits 91 % amino acid sequence identity with the Rab6a protein. Rab6b also 
localises to the Golgi apparatus and interacts with known Rab6a effector proteins, 
but seems to be expressed in a tissue-specific manner, predominantly in brain 
(Opdam et al., 2000). The third Rab6 isoform, Rab6c, was described to play a role 
in multidrug resistance in the human breast cancer cell line MCF7/AdrR (Shan et al., 
2000). However, it is unclear whether Rab6c functions as a classical Rab GTPase in 
terms of membrane anchoring and GTPase cycle. Whereas Rab6a and Rab6b are 
both 209 amino acids long and end at their C-terminus with two cysteines as 
prenylation sites, Rab6c contains a C-terminal extension of 46 amino acids, 
therefore lacks the C-terminal prenylation sequence needed for membrane 
attachement. 
Rab6a is the best-characterised Rab6 isoform and is also the subject of this 
work. Unless otherwise stated Rab6a will be referred to as Rab6. In terms of 
intrinsic GTP hydrolysis Rab6 represents a special member of the Rab family. 
Bergbrede et al., 2005 showed that recombinant Rab6, purified from E. coli, is 
extremely stable in its GTP bound state and displays a very slow intrinsic GTP 
hydrolysis rate. The rate of GTP hydolysis was in the case of Rab6 5.0 x 10-6 s-1, 
which is very slow compared to other Rab GTPases (Rab5: 5.5 x 10-4 s-1, Rab7: 4.5 
x 10-5 s-1) Therefore, Bergbrede et al., 2005 were able to crystallise, for the first 
time, a wild-type Rab (Rab6) together with bound GTP instead of using Rab mutants 
or complexes of wild-type Rab with non-hydrolysable GTP analogues. The structural 
data obtained from these Rab6 crystals could explain the slow GTP hydolysis rate of 
Rab6. First, Rab6 has a very flexible Switch II region, which is important for the 
catalytic mechanism of GTP hydrolysis, and more efficient when more constrained 
as in the case of Rab5. Second, a bulky tyrosine residue in Switch I forms hydrogen 
bonds with the γ-phosphate of GTP, thus shielding the active site like a lid. This 
tyrosine residue is absent in the fast hydrolysing Rab5, and could be important for a 
slow intrinsic hydrolysis rate. 
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Although Rab6 itself is well characterised, there is no GEF for Rab6 known to date 
and the circumstances of Rab6 activation remain obscure. Also the mechanism of 
Rab6 inactivation by GTP hydrolysis in coordination with a GAP is not fully 
understood. Some years ago, a protein called GAPCenA was published to act as 
Rab6 GAP on wild-type Rab6 (Cuif et al., 1999). However, functional in vivo data 
are missing and there are no follow-up studies confirming the role of GAPCenA as a 
Rab6 GAP. 
1.4.2 Rab6 function in membrane transport 
The role of Rab6 in membrane traffic has been studied intensively for more than ten 
years, yet there is some controversy within the published data. Whereas the 
majority of groups claim a function of Rab6 in retrograde transport, there are also 
publications in favour of Rab6 regulating forward transport. Most studies rely on the 
overexpression of Rab6 mutants, like Rab6Q72L (GTP restricted “active” mutant, 
which cannot hydrolyse GTP) and Rab6T27N (GDP restricted “inactive” mutant, which 
inhibits the GTP exchange reaction) (see also 1.3.2 and 1.3.3 and (Martinez et al., 
1994)). Following the trafficking of a soluble secreted form of alkaline phosphatase 
(SEAP) and of the membrane protein hemagglutinin of influenza virus (HA) in co-
expression with Rab6 wild-type and mutants Martinez et al., 1994 obtained the first 
hints for a role of Rab6 in maintaining Golgi morphology and membrane traffic within 
the Golgi stack. However, it was not clear from their data whether Rab6 acts rather 
by inhibiting forward or promoting retrograde transport. The same group showed 
some years later that Golgi resident proteins, like the trans Golgi enzyme β-1,4-
galactosyltransferase, become relocated to the ER upon over-expression of Rab6 
wild-type and Rab6Q72L (Martinez et al., 1997), which would rather speak for a 
positive regulation of retrograde transport by Rab6. 
Another approach to elucidate the function of Rab6 was taken by Mayer et al., 1996 
where the authors used Rab6 specific antibodies in a cell free Golgi membrane 
system. The authors found a block in cis to medial Golgi transport of the marker 
protein vesicular stomatitis virus protein G protein (VSV-G) when inhibiting Rab6 
function by antibodies and therefore concluded that Rab6 plays a role in promoting 
forward transport through the Golgi apparatus. In contrast, the study of Girod et al., 
1999 provides evidence for a Rab6 dependent Golgi to ER recycling pathway that is 
utilised by Golgi resident enzymes and Shiga toxin. Both, Golgi enzyme and Shiga 
toxin retrograde transport to the ER was blocked in Rab6T27N expressing cells. 
These data were supported by live cell fluorescent studies of White et al., 1999. 
Fluorescent-protein tagged Rab6 was expressed in HeLa cells and monitored 
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together with the retrograde cargo Shiga toxin. From the accumulation of Shiga 
toxin in Rab6 positive structures, which then fused with ER membranes, the authors 
concluded, that Rab6 defines special Golgi to ER retrograde transport carriers. 
These Rab6 positive transport carriers seem to act independently of the COPI 
machinery as proteins containing a KDEL-sequence were retrieved to the ER 
independently of Rab6 through the classical COPI-dependent retrograde pathway 
(Girod et al., 1999; White et al., 1999). The plant toxin Ricin, however, was reported 
to use neither the COPI nor the Rab6 dependent retrograde pathway to reach the 
ER (Chen et al., 2003), which leaves the question of how many different routes from 
the Golgi apparatus back to the ER exist. 
Another complication of the Rab6 story came along with the detection of a 
Rab6a splice variant that differs from Rab6a only by three amino acids and was 
called Rab6a’ (Echard et al., 2000). Whereas Mallard et al., 2002 proposed that 
Rab6a’ is functionally distinct from Rab6a, and regulates endosome to Golgi 
transport, Young et al., 2005 saw no functional difference between the two isoforms. 
The latter data were obtained using small interfering RNAs directed against either 
Rab6a or Rab6a’, while the study of Mallard et al., 2002 was based on over-
expression of mutant Rab6a and 6a’ proteins. The latest comparative study of 
Rab6a and 6a’ (Del Nery et al., 2006), though using sequence specific siRNA as 
well, comes to the conclusion that Rab6a and 6a’ fulfil different tasks in membrane 
trafficking. The authors suggest that, in contrast to earlier publications, Rab6a is 
dispensable in membrane traffic and Rab6a’ is the important splice variant 
regulating Golgi to ER trafficking, and additionally cell cycle progression in HeLa 
cells (Del Nery et al., 2006; Miserey-Lenkei et al., 2006). 
1.4.3 Rab6 effector proteins 
A link between Rab6 regulated transport processes and the cytoskeleton was 
provided by two independent research groups (Matanis et al., 2002; Short et al., 
2002). Both groups found that Rab6 binds the two mammalian homologues of 
Drosophila Bicaudal-D, Bic-D1 and Bic-D2. The coiled-coil proteins Bic-D1/2 have 
been shown to bind the dynein-dynactin motor complex through interaction with the 
dynamitin subunit of dynactin (Hoogenraad et al., 2001). Furthermore, Rab6 can 
interact directly with p150glued, a core component of the dynactin complex (Short et 
al., 2002). These findings suggest that Rab6 can interact with dynactin directly via 
p150glued or indirectly via Bic-D1/2. Hence, Rab6 together with Bic-D proteins may 
be involved in the dynein-dynactin dependent capture and movement of Golgi 
derived vesicles along microtubules. 
Introduction 
 
28 
Recently, the protein OCRL1 has been shown to bind several Rabs and interact 
strongest with the endosomal Rab5 and with the Golgi localised Rabs Rab1 and 
Rab6 (Hyvola et al., 2006). OCRL1 is an inositol polyphosphate 5-phosphatase and 
regulates the levels of different phosphoinositides at different places within the cell. 
Mutation of OCRL1 causes the x-chromosome linked disease oculocerebrorenal 
syndrome of Lowe, which underlines the importance of correct lipid signalling and 
regulation by lipid kinases and phosphatases. Interaction with Rab5 and Rab6 is 
required for OCRL1 localisation to endosomes and to the Golgi apparatus, 
respectively. Interestingly, Rab5 and Rab6 can also stimulate the phosphatase 
activity of OCRL1 after membrane recruitment (Hyvola et al., 2006) and over-
expression of an inactive form of OCRL1 changes endosome and Golgi morphology 
(Choudhury et al., 2005). This highlights, that regulation of membrane trafficking 
goes far beyond pure protein-protein interactions but also involves lipid-signalling 
pathways. 
Several other Rab6 binding proteins have been identified by yeast-2-hybrid 
screening or pulldown assays (Echard et al., 1998; Fridmann-Sirkis et al., 2004; 
Liewen et al., 2005; Monier et al., 2002; Rosing et al., 2007; Teber et al., 2005). Yet, 
their specificity and functional relationship with Rab6 remains to be explored. Rab6 
could play a role in various processes along Golgi related transport routes by 
recruiting different effector proteins. The best characterised Rab6 effector 
complexes to date are Bic-D1/2 and p150glued as linker to motor protein function for 
vesicle motility and OCRL1 as lipid phosphatase giving membrane identity to the 
Golgi complex and other organelles. 
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2 Identification and Characterisation of PIST as a novel 
Rab6 effector protein 
2.1 Aim of the work 
Rab6 is a Golgi localised Rab GTPase that can interact with the dynein-dynactin 
microtubule motor complex, either directly through the p150glued subunit or indirectly 
through the coiled-coil proteins Bic-D1 and Bic-D2 (Matanis et al., 2002; Short et al., 
2002). In this way, Rab6 facilitates the minus-end-directed transport of vesicles 
along microtubules. However, the nature of these Rab6 regulated transport vesicles 
and the exact function of minus-end-directed movement is unclear. In general, Rab 
GTPases act as molecular on/off switches for protein interactions. Only in their 
active GTP-bound state Rabs are able to recruit effector proteins, which then 
provide the functional properties needed. To find out more about the function of a 
specific Rab means at the same time to get to know its effector proteins. The aim of 
this part of the work was therefore to identify and characterise novel Rab6 effector 
proteins in order to elucidate the molecular mechanisms underlying Rab6 function. 
2.2 Results 
2.2.1 Identification of PIST as a putative Rab6 effector 
To identify novel Rab6 effector proteins a GST-pulldown experiment from rat liver 
cytosol was performed. The liver is an organ where extensive secretion takes place. 
Hence, liver cells are enriched in Golgi membranes and represent an ideal source 
for Golgi associated proteins. A simple membrane fraction procedure can be used to 
isolate two fractions, the Golgi membranes enriched in tightly associated Golgi 
membrane and peripheral membrane proteins, and a cytosolic fraction with more 
loosely associated and soluble Golgi proteins. For the GST-pulldown experiment, 
either the active GTP-restricted point mutant of human Rab6 (Rab6Q72L), or as a 
control the inactive GDP-restricted mutant Rab6T27N, were immobilised on 
glutathione sepharose. Both proteins were purified from E. coli as 6xHisGST fusion 
proteins using Ni-NTA agarose. Rab effector proteins are expected to bind 
preferentially the active GTP-bound conformation of a Rab (see 1.3). Coomassie 
brillant blue (CBB) staining of the eluates showed several bands in the pulldown 
with Rab6Q72L, which could not be seen in the control lane (Figure 2.1 A). MALDI-
TOF mass spectrometric analysis identified known Rab6 interaction partners 
p150glued and Bic-D2 (Matanis et al., 2002; Short et al., 2002), as well as a protein 
named PIST (PDZ domain protein interacting specifically with TC10). Tryptic 
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peptides derived from this protein were not found in the corresponding gel region of 
the control pulldown with Rab6T27N, suggesting that PIST may be a GTP-dependent 
binding protein of Rab6. 
 
 
Figure 2.1 Identification of PIST as a Rab6 interacting protein from rat liver cytosol. (A) CBB 
staining of the GST-pulldown experiment with Rab6T27N and Rab6Q72L. (B) Domain structure of 
the human 454 amino acid protein PIST with two coiled-coil (CC) regions and PDZ domain. 
PIST is a ubiquitously expressed 55 kDa protein also known as GOP/C (Golgi 
associated PDZ and coiled-coil motif containing protein), FIG (fused in glioblastoma) 
and CAL (CFTR associated ligand) (Charest et al., 2003; Cheng et al., 2002; 
Neudauer et al., 2001; Yao et al., 2001). PIST is not evolutionary conserved and is 
only found in mammals and primates. The rat protein discovered in the pulldown 
experiment exhibits approx. 90 % sequence identity with the human homologue. In 
humans there are two different isoforms of PIST (Entrez protein accession numbers 
NP_065132 (isoform A 462 aa’s) and NP_001017408 (isoform B 454 aa’s)). 
For cloning and subsequent biochemical and cell biological analysis, the nucleotide 
sequence encoding the PIST protein was amplified from a human liver cDNA library. 
Nucleotide sequence analysis showed that only the cDNA encoding the shorter 
isoform of the protein could be obtained. The shorter isoform lacks 8 amino acids 
within the N-terminal coiled-coil region of the protein, but so far there are no data 
available about functional differences between the two isoforms of the PIST protein. 
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PIST has a simple two domain architecture, and consists of two coiled-coil regions 
in the N-terminal half of the protein and a C-terminal PDZ domain (Figure 2.1 B). 
Coiled-coil protein folding motifs are thought to form extended rod-shaped 
structures, which can be both, rigid or highly dynamic and therefore fulfil various 
functions within the cell (Burkhard et al., 2001; Gillingham and Munro, 2003). The 
PDZ domain is a classical protein-protein interaction domain that binds C-terminal or 
internal peptide sequences in target proteins (Ponting et al., 1997). Often, PDZ 
domains are involved in scaffolding and assembly of multi-protein complexes. PIST 
was shown to bind via its PDZ domain the Wnt ligand receptor frizzled (Yao et al., 
2001), the plasma membrane chloride channel CFTR (Cheng et al., 2002), the 
neural transmembrane protein CALEB/NGC (Hassel et al., 2003) and the Rho 
effector Rhotekin (Ito et al., 2006) and could be involved in intracellular trafficking of 
these proteins. Furthermore, PIST was shown to interact with the Rho-family 
GTPase TC10 (Neudauer et al., 2001) and with the SNARE syntaxin6 (Charest et 
al., 2001). Still, the exact function of PIST remains obscure. PIST knock-out mice 
are viable and show no defects except infertility in male mice due to a lack in 
acrosome formation (Yao et al., 2002). 
2.2.2 Generation and validation of a PIST specific antibody 
In order to further investigate the Rab6 binding capacity of PIST and also the 
functional relationship of this interaction, a rabbit polyclonal antibody was generated. 
Full-length 6xHis-tagged human PIST was purified from E.coli and sent to Charles 
River Laboratories for immunisation (see 5.4.7). PIST specific antibodies were 
purified from the final bleed out. Figure 2.2 shows the characterisation of the purified 
antibody. R-α-PIST recognises recombinant 6xHis-PIST as well as endogenous 
PIST from HeLa extract in Western blotting (Figure 2.2 A). Also in 
immunoprecipitation (IP) from HeLa extract the antibody, but not the pre-immune 
serum, gives a clean and strong signal (Figure 2.2 B), which could be confirmed to 
be PIST by mass spectrometric analysis of a CBB stained immunoprecipitated band 
in a similar experiment (see Figure 2.12). 
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Figure 2.2 Characterisation of the purified PIST antibody in Western blotting (A) and 
immunoprecipitation (B). (A) R-α-PIST was tested on 20 µg HeLa extract and on 20 ng 
recombinant 6xHis-PIST. (B) An immunoprecipitation experiment was performed using either 
pre-immune serum or purified R-α-PIST. Precipitated PIST was detected on a Western blot by 
R-α-PIST and HRP-coupled proteinA. 
2.2.3 PIST binds Rab6 in a GTP-dependent fashion 
The rat homologue of PIST was identified in a large-scale Rab6 pulldown from rat 
liver cytosol. To confirm the interaction of human PIST with Rab6 a pulldown 
experiment from HeLa cell extract was performed and probed with the validated 
PIST specific antibody. Bacterially expressed GST-tagged Rab6 was used as wild-
type, active GTP-restricted mutant and inactive GDP-restricted mutant. Rab effector 
proteins are expected to bind the active pool of a Rab in its GTP-bound 
conformation, which is mimicked by the QL mutant and also represented by a 
fraction of wild-type Rab. On the contrary, effectors should not bind the GDP-bound 
conformation of the Rab, mimicked by the TN mutant (see 1.3). 
In Figure 2.3 this is true for the known Rab6 interactors p150glued and Bic-D1 
(Matanis et al., 2002; Short et al., 2002). p150glued, a dynactin core component, is 
precipitated with Rab6wt and Rab6Q72L, but not with Rab6T27N. Compared to the input 
lane relatively little p150glued is in complex with Rab6. This can be explained by the 
fact that p150glued/dynactin has various functions and binding partners within the cell 
(Habermann et al., 2001; Vaughan et al., 2002; Watson et al., 2005; Watson and 
Stephens, 2006) and obviously only a small proportion functions together with Rab6 
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at the Golgi apparatus. Also Bic-D1 is precipitated by Rab6Q72L, but only very little 
by wild-type Rab6, which cannot be explained at this point. Unspecific signals in the 
Rab6T72N pulldown, marked by asterisks, are most likely cross-reactions with 
impurities in the Rab6T72N protein preparation. 
PIST shows the same pattern of Rab6 binding like p150glued in the same 
pulldown experiment and is bound by Rab6wt and Rab6Q72L but not Rab6T27N. The 
coiled-coil protein p115, known to interact with Rab1 at the cis-Golgi (Allan et al., 
2000; Moyer et al., 2001), served as a negative control and could not be detected in 
the Rab6 pulldown. Therefore it can be concluded that the GST-pulldown was 
specific for Rab6 binding proteins and that human PIST binds Rab6 in a GTP-
dependent manner. 
 
Figure 2.3 PIST binds Rab6 in a GTP-dependent fashion. Pulldown experiment from HeLa cell 
lysate with recombinant GST-tagged Rab6 wild-type (wt) and active (Q72L) and inactive 
(T27N) mutant. The Western blot containing the input of HeLa extract and the pulldown 
reactions was probed for PIST, p150glued, Bic-D1 and p115. Asterisks mark unspecific signals 
of the Bic-D1 antibody in the Rab6T27N pulldown. 
2.2.4 PIST is a specific binding partner of Rab6 and not of TC10 
PIST was reported to interact with the Rho family GTPase TC10 in yeast two-hybrid 
and in an in vitro binding assay (Neudauer et al., 2001). However, the authors did 
not examine the full-length protein but only a fragment of PIST (amino acids 155-
320), which corresponds to the second coiled-coil, a bit of the PDZ domain and the 
sequence inbetween these domains.  
To clarify the point whether full-length PIST is able to bind TC10 or Rab6, or 
both GTPases to the same extent, the nucleotide sequence encoding the TC10 
protein was amplified from a human fetus cDNA library. First, primers were 
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designed and used according to the mRNA sequence corresponding to the TC10 
protein described in Neudauer et al., 2001 (Entrez nucleotide accession number 
AF498976). However, even several PCRs did not produce amplified DNA of the 
expected length. After an extensive search of expressed sequence tags (ESTs) for 
the respective TC10 sequence, AF498976 turned out to be wrong. Instead, in all 
corresponding ESTs, an insertion of two nucleotides after the putative TC10 start 
codon shifted the reading frame and turned the second ATG into the real start 
codon. In summary, the originally described TC10 protein used in Neudauer et al., 
2001 was 8 amino acids too long at the N-terminus and therefore an artefact. The 
new TC10 gene sequence was published recently as Ras homolog gene family 
member Q (ARHQ) under the Entrez number NM_012249. 
In order to address the question of specificity of the PIST-Rab6 interaction a 
comprehensive yeast two-hybrid analysis with full-length PIST against a 
representative set of Rab GTPases and against TC10 was carried out (Figure 2.4). 
The nucleotide sequence encoding the PIST protein was fused to the nucleotide 
sequence of the activation domain of the GAL4 promotor (GAL4 AD) in the vector 
pAct2, and the nucleotide sequences encoding the respective GTPases were fused 
to the nucleotide sequence of the GAL4 binding domain (GAL4 BD) in the vector 
pFBT9. The resultant fusion proteins were screened for interaction in the host strain 
PJ69-4A allowing for growth on QDO medium lacking the amino acids leucin, 
tryptophan, adenin and histidin. Tested against 52 Rab GTPases in their GTP-
restricted conformation (QL mutants) PIST interacted with Rab6a and Rab6b only 
(Figure 2.4). At the same time PIST did not interact with TC10Q67L (Figure 2.4), 
suggesting that among the tested GTPases full-length PIST is specific for Rab6 in 
yeast two-hybrid.  
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Figure 2.4 PIST is a specific binding partner of Rab6 in yeast two-hybrid. Yeast two-hybrid 
interaction of full-length PIST against a set of human Rabs and the Rho GTPase TC10 in the 
active conformation (QL mutant). Transformants were grown on synthetic complete medium 
lacking leucin and tryptophan (SC –LW) and interaction was screened on quadrupel drop-out 
medium (QDO) lacking the amino acids leucin, tryptophan, adenin and histidin. 
In Neudauer et al., 2001 the authors claim that recombinant PIST(155-320) binds 
TC10 in vitro. However, this result could not be verified using full-length PIST in an 
in vitro binding assay with GST-tagged TC10 (Figure 2.5). 6xHis-tagged PIST was 
binding GST-Rab6wt and GST-Rab6Q72L but not GST-Rab6T27N, confirming a GTP-
dependency of the interaction. No binding at all could be observed to GST-TC10 
protein, neither to wild-type nor to the active QL mutant. The recovery of GTPase 
was comparable for all binding reactions (bound) except for TC10T23N. This can be 
neglected because effector proteins are not expected to bind the inactive TN mutant 
anyway. The fact that there is no visible band of PIST in the TC10 binding reactions 
with wild-type and active TC10 (TC10Q67L) supports the conclusion that PIST is not 
interacting with TC10 in vitro. Compared to the loading of PIST (1 µg) Rab6-bound 
PIST was in the µg range, suggesting a stable binding of these proteins. 
Furthermore, the direct binding experiment showed that the interaction of PIST with 
Rab6 is direct and not mediated by other proteins. 
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Figure 2.5 PIST does not bind TC10 but Rab6 in vitro. CBB staining of an in vitro binding 
assay of 6xHis-tagged PIST with GST-tagged Rab6 or TC10 GTPase as wild-type, active 
mutant (QL) and inactive mutant (TN). For comparison 1 µg of PIST and of the GTPase (input) 
is shown next to the binding reaction (bound). 
2.2.5 PIST is a Golgi localised protein 
Rab6 is a trans Golgi localised GTPase and the interaction of active Rab6 with PIST 
should therefore take place at the Golgi apparatus. Immunofluorescence staining 
with the purified PIST specific antibody R-α-PIST showed, that PIST localises to the 
perinuclear region of HeLa cells (Figure 2.6). Co-staining with the Golgi markers 
GM130, Golgin97 and TGN46 revealed that PIST is a Golgi localised protein. 
TGN46, like its rat homologue TGN38, is an extensively glycosylated type 1 
membrane protein which localises primarily to the trans Golgi network (TGN) (Luzio 
et al., 1990; Ponnambalam et al., 1996). Also Golgin97 was shown to be a TGN 
localised protein (Griffith et al., 1997), whereas GM130 is a cis-Golgi localised Golgi 
matrix protein (Nakamura et al., 1995). As there is a better overlap of PIST staining 
with the trans Golgi markers Golgin97 and TGN46 than with the cis Golgi marker 
GM130, PIST is supposed to be a protein associated with the trans Golgi 
compartments. 
Because the only available antibody against Rab6 is a rabbit polyclonal 
antibody, cells could not be stained for PIST and Rab6 at the same time. However, 
in its active state Rab6 is anchored in Golgi membranes and could therefore be 
regulating the recruitment of PIST to the Golgi apparatus. PIST does not contain 
any transmembrane regions or lipid modifications for membrane anchoring and is 
therefore regarded a cytosolic protein (Charest et al., 2001). How PIST is recruited 
to the Golgi was therefore examined further. 
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Figure 2.6 PIST is a Golgi localised protein. Immunofluorescent staining of HeLa cells with 
purified R-a-PIST (red), costained for the Golgi markers GM130, Golgin97 and TGN46 (green). 
DNA was visualised with DAPI (blue). Bar indicates 10 µm in all panels. 
2.2.6 Domain specific Rab6 binding and Golgi localisation of PIST 
In addition to a PDZ domain in the C-terminal region PIST possesses two coiled-coil 
stretches in the N-terminal half. Coiled-coil proteins have been shown before to 
interact with small GTPases of the Rab and Arl family to be recruited to membrane 
domains (reviewed in Barr and Short, 2003 and Short et al., 2005). Thus, the 
question was, which domain in PIST mediates Rab6 binding and whether the 
interaction with Rab6 is a prerequisite for the Golgi targeting of PIST. 
For this purpose five different fragments of PIST were generated representing 
different combinations of the first and second coiled-coil domain (CC1 and CC2) and 
the PDZ domain (Figure 2.7 A). In yeast two-hybrid analysis with Rab6Q72L only 
PIST fragments containing CC1, that is PISTfl, PIST1-255 and PIST1-141, were able to 
interact with Rab6, detected by growth on QDO (Figure 2.7 A). This result could be 
reproduced with recombinant proteins in an in vitro binding experiment using 6xHis-
tagged PIST and GST-tagged Rab6 proteins. Whereas proteins with CC1 bound the 
GTP-restricted mutant Rab6Q72L (Figure 2.7 B, closed triangles), proteins with CC2 
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and/ or the PDZ domain were not able to bind Rab6 in vitro (Figure 2.7 B, open 
triangles). One construct (PIST142-255) containing CC2 could not be expressed in E. 
coli and was therefore not tested in this assay. However, this PIST fragment did not 
interact with Rab6 in yeast two-hybrid and is furthermore represented by the longer 
fragment PIST142-454, which did not bind Rab6 in vitro. All Rab6 binding PIST 
fragments (PISTfl, PIST1-255 and PIST1-141) exhibit specificity for the active Rab6 
mutant (Rab6Q72L) and do not bind inactive Rab6T27N. Therefore the first coiled-coil 
region of PIST is required for GTP-dependent Rab6 binding. 
 
 
Figure 2.7 The first coiled-coil domain of PIST is required for Rab6 binding. (A) Yeast two-
hybrid analysis of interaction of GAL4 AD-PIST fusion proteins with the GAL4 BD-Rab6Q72L 
fusion protein. Also shown is the schematic of dissecting full-length PIST into fragments. (B) 
CBB staining of an in vitro binding assay of 6xHis-tagged PIST fragments with GST-tagged 
Rab6, highlighting bound PIST with closed and unbound PIST with open triangles. 
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As PIST carries no structural features for direct membrane insertion or association, 
its localisation to Golgi membranes is most likely dependent on protein-protein or 
protein-lipid interactions. Whether Rab6 binding is required to target PIST to the 
Golgi apparatus should be addressed by overexpression of GFP-tagged PIST frag-
ments in HeLa cells (Figure 2.8). In untreated HeLa cells the GFP signal of PISTfl 
and  PIST1-255 was found almost exclusively in the perinuclear region whereas the 
signal of PIST142-255 and PIST142-454 was less clear at the Golgi and showed cytosolic 
background staining. PIST1-141 and PIST256-454 were targeted mainly to the nucleus. 
However, coiled-coil regions as well as PDZ domains tend to dimerise and PIST has 
been previously shown to form homodimers (Neudauer et al., 2001). In order to 
make sure that Golgi targeting of GFP-PIST is not due to dimerisation with the 
endogenous protein, the localisation of GFP-PIST fragments was also determined in 
HeLa cells depleted of PIST by siRNA prior to transfection with GFP-constructs (see 
Figure 2.15 for PIST siRNA). Because the siRNA duplex was directed against a 
sequence within the PDZ domain of PIST the GFP signal of PISTfl, PIST142-454 and 
PIST256-454 was silenced and only PIST1-255, PIST1-141 and PIST142-255 could be 
detected in the siRNA background. Out off these three, PIST1-255 (CC1 and CC2) 
showed Golgi targeting and PIST142-255 (CC2) a less prominent perinuclear signal 
with high cytosolic background, similar to the result seen with control cells. PIST1-141 
(CC1) was again not able to target to the Golgi and was mainly nuclear as in control 
cells. 
These results suggest that the second coiled-coil domain of PIST is sufficient 
to localise the protein at Golgi membranes. However, a better targeting is achieved 
when both coiled-coils are present. In contrast, CC1 alone is not enough for Golgi 
localisation of PIST while the PDZ domain seems to have no impact on the 
intracellular targeting of the protein. 
Taken together, these results show that the Golgi localised protein PIST is 
able to bind Rab6 via its first coiled-coil domain, as shown in Figure 2.7. However, 
the interaction with Rab6 seems not to be the critical step for the localisation of PIST 
to Golgi membranes, because in overexpression experiments another part of the 
protein, the second coiled-coil region is required for Golgi targeting (Figure 2.8). A 
summary of both, Rab6 binding and Golgi targeting of the various PIST fragments is 
shown in Figure 2.9. 
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Figure 2.8 PIST targets to the Golgi apparatus via CC2. HeLa cells, either untreated or 
depleted of PIST by siRNA, were transfected with GFP-PIST constructs for 24 hours and fixed. 
Bar indicates 10 µm in all panels. 
 
Figure 2.9 PIST binds Rab6 via CC1 and targets to the Golgi via CC2. Depicted here is a 
summary of the results from Figure 2.7 and Figure 2.8. 
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2.2.7 Interfering with Rab6 levels does not affect PIST at the Golgi 
The data from chapter 2.2.6 indicate that PIST localises to Golgi membranes 
independently of Rab6. To further test this, the role of Rab6 in PIST targeting was 
characterised in more detail. If PIST's localisation is indeed independent of Rab6, 
altering levels of Rab6, especially decreasing active membrane bound Rab6, should 
not affect the distribution of PIST at the Golgi. 
Over-expression of Rab mutants is one tool to interfere with the endogenous 
level of active GTPase. The pool of active Rab is increased by over-expression of 
the GTP-restricted QL mutant whereas the pool of inactive Rab is elevated by over-
expression of the GDP-restricted TN mutant. Over-expression of wild-type Rab 
controls general effects, generated by increased Rab levels independent of the 
mutation. Rab effector interactions occur with the active state of the GTPase and 
should in theory be titrated out by the inactive TN mutant. If an effector protein 
requires the interaction with active Rab for its membrane localisation, its localisation 
should be altered in cells expressing inactive Rab. 
Figure 2.10 displays the over-expression of GFP-Rab6wt, GFP-Rab6Q72L and 
GFP-Rab6T27N in HeLa cells. Co-staining with the transmembrane protein TGN46 
proves that the Golgi morphology was normal in transfected and untransfected cells 
and that GFP-Rab6wt and GFP-Rab6Q72L localised to the Golgi, whereas GFP-
Rab6T27N was mainly distributed in the cytosol and in the nucleus. Golgin160, a 
peripheral Golgi membrane protein (Fritzler et al., 1993; Misumi et al., 1997), was 
unaltered in all Rab6 transfected cells. Also PIST did not change its Golgi 
localisation irrespective of which Rab mutant was over-expressed, consistent with 
the idea that PIST targets to the Golgi independently of Rab6. However, Bic–D1, 
another Rab6 effector protein which was described to target to the TGN in a Rab6 
dependent fashion (Matanis et al., 2002), was not displaced from the Golgi by the 
over-expression of the inactive mutant GFP-Rab6T27N. This is an unexpected result 
and weakens the significance of the over-expression experiment. 
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Figure 2.10 Rab6 over-
expression has no effect 
on the Golgi localisation of 
PIST. HeLa cells were 
transfected for 24 hours 
with GFP-Rab6wt, GFP-
Rab6Q72L and GFP-
Rab6T27N (green), fixed 
and stained for Bic-D1, 
PIST, Golgin160 and 
TGN46 (red). DNA was 
visualised with DAPI (blue). 
Bar indicates 10 µm in all 
panels. 
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The limitation of over-expressing Rab mutants in cells is probably the presence of 
the endogenous Rab, which could mask any effects of the mutant proteins. Thus, 
another approach was taken to analyse the influence of Rab6 on the Golgi locali-
sation of PIST, depletion of Rab6 from cells using small interfering RNA (siRNA). 
The result of this approach is depicted in Figure 2.11. Compared to control 
cells depleted of the nuclear envelope protein LaminA (Elbashir et al., 2001) Rab6 
staining was gone after 72 hours of Rab6 siRNA while the staining pattern for 
TGN46 and p115 was unaltered, representing a normal Golgi morphology in HeLa 
cells. The polyclonal antibody against Rab6 exhibits a high cytosolic and nuclear 
background staining, but the Golgi localised pool of Rab6 was clearly reduced in 
Rab6 siRNA, suggesting that little or no active GTPase was left. Under these 
conditions PIST was unchanged, and it localised to the normal Golgi structure 
marked by TGN46 as in control cells. On the other hand, Bic-D1 staining was clearly 
lost from the Golgi in Rab6 depleted cells suggesting that Bic-D1 indeed needs to 
bind Rab6 to be targeted to Golgi membranes whereas PIST relies on other binding 
partners or mechanisms for Golgi localisation. 
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Figure 2.11 Depletion of Rab6 by siRNA redistributes Bic-D1 off the Golgi but has no effect on 
the localisation of PIST. HeLa cells were transfected with either Rab6 or LaminA siRNA 
duplexes for 72 hours, fixed and stained for Rab6, PIST or Bic-D1 (red) and TGN46 or p115 
(green). DNA was visualised with DAPI (blue). Bar indicates 10 µm in all panels. 
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2.2.8 Golgin160 is a binding partner of PIST 
Known binding partners of PIST are so far restricted to its PDZ domain and seem to 
be cargo proteins instead of targeting factors for PIST (Cheng et al., 2002; Hassel et 
al., 2003; Ito et al., 2006; Wente et al., 2005; Yao et al., 2001). Therefore, identifying 
proteins important for recruitment of PIST to the Golgi could help explaining the 
function of PIST and of Rab6. In order to identify so far unknown binding partners 
for PIST a large-scale immunoprecipitation (IP) was performed (Figure 2.12). Assay 
buffer or 293T total cell lysate was incubated with either pre-immune serum as 
unspecific control or the purified R-α-PIST antibody to precipitate PIST specific 
binding proteins. Bands visible also in the buffer control, originating from the 
antibody preparation itself, were ignored and only bands visible in the IP with R-α-
PIST from 293T extract were excised. A gel piece of the corresponding position and 
size in the lane of the IP with pre-immune serum was excised as well to serve as a 
background control for mass spectrometric analysis. A faintly staining band in the 
molecular weight region of 160 – 180 kDa was identified by MALDI-TOF as the 
known Golgi localised protein Golgin160 (Fritzler et al., 1993; Misumi et al., 1997). 
The strongly staining band above the antibody heavy chain (about 55 kDa) turned 
out to be PIST itself. 
 
 
Figure 2.12 CBB staining of a large-scale immunoprecipitation (IP) from 293T extract, leading 
to the identification of Golgin160 as a binding partner of PIST. 
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Golgin160 is a peripheral membrane protein at the cytoplasmic face of Golgi 
membranes. Hicks and Machamer, 2002 showed that its N-terminal head domain is 
required for Golgi targeting, but the exact mechanism is unknown. The C-terminal 
two thirds of the protein are made of coiled-coil regions. Thus, Golgin160 belongs to 
the family of golgins, which are implicated in the maintenance of Golgi structure and 
integrity of membrane trafficking pathways (Barr and Short, 2003). Interestingly, the 
head of Golgin160 is cleaved by caspase-2 during apoptosis. The cleavage is 
required for the efficient disassembly of the Golgi and the propagation of apoptotic 
signals (Maag et al., 2005; Mancini et al., 2000). Interactions with Golgin160 at the 
Golgi could therefore be important for the structural integrity of Golgi membranes. 
The nature and functional relationship of the interaction of PIST with Golgin160 
should be examined further. 
Golgin160 could be confirmed as a binding partner for PIST via yeast two-
hybrid analysis and immunoprecipitation from HeLa extract (Figure 2.13). In yeast 
two-hybrid analysis, full-length Golgin160 interacted strongly with PISTfl and 
PIST142-454 but not with the other fragments of PIST (Figure 2.13 A). The binding 
region within PIST might be positioned in-between the second coiled-coil and the 
PDZ domain because neither PIST142-255, containing CC2, nor PIST256-454, 
containing PDZ, gave a signal with Golgin160 in yeast two-hybrid analysis. In an 
immunoprecipitation experiment Golgin160 could be co-precipitated together with 
PIST by the PIST specific antibody R-α-PIST (Figure 2.13 B). Compared to the 
amount of PIST in total cell extract, the bulk of the protein was precipitated by the 
antibody and nothing at all by pre-immune serum. Golgin160 was co-precipitated, 
however, relatively little compared to the amount of protein in the loaded HeLa 
extract. Still, both proteins bound each other and the question remained whether 
Golgin160 could be the targeting factor for PIST being localised at the Golgi. 
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Figure 2.13 Golgin160 is a binding partner of PIST. (A) Yeast two-hybrid analysis of full-length 
Golgin160 against PIST full-length and PIST fragments, screening for interaction on QDO 
medium. (B) Co-immunoprecipitation of PIST and Golgin160 from HeLa extract by R-a-PIST. 
2.2.9 PIST is unaltered in Golgin160 depleted cells  
To address the role of Golgin160 in terms of PIST targeting and function Golgin160 
was depleted from HeLa cells using siRNA. After 72 hours of siRNA Golgin160 
protein levels dropped below the detection threshold in western blotting (Figure 2.14 
A). GM130 and PIST levels remained the same in LaminA control siRNA and 
Golgin160 siRNA. Equal tubulin levels are shown as a loading control for equal total 
protein amounts on the blot. When Golgin160 depleted cells were stained for 
TGN46 a partial breakdown of the Golgi ribbon structure into ministacks was 
observed (Figure 2.14 B). PIST, and also Rab6, remained Golgi localised in these 
ministacks, as seen by the overlap with the TGN46 signal. 
These results suggest that Golgin160 has no impact on the localisation of 
PIST at Golgi membranes. However, Golgin160 seems to function in maintaining 
the ribbon-like structure of the Golgi as in cells without detectable Golgin160 the 
ribbons break apart to form ministacks. 
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Figure 2.14 Depletion of Golgin160 by siRNA has no effect on the Golgi localisation of PIST. 
(A) Western blot of LaminA and Golgin160 siRNA cells probed for Golgin160, GM130, PIST 
and Tubulin. (B) Immunofluorescence of LaminA and Golgin160 siRNA cells, stained for 
Golgin160, Rab6 or PIST (red) and TGN46 (green). DNA was visualised with DAPI (blue). Bar 
indicates 10 µm in all panels. 
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2.2.10 Depletion of PIST does not have an effect on Golgi structure 
So far it is unclear how and why PIST is targeted to Golgi membranes. As a coiled-
coil protein it might also fulfil structural functions within the Golgi stack, like many 
other coiled-coil proteins are building up the so-called Golgi matrix (Barr and Short, 
2003). In this case depletion of PIST would most likely result in a change of Golgi 
structure, as seen with cells depleted of Golgin160 (Figure 2.14) and other Golgins. 
However, knockdown of PIST by siRNA had no such effect, as can be seen in 
Figure 2.15. After 72 hours of PIST siRNA the level of PIST in HeLa cells was 
clearly reduced, whereas GM130 was equal to control conditions (Figure 2.15 A). 
Tubulin was probed to show equal protein levels of LaminA control and PIST siRNA 
samples on the Western blot. Also in immunofluorescence PIST was depleted after 
72 hours of siRNA. Under these conditions both Golgi markers GM130 and TGN46 
were unaltered as well as the PIST binding partners Rab6 and Golgin160 (Figure 
2.15 B). So, PIST depletion has neither an effect on Golgi structure nor on its 
binding partners Rab6 and Golgin160 which leaves the question about PIST’s 
function in HeLa cells still unanswered. 
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Figure 2.15 Depletion of PIST by siRNA has no effect on Golgi morphology and the 
localisation of Rab6 and Golgin160. (A) Western blot of LaminA and PIST siRNA cells probed 
for PIST, GM130 and Tubulin. (B) Immunofluorescence of LaminA and PIST siRNA cells, 
stained for PIST, Rab6 or Golgin160 (red) and GM130 or TGN46 (green). DNA was visualised 
with DAPI (blue). Bar indicates 10 µm in all panels. 
Results 
 
51 
2.3 Conclusions 
In this part of the work the coiled-coil and PDZ domain protein PIST was identified 
and characterised as a novel Rab6 binding protein. For the characterisation of PIST 
a polyclonal antibody was generated and validated. Both, the recombinant protein 
purified from E. coli and endogenous PIST from HeLa extract bound Rab6 in a GTP-
dependent manner. Yeast two-hybrid analysis as well as direct binding assays 
showed that the N-terminal coiled-coil region of PIST is necessary for the interaction 
with Rab6. Within the Rab family of GTPases the interaction of PIST is specific for 
Rab6. An interaction with the Rho family GTPase TC10, as published by Neudauer 
et al., 2001, could not be confirmed, either by yeast two-hybrid analysis or by direct 
binding assays. Additionally, when cloning the TC10 gene, the original database 
entry turned out to contain errors. According to expressed sequence data and 
confirmed by cloning of the respective nucleotide sequence from various cDNA 
libraries, the sequence of the TC10 protein is 8 amino acids shorter from the N-
terminus than published by Neudauer et al., 2001. 
Immunofluorescent staining of HeLa cells revealed that PIST is a Golgi 
localised protein. The Golgi targeting region was mapped to the second coiled-coil 
domain of PIST. Also in cells depleted of endogenous PIST the second coiled-coil 
was sufficient to localise to Golgi membranes. Thus, Rab6 binding and Golgi 
localisation are accomplished by two different regions in PIST, namely the first 
coiled-coil for Rab6 binding and the second coiled-coil region for Golgi localisation. 
In line with this, alteration of Rab6 levels by over-expression or siRNA had no effect 
on the Golgi localisation of PIST. Subsequently, the search for PIST binding 
proteins should clarify the question how PIST is targeted to the Golgi apparatus, 
where it interacts with Rab6. A member of the golgin family, Golgin160 was 
identified to co-immunoprecipitate with PIST from cell extract. The interaction 
between PIST and Golgin160 could be confirmed by yeast two-hybrid analysis, 
where full-length PIST and a region containing the second coiled-coil plus the 
sequence before the PDZ domain bound Golgin160. The depletion of Golgin160 
using siRNA resulted in a fragmentation of the Golgi into mini stacks, but had no 
effects on the localisation of PIST to Golgi membranes. Concomitantly, the siRNA-
mediated depletion of PIST exhibited no apparent phenotype on Golgi structure and 
localisation of its binding proteins Golgin160 and Rab6. 
In summary, PIST is a high affinity binding partner of Rab6 in vitro and in 
vivo, but the functional relationship between these proteins remains unclear. The 
Golgi localised coiled-coil protein Golgin160 is also capable of binding PIST, but not 
required to target PIST to Golgi membranes. 
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3 Rab GTPase-activating proteins defining Shiga toxin 
and epidermal growth factor uptake pathways 
3.1 Aim of the work 
Activated Rab GTPases regulate membrane trafficking steps by recruiting effector 
proteins with various functions to a target membrane. The active state of a Rab is 
switched off by interaction with its specific Rab GTPase-activating protein (GAP), 
which catalyses the GTP hydrolysis reaction and turns the Rab into the inactive 
GDP-bound state. It has been shown before in the case of Rab5 that transient 
expression of a RabGAP can be used to inactivate the endogenous pool of a Rab 
and in this way interfere with the process this Rab is involved in (Haas et al., 2005). 
Non-specific effects of RabGAP expression can easily be discriminated from the 
specific effects of Rab inactivation by use of an inactive point mutant in which the 
catalytic arginine residue is replaced by alanine (Haas et al., 2005). 
The retrograde transport of Shiga toxin from the cell surface to the ER is a 
multi-step process (Sandvig et al., 2002). Because each membrane trafficking step 
is thought to be regulated by a discrete set of Rabs (Zerial and McBride, 2001), it is 
likely that several Rabs are implicated in Shiga toxin trafficking. However, only Rab6 
has been shown to be involved in the retrograde transport of Shiga toxin to date 
(Girod et al., 1999; Mallard et al., 2002; White et al., 1999). In order to better 
understand the mechanisms of retrograde trafficking, the aim of this part of the work 
was to identify Rab GAPs that interfere with the transport of Shiga toxin from the cell 
surface to the Golgi apparatus. First, conditions to follow Shiga toxin within the cell 
were established and validated using the published Rab6 GAP GAPCenA (Cuif et 
al., 1999). To find Rab GAPs that act specifically on the retrograde route of Shiga 
toxin to the Golgi and not on general endocytic pathways, a second functional assay 
for the uptake of epidermal growth factor (EGF) and its receptor to early endosomes 
was used. In total, 39 human TBC domain proteins, predicted to act as Rab GAPs, 
were screened in both Shiga toxin transport and EGF uptake assays. In combination 
with biochemical analysis, of the 60 Rabs and 39 RabGAPs, respective Rab – 
RabGAP pairs involved in either pathway were then identified. 
3.2 Results 
3.2.1 Establishment of the Shiga toxin and EGF retrograde transport assay 
One method to study Shiga toxin trafficking is to use of fluorescently labelled B-
subunit (STxB) in combination with immunofluorescence microscopy. Toxin B-
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subunit can be recombinantly expressed and purified from E. coli (see 5.7.1). Cells 
are then incubated with fluorescently labelled B-subunit and observed over a period 
of time. Together with intracellular markers, like resident Golgi proteins, the 
transport of STxB can be followed. This assay can be performed in a high-
throughput format and was therefore suitable to screen Rab GAPs for their ability to 
inhibit retrograde transport of Shiga toxin between the plasma membrane and the 
Golgi apparatus 
 To establish the right conditions for uptake and retrograde transport of the 
Shiga Toxin B-subunit (STxB) to the Golgi apparatus a time course experiment was 
performed (see Figure 3.1). Fluorescently labelled STxB was bound to HeLa cells 
on ice for 30 minutes, before starting the uptake of the toxin at 37 °C by quenching 
with warm growth medium. The cells were fixed with PFA after the indicated times 
and imaged by immunofluorescence microscopy. Initially (0 min), fluorescently 
labelled B-subunit was bound to the cell surface of HeLa cells. After 30 minutes at 
37 °C STxB was internalised and had partially reached the Golgi, marked by co-
staining with the cis-Golgi marker GM130. This Golgi associated pool of STxB was 
clearly visible in the majority of cells after 60 minutes of uptake. 
 
 
Figure 3.1 Shiga toxin B-subunit (STxB) reaches the Golgi compartment after 60 minutes. 
Fluorescently labelled STxB (red) was bound to the surface HeLa cells on ice (0 min) and 
internalised at 37 °C for 30 or 60 minutes. Co-staining with GM130 (green) marked the Golgi 
apparatus, DNA was visualised with DAPI (blue). Bar indicates 10 µm in all panels. 
Results 
 
54 
Earlier steps in STxB endocytosis were visualised by another time course 
experiment in a co-uptake with fluorescently labelled epidermal growth factor (EGF). 
It is known from previous experiments that EGF uptake and trafficking to the early 
endosome takes place within the first 20 to 30 minutes at 37 °C (Haas et al., 2005). 
Therefore this experiments shows if STxB follows the same route as EGF before 
being diverted to the Golgi apparatus. Figure 3.2 shows that both ligands bound to 
the cell surface of HeLa cells efficiently, and became internalised into small punctate 
structures after 10 to 20 minutes. After this, the two markers separated and STxB 
accumulated in the perinuclear region from 30 to 60 minutes, shown before to 
correspond to Golgi stacks (Figure 3.1), while EGF remained in punctate endosomal 
structures best visible after 30 minutes. Interestingly, while both ligands have been 
reported to be taken up by clathrin dependent pathways (Nichols et al., 2001; 
Sandvig et al., 1989) the kinetics of uptake were clearly different. This indicates that 
there may be some differences in the mechanistic details of the two uptake 
pathways, such as the requirement for Rab GTPases. For further experiments, it 
was therefore decided to take 60 minutes uptake of Shiga toxin to measure the 
efficiency of its transport to the Golgi, and 30 minutes uptake of EGF to measure its 
uptake into early endosomes. 
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Figure 3.2 Comparison of the Shiga toxin and EGF uptake pathways. Fluorescently labelled 
STxB (red) and EGF (green) were bound to the surface of HeLa cells (0 min) and internalised 
at 37 °C for the indicated times. DNA was visualised with DAPI (blue). Bar indicates 10 µm in 
all panels. 
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3.2.2 Shiga toxin transport but not EGF uptake is Rab6 dependent 
Rab6 has been shown before to be required for Shiga Toxin transport from 
endosomes to the Golgi apparatus (Mallard et al., 2002; White et al., 1999) while the 
uptake of EGF should be Rab6 independent. To verify this, the effects of Rab6 
depletion were examined (Figure 3.3 and Figure 3.4). Both isoforms of Rab6, 
Rab6a/a’ and Rab6b, were depleted using siRNA and immunostained with 
antibodies against the trans Golgi marker TGN46, the Rab6 effector protein Bic-D1 
and Rab6 itself (shown in Figure 3.3 A). According to the antibody staining Rab6 
seemed to be depleted from Rab6 siRNA cells while Golgi structure was like in 
control cells. Importantly, the Rab6 effector Bic-D1 (Matanis et al., 2002; Short et al., 
2002) was redistributed from Golgi membranes to the cytoplasm in Rab6 siRNA 
cells, which served as a control for the efficient depletion of the active pool of Rab6. 
Additionally, cells depleted of Rab6 and control cells were transfected with 
GFP-tagged versions of either Rab6a or Rab6b for 24 hours and probed on Western 
blot for GFP signal (Figure 3.3 B). After a total of 72 hours siRNA for Rab6a or 
Rab6b both GFP-tagged proteins were reduced or completely depleted compared to 
the expression in control cells. Tubulin was probed as a loading control, the levels of 
which were equal in Rab6 siRNA and control cells. Because over-expressed Rab6 
was depleted by specific single siRNAs it was assumed, that also the endogenous 
pools of Rab6a/a’ and Rab6b were gone in the treatment with both siRNA duplexes 
mixed 1:1. In further descriptions this treatment will be called simply Rab6 siRNA. 
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Figure 3.3 Depletion of Rab6a and Rab6b by siRNA. (A) HeLa cells were treated for 72 hours 
with mixed Rab6a and Rab6b (1:1) siRNA duplexes and stained with antibodies against Rab6 
or Bic-D1 (red) and the trans Golgi marker TGN46 (green). DNA was visualised with DAPI 
(blue). Bar indicates 10 µm in all panels. (B) HeLa cells treated for 48 hours with either control 
(-) or specific (+) siRNA duplexes were transfected for 24 hours with constructs for the 
corresponding GFP-tagged Rab as indicated in the figure. Cell extracts were western blotted 
for GFP to detect the expression of the Rabs. Blots were re-probed for tubulin as a loading 
control.  
Subsequently Rab6 depleted HeLa cells were assayed for STxB and EGF uptake. 
Figure 3.4 depicts the immunofluorescent pictures of this experiment. Whereas in 
control siRNA cells STxB was transported to the trans Golgi network efficiently, 
marked by the strong perinuclear signal overlapping with TGN46 staining (60 min), 
the Golgi localised pool of STxB in Rab6 siRNA was significantly reduced. This 
reduction was not due to reduced STxB levels in general as initial binding of the 
toxin B-subunit (0 min) was comparable. However, no complete block of STxB 
transport to the Golgi could be observed, which might be linked to siRNA efficiency 
or redundancy of Rab regulated transport pathways. 
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The partial block of STxB in Rab6 depleted cells seemed to be specific because 
EGF was taken up normally into early endosomal structures, marked by EEA1, in 
both control and Rab6 siRNA cells. 
 
 
Figure 3.4 Shiga toxin but not EGF uptake is Rab6 dependent. HeLa cells were treated for 72 
hours with control or Rab6 siRNA and used for STxB (red) or EGF (green) uptake assays and 
co-stained for TGN46 (green) or EEA1 (red). DNA was visualised with DAPI (blue). Bar 
indicates 10 µm in all panels. 
For functional studies of a Rab GTPase, shifting the GTPase cycle towards inactive 
Rab GTPase by over-expression of its specific GTPase activating protein (GAP) can 
be used as a method instead of depleting the Rab itself by siRNA. This was shown 
before to work beautifully with Rab5 and its GAP RabGAP-5 (Haas et al., 2005). 
Since this method overcomes the problem of siRNA efficiency and specificity it 
should be tested whether the GAP for Rab6 could inhibit Shiga toxin transport to the 
Golgi equally well or even more efficiently than shown in the Rab6 siRNA 
experiment. 
Results 
 
59 
3.2.3 TBC1D11/GAPCenA acts on Rab4 and does not block Shiga toxin 
transport 
It has previously been reported that TBC1D11/GAPCenA is the GAP for Rab6 (Cuif 
et al., 1999) and this was therefore tested for its ability to block trafficking of Shiga 
toxin to the Golgi apparatus (Figure 3.5). Surprisingly the expression of GAPCenA 
had no obvious effect on the transport of Shiga toxin to the Golgi apparatus (Figure 
3.5 A). STxB was bound to the surface evenly (0 min) and had reached the 
perinuclear compartment after 60 minutes in both, transfected and untransfected 
cells. Also, the ability of Rab6 or of the Rab6-dependent effector Bic–D1 to target to 
Golgi membranes was not impaired in GAPCenA expressing cells (Figure 3.5 B). 
 
 
Figure 3.5 TBC1D11/GAPCenA does not block Shiga toxin transport. (A) HeLa cells 
transfected with GFP-tagged TBC1D11/GAPCenA (green) were used for Shiga toxin uptake 
assays (red). (B) The ability of Rab6 or Bic-D1 (red) to localise to the Golgi was tested in cells 
expressing GFP-tagged TBC1D11/GAPCenA (green). DNA was visualised with DAPI. Bar 
indicates 10 µm in all panels. 
GAPCenA was therefore investigated further to find out if it has the biochemical 
properties expected of a Rab6 GAP. Confirming previous findings (Cuif et al., 1999), 
a C-terminal fragment of GAPCenA was identified when Rab6 was screened against 
a yeast-two-hybrid cDNA library. However, this fragment corresponding to a 
predicted coiled-coil region adjacent to the GAP domain (aa 723-998) does not 
show specific interaction with Rab6, and binds human Rabs of many different 
subfamilies when tested against a representative collection of human Rabs (Figure 
3.6). When full-length GAPCenA was tested, it showed a strong interaction with 
Rab4, a weaker interaction with Rab11, and only a very weak interaction with Rab6. 
A more detailed analysis, where GAPCenA deletion mutants lacking the N-terminal 
PTB domain (aa 201-998) or the C-terminal coiled-coil region (aa 1-723) were 
tested, revealed that regions N- and C-terminal to the core TBC domain contribute 
to the recognition of specific Rabs. 
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Figure 3.6 Interaction specificity of TBC1D11/GAPCenA with human Rab GTPases involves 
regions outside the TBC domain. A schematic of TBC1D11/GAPCenA shows the putative 
phosphotyrosine binding domain (PTB; blue), the TBC domain (red), and a C-terminal coiled-
coil region (green). GTP-locked mutants of the Rabs indicated were tested using the yeast 
two-hybrid assay against full-length TBC1D11/GAPCenA, deletion mutants lacking the N-
terminal PTB domain or the C-terminal predicted coiled-coil region, and the C-terminal coiled-
coil region only, which was identified by an unbiased yeast two-hybrid library screen. In all 
cases, five independent colonies were tested on SC-LW and QDO. Growth on QDO indicates 
an interaction between bait and prey. 
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These results suggested that Rab6 might not be the target for TBC1D11/GAPCenA 
after all, and biochemical assays were carried out to test this. For measuring GTP-
hydrolysis Rab proteins were first loaded with GTP, which was traced with [γ-32P]-
GTP, and then incubated together with TBC1D11/GAPCenA (see 5.7.4). In 
agreement with the yeast two-hybrid data, TBC1D11/GAPCenA had strong GAP 
activity towards Rab4 and a lesser activity towards Rab11 (Figure 3.7). Only very 
weak activity was detected towards Rab2 and Rab14, which fall into the same Rab 
subfamily as Rabs 4 and 11, showing that TBC1D11/GAPCenA can discriminate 
between closely related Rabs. No significant activity could be detected towards 
Rab6 or any of the other Rabs tested (Figure 3.7). It was previously suggested that 
Rab6 has to be prenylated in order to be an efficient substrate for 
TBC1D11/GAPCenA (Cuif et al., 1999). However, no GAP activity could be seen 
when prenylated Rab6 purified from insect cells was used (Figure 3.7, Rab6Sf9). It 
should be also noted that Rab4 was prepared in bacteria, and therefore not 
prenylated, yet was still an excellent substrate for TBC1D11/GAPCenA. In 
summary, these data show that TBC1D11/GAPCenA is a GAP for Rab4 but not 
Rab6, and that it does not alter the trafficking of Shiga toxin to the Golgi apparatus. 
 
 
Figure 3.7 TBC1D11/GAPCenA is a GAP for Rab4. GAP assays were performed using 0.5 pmol 
recombinant TBC1D11/GAPCenA (filled bars) or a buffer control (open bars) and 100 pmol of 
the Rabs indicated in the figure. Two preparations of Rab6 were used: one from bacteria 
(Rab6), the other a prenylated preparation produced in insect cells (Rab6Sf9). 
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3.2.4 A subset of human RabGAPs influences Shiga toxin transport 
An unbiased approach was therefore taken to identify which RabGAPs act on the 
Shiga toxin transport pathway. Cells expressing the various predicted wild type 
human RabGAPs were tested blindly for their ability to inhibit the transport of Shiga 
toxin to the Golgi apparatus (Table 3.1 and Figure 3.8). Candidate positives from the 
first round of screening were then re-tested, comparing the effects of wild type GAP 
to that of catalytically inactive point mutant. In this screen, 6 of 39 predicted GAPs 
showed catalytic activity dependent effects on Shiga toxin trafficking to the Golgi 
apparatus: EVI5, RN-tre, TBC1D10A, TBC1D10B, TBC1D10C and TBC1D17 (Table 
3.1, white on dark gray background and Figure 3.8). 
Table 3.1 Effects of human TBC-domain containing proteins on Shiga toxin transport. HeLa 
cells were transfected for 24 h with GFP-tagged wild type or catalytically inactive Rab GAPs. 
These cells were then used for Shiga toxin B-subunit (STxB) or EGF-uptake assays, and the 
uptake of STxB and EGF scored at 1 h or 30 minutes, respectively. A 0 minute time point was 
also taken to verify that both STxB and EGF were bound to the cell surface with equal 
efficiency for all conditions. The localization of the GFP-tagged Rab GAPs was also scored. 
Fields with dark gray background show the positive Rab GAP candidates blocking STxB. 
Empty fields mean “not determined” (nd). Notes: 1) Some highly expressing cells failed to 
bind EGF at the zero time point, indicating a defect in the trafficking of EGF receptor to the 
cell surface. However, the majority of cells bound and took up EGF as normal. 2) The 
RabGAP-5 GAP domain was used for this experiment. 3.) The PARIS-1 longer splice variant 
gave results indistinguishable from TBC1D2. 4) Expression triggered extensive cell death. 
Wild type TBC domain Catalytically inactive TBC domain 
Rab GAP 
STxB 
(1h) 
GAP 
localization 
EGF 
(30 min) Golgi 
STxB 
(1 h) 
GAP 
localization 
EGF 
(30 min) 
EVI-5 Golgi and 
vesicular 
Cytosolic Early 
endosomes1 
Intact Golgi Tubules, 
cytosolic 
nd 
RN-tre Cell 
surface 
and 
vesicular 
Cell surface Early 
endosomes1 
Fragmented Golgi Cell surface nd 
RUTBC1 Golgi Cytosolic, 
nuclear 
Early 
endosomes 
    
RUTBC2 Golgi Cytosolic Early 
endosomes 
    
RabGAP-5 
(RUTBC3) 
Golgi Cytosolic Cell surface Intact Golgi2 Cytosolic Early endosomes 
TBC1D1 Golgi Cytosolic Early 
endosomes 
    
TBC1D23 Golgi Cytosolic Early 
endosomes 
    
TBC1D3B4 Recycling 
endosomes 
Vacuoles nd     
TBC1D4 Golgi Cytosolic Early 
endosomes 
    
TBC1D5 Golgi Cytosolic Early 
endosomes 
    
TBC1D6 nd       
TBC1D7 Golgi Cytosolic, 
nuclear 
Early 
endosomes 
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Wild type TBC domain Catalytically inactive TBC domain 
Rab GAP 
STxB 
(1h) 
GAP 
localization 
EGF 
(30 min) Golgi 
STxB 
(1 h) 
GAP 
localization 
EGF 
(30 min) 
TBC1D8 Golgi Reticular, 
cytosolic 
Early 
endosomes 
    
TBC1D10A Recycling 
endosomes 
Cell surface Early 
endosomes1 
Intact Golgi Cell surface nd 
TBC1D10B Recycling 
endosomes 
Cell surface Early 
endosomes 
Intact Golgi Cell surface nd 
TBC1D10C Recycling 
endosomes 
Filopodia, 
cell surface 
Early 
endosomes 
Intact Golgi Cell surface nd 
TBC1D11 
(GAPCenA) 
Golgi Cytosolic Early 
endosomes 
Intact nd nd nd 
TBC1D12 nd       
TBC1D13 Golgi Cytosolic, 
nuclear 
nd     
TBC1D14 Recycling 
endosomes 
Recycling 
endosomes 
Early 
endosomes 
Fragmented Recycling 
endosomes 
Recycling 
endosomes 
nd 
TBC1D15 Golgi 
fragments 
Cytosolic, 
nuclear 
Early 
endosomes1 
Fragmented    
TBC1D16 Golgi Cytosolic nd     
TBC1D17 Vesicular Cytosolic Early 
endosomes 
Intact Golgi Cytosolic nd 
TBC1D18 Golgi Cytosolic nd     
TBC1D19 Golgi Cytosolic, 
nuclear 
nd     
TBC1D20 Vesicular ER Early 
endosomes1 
Fragmented    
TBC1D21 Golgi Cytosolic nd     
TBC1D22A Golgi 
fragments  
Cytosolic, 
nuclear 
Early 
endosomes 
Fragmented Recycling 
endosomes 
Cytosolic/ 
nuclear 
nd 
TBC1D22B Golgi 
fragments 
Cytosolic, 
nuclear 
Early 
endosomes 
Fragmented Recycling 
endosomes 
Cytosolic/ 
nuclear 
nd 
USP6 Golgi Cell surface nd     
AK074305 Golgi Cytosolic nd 
 
    
KIAA1055 Golgi Cytosolic nd     
KIAA0676 Golgi Cytosolic nd     
KIAA0882 nd       
NP_060222 nd       
NP_060779 Golgi Cytosolic, 
Golgi 
nd     
EVI5-like Golgi Cytosolic, 
aggregates 
nd     
KIAA0984 Vesicular Cytosolic, 
aggregates 
Early 
endosomes1 
Fragmented Vesicular Cytosolic, 
aggregates 
nd 
KIAA1171 Golgi Cell surface nd     
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Figure 3.8 A subset of human Rab GAPs influence Shiga toxin transport. Shiga Toxin uptake 
assays were performed on HeLa cells transfected with a library of wild type human Rab GAPs 
listed in Table 3.1. Those Rab GAPs showing a block in Shiga toxin uptake were re-tested as 
catalytically inactive RA mutants. (A) To measure the extent of Shiga toxin uptake, cells were 
fixed and stained for a Golgi marker. The percentage of untransfected and transfected cells 
where STxB had not reached the Golgi was counted for each condition, and the specific 
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reduction in Shiga toxin transport calculated by subtracting these two figures (transfected – 
untransfected cells). These numbers are plotted on the bar graph. The dotted line indicates 
the cut-off chosen for consideration as a positive. (B) Images of the Rab GAPs (green) 
showing a catalytic activity dependent block or reduction in Shiga toxin (red) uptake after 60 
minutes are shown. DNA was visualised with DAPI (blue). Bar indicates 10 µm in all panels. 
TBC1D14 was excluded from the list of positive candidate GAPs after the second 
round of screening because the inhibitory effect on Shiga toxin trafficking was also 
seen with the catalytically inactive mutant of TBC1D14 suggesting that these effects 
were not due to Rab inactivation but due to another mechanism independent of the 
GAP activity of TBC1D14. 
To confirm that the lack of a Golgi signal for Shiga toxin after 60 minutes of 
uptake was not simply due to disruption of the Golgi, the integrity of this organelle 
was tested using markers for the cis- and trans-Golgi compartments (Figure 3.9). 
This resulted in the elimination of GAPs such as TBC1D22A and TBC1D22B where 
the Golgi was fragmented and Shiga toxin was found to localise to these fragments. 
In contrast, RN-tre, although fragmenting the Golgi (Figure 3.9), caused a block of 
Shiga toxin in more peripheral structures discrete from the Golgi dependent on its 
catalytic activity and was therefore counted as a positive (Figure 3.8). It should be 
noted already at this point that RabGAP-5, a Rab5 GAP (Haas et al., 2005), did not 
show a phenotype in Shiga toxin uptake (see Figure 3.8 A) pointing to the fact that 
Shiga toxin endocytosis is independent of Rab5. 
The question remained whether any of the positive Rab GAPs blocking Shiga 
toxin transport to the Golgi apparatus acts on Rab6. To answer this, positive Rab 
GAPs were co-transfected with the Rab6 effector Bic-D1, whose Golgi localisation is 
dependent on active Rab6 (Figure 3.3). Interestingly, none of the positive GAPs 
were able to cause release of Bic-D1 from Golgi membranes (Figure 3.10), 
suggesting that they do not act on Rab6 but rather on other Rab GTPases. 
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Figure 3.9 Effect of Rab GAPs blocking Shiga toxin uptake on Golgi morphology. HeLa cells 
transfected for 24 hours with the GFP-tagged Rab GAPs (green) indicated in the figure were 
fixed and then stained for GM130 (blue) and TGN46 (red). Bar indicates 10 µm in all panels. 
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Figure 3.10 Effect of Rab GAPs blocking Shiga toxin uptake on the Rab6 effector Bic-D1. HeLa 
cells co-transfected for 24 hours with the GFP-tagged Rab GAPs (green) indicated in the 
figure and Myc-tagged Bic-D1 (red) were fixed and then stained with mouse anti-Myc 
antibodies and Cy3-conjugated anti-mouse secondaries. DNA was visualised with DAPI 
(blue). Bar indicates 10 µm in all panels. 
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To further validate the screening results observed with the fluorescently labelled B-
subunit of Shiga toxin, screen positives were tested for their ability to protect cells 
against the cytotoxic effects of fully active Shiga-like toxin 1 (Figure 3.11). This 
assay measures protein synthesis, which is inhibited if Shiga toxin can reach the ER 
and enter the cytoplasm and is therefore a more stringent measure of Shiga toxin 
trafficking than fluorescent assays (Spooner et al., 2004). Figure 3.11 shows that 
EVI5, RN-tre and TBC1D17 indeed protected cells against Shiga-like toxin 1. The 
IC50 values in wild-type GAP expressing cells were significantly higher than in RA 
mutant GAP expressing cells, and the protection was between 1.87- and 3.35 fold. 
The TBC1D10 family of GAPs showed variable extents of protection, it is therefore 
unclear if these represent specific positives with this assay. Importantly, RabGAP-5, 
with a fold protection of 1.07, did not exhibit a protective effect, and this is in perfect 
consistency with the fluorescent data (Figure 3.8). 
 
 
Figure 3.11 A subset of human Rab GAPs protects cells against fully active Shiga-like toxin 1. 
Cytotoxicity assays were performed using the Rab GAPs listed in the figure. The IC50 of 
Shiga-like toxin 1 was measured in HeLa cells expressing either the wild type (WT) or the 
catalytically inactive (RA) mutant GAPs. These values were then corrected for transfection 
efficiency averaging 13.9 - 18.7 %. An increase in the IC50 for WT compared with RA GAPs 
indicates reduced cytotoxicity, which is plotted in the graph as the fold protection, with 1 
(dotted line) corresponding to no protection (n ≥ 3). The corrected IC50 values for each 
condition are shown above each column, and the IC50 of empty vector-transfected control 
cells was 3.5 ng/ml. Error bars represent SD. 
In summary, this means that the trafficking pathway of Shiga toxin from the cell 
surface to the Golgi is defined by the Rab GAPs EVI5, RN-tre and TBC1D17, and 
possibly the TBC1D10 family. 
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3.2.5 Only RabGAP-5 is able to block EGF uptake 
Next it should be determined whether the inhibitory effect of this set of Rab GAPs is 
specific for the Shiga toxin pathway or whether they also give a block in endocytosis 
of epidermal growth factor (EGF). In order to address this question in an unbiased 
way the full set of human Rab GAP candidates (Table 3.1) was tested blindly in 
EGF uptake assays (Figure 3.12). Since EGF was not bound to all cells equally, 
both the percentage of transfected cells not binding EGF at 0 minutes and of cells 
showing a block of EGF endocytosis at 30 minutes were counted and compared in 
Figure 3.12 A. The result clearly shows that only one Rab GAP, that is RabGAP-5, 
was able to block EGF transport to early endosomes, whereas the Shiga toxin 
blocking Rab GAPs had no effect on endocytosis of EGF (Figure 3.12 B). 
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Figure 3.12 Rab GAPs altering Shiga toxin  transport do not prevent EGF uptake. (A) EGF 
uptake assays were performed on HeLa cells transfected with a library of wild type human 
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Rab GAPs listed in Table 3.1. The number of cells binding and then taking up EGF was 
counted. The graph shows cells either failing to bind (open bars) or take up (filled bars) EGF. 
(B) The initial bound EGF at 0 minutes of transport, and extent of EGF transport at 30 minutes 
are shown for GAPs that had an effect on Shiga toxin transport, as indicated in the figure. 
EGF is in red, transfected Rab GAPs in green and DNA is stained in blue. Bar indicates 10 µm 
in all panels. 
3.2.6 Different RabGAPs define Shiga toxin and EGF uptake pathways 
Although RN-tre was initially suggested to act on Rab5 and hence the EGF uptake 
pathway (Lanzetti et al., 2000), more recently another GAP, RabGAP-5 has also 
been proposed to fulfil this function (Haas et al., 2005). To clarify this point, the 
effects of RN-tre and RabGAP-5 on the uptake of EGF and Shiga toxin were directly 
compared (Figure 3.13 and Figure 3.14). RabGAP-5 was able to block the uptake of 
EGF (Figure 3.13 A), and to displace the Rab5-dependent effector molecule EEA1 
from endosomes (Figure 3.13 B) which is consistent with its function of inactivating 
Rab5. RN-tre or the catalytically inactive point mutant of RabGAP-5 did not show 
these effects on EGF uptake. Also, the localisation of EEA1 on endosomes is 
normal in RN-tre or RabGAP-5R165A expressing cells. 
In contrast, RN-tre was able to block the transport of Shiga toxin to the Golgi 
apparatus (Figure 3.14 A) and caused partial fragmentation of the Golgi apparatus 
(Figure 3.14 B), consistent with previous observations that its target, Rab43✷, is 
localised to this organelle (Haas et al., 2005). RabGAP-5 or the catalytically inactive 
point mutant of RN-treR150A did not show these effects on Shiga toxin transport and 
Golgi structure. 
In some cells expressing very high levels of RN-tre EGF uptake was indeed 
blocked. However, further investigation revealed that these cells lack detectable 
EGF receptor on the cell surface, and therefore the apparent uptake block is due to 
lack of EGF binding, and not a defect in endocytosis of the receptor-ligand complex. 
One explanation for the reduced level of EGF receptor at the cell surface could be 
the disrupted Golgi apparatus seen in RN-tre expressing cells (Figure 3.14 B). So, 
any effects of RN-tre on EGF receptor uptake would appear to be indirect. 
                                            
✷ Note that Rab43 was previously referred to as Rab41 (Haas2005), which is consistent with the 
naming in mice. However, the gene nomenclature has been clarified, so that this gene is now called 
Rab43 in human and mouse. 
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Figure 3.13 RabGAP-5 but not RN-tre defines the EGF uptake pathway. (A and B) HeLa cells 
were transfected for 24 hours with RabGAP-5, the catalytically inactive mutant RabGAP-5R165A, 
or RN-tre. (A) EGF uptake assays were performed, and the initial bound EGF at 0 minutes of 
transport, and the extent of EGF transport at 30 minutes are shown in the figure. EGF is in 
red, transfected Rab GAPs in green and DNA is stained in blue. (B) The cells were stained for 
the transfected Rab GAPs (green) and  EEA1 (red). DNA was visualised with DAPI (blue). Bar 
indicates 10 µm in all panels. 
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Figure 3.14 RN-tre but not RabGAP-5 defines the Shiga toxin transport pathway. (A and B) 
HeLa cells were transfected for 24 hours with RN-tre, the catalytically inactive mutant RN-
treR150A, or RabGAP-5. (A) Shiga toxin uptake assays were performed, and the initial bound 
STxB at 0 minutes of transport, and the extent of STxB transport at 60 minutes are shown in 
the figure. STxB is in red, transfected Rab GAPs in green and DNA is stained in blue. (B) The 
cells were stained for the transfected Rab GAPs (green) and  GM130 (red). DNA was 
visualised with DAPI (blue). Bar indicates 10 µm in all panels. 
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3.2.7 Biochemical identification of target Rabs 
It was shown before that six out of 39 human Rab GAPs could block the transport of 
Shiga toxin to the Golgi apparatus (Figure 3.8 and Figure 3.11), and only RabGAP-5 
the endocytosis of EGF (Figure 3.12). For a better understanding of the molecular 
details of Shiga toxin and EGF trafficking it would be necessary to know the target 
Rabs of the positive Rab GAPs. Therefore these GAPs were tested for their ability 
to accelerate GTP hydrolysis by a specific Rab in biochemical assays with a 
representative set of human Rabs (Figure 3.15). At least one member of every Rab 
subfamily was tested. For every Rab GAP all the indicated Rabs were analysed in 
the very same experiment, so that GTP-hydrolysis rates could be compared directly 
within the set of Rabs. These data clearly show that of the Rabs tested, the Rab5a-c 
subfamily are substrates for RabGAP-5, while RN-tre acts on Rab43. EVI5 showed 
strong and specific activity towards Rab35, with over 1200 pmoles GTP hydrolysed 
per hour, however, Rab35 was found to be weakly (6-fold less) activated with a 
number of the GAPs tested here, suggesting that this may be a false positive hit. 
The substrate of TBC1D10B and TBC1D17 could not be identified with certainty 
from the data obtained. Careful analysis of the pattern of GTP hydrolysis, suggests 
that TBC1D10B might act on Rab22a/ Rab31, which fall into the same branch of the 
Rab5 subfamily, while TBC1D17 might be a GAP for Rab21 (Figure 3.15). 
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Figure 3.15 Biochemical screening for the target Rabs of specific TBC-domain proteins. 
Biochemical assays for GTP-hydrolysis were performed with the Rabs and GAPs indicated, 
using the procedure described in the methods. All reactions were carried out for 60 minutes. 
To determine the specific activity towards a range of GTPases, 0.5 pmoles RN-tre, RabGAP-5, 
EVI5, TBC1D10B, and TBC1D17 were tested against 100 pmoles of the Rab GTPase indicated. 
The basal GTP hydrolysis seen with a buffer control was substracted for each GTPase. 
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3.2.8 Functional verification of target Rabs for RN-tre and RabGAP-5 
If the effects of RabGAP-5 on EGF uptake are mediated through Rab5, and those of 
RN-tre on Shiga toxin transport are mediated through Rab43, then cells depleted of 
these Rabs should display a similar defect like that seen on over-expressing the 
respective GAP, since both conditions reduce the pool of active Rab on target 
membranes. This was tested by siRNA experiments depleting either the Rab5a-c 
subfamily or Rab43 from HeLa cells (Figure 3.16 F) and testing these cells in EGF 
and Shiga toxin uptake assays (Figure 3.16 A-D). 
In line with the prediction, EEA1 failed to localise to endosomes and there 
was a strong reduction in EGF uptake in cells depleted of Rab5 (Figure 3.16 A). 
These cells were still able to transport Shiga toxin to the Golgi apparatus similar to 
the control cells (Figure 3.16 B). In contrast the Golgi was disorganised and there 
was a strong reduction in the transport of Shiga toxin to the Golgi in cells depleted of 
Rab43 (Figure 3.16 C). However, these cells were still able to take up EGF similar 
to the control cells (Figure 3.16 D). Consistent with a role for RN-tre and Rab43 in 
the transport of Shiga toxin to the Golgi apparatus, Rab43 localised to this organelle 
and showed a staining pattern most similar to the trans-Golgi marker TGN46 (Figure 
3.16 E). Rab43 showed no overlap with the early endosome marker EEA1 (Figure 
3.16 E), suggesting it does not function at early endosomes. 
To control the efficiency of siRNA mediated knockdown, cells depleted of 
Rabs 5a-c or 43 and control cells were transfected with GFP-tagged versions of 
either Rab5a, 5b, 5c or Rab43 for 24 hours and probed on Western blot for GFP 
signal (Figure 3.16 F). After a total of 72 hours siRNA for Rab5a-c or Rab43 each 
GFP-tagged protein was reduced or completely depleted compared to the 
expression in control cells. Tubulin was probed as a loading control, the levels of 
which were equal in Rab5a-c or Rab43 siRNA and control cells. Because over-
expressed Rabs were depleted by specific siRNAs it was assumed, that also the 
endogenous pools of the respective Rabs were depleted from cells. 
Depletion of Rab21, Rab22a, Rab31 and Rab35 by RNA interference had no 
clear effects on either Shiga toxin or EGF uptake (data not shown) and it is therefore 
unclear if these Rabs are the targets of the TBC1D10 family of GAPs, TBC1D17, 
and EVI5. Thus, it will require further investigation to find and validate the targets of 
these GAPs. 
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Figure 3.16 Functional verification of the targets of RN-tre and RabGAP-5. HeLa cells were 
transfected with siRNA duplexes to deplete (A and B) all three isoforms of Rab5, or (C and D) 
Rab43. (A and D) EGF uptake assays were performed, and the extent of EGF transport at 30 
minutes is shown in the figure. EGF is in green, and EEA1 is in red. (B and C) Shiga toxin 
uptake experiments were performed, and the extent of STxB transport to the Golgi at 60 
minutes is shown in the figure. STxB is in red and GM130 is in green. (E) HeLa cells 
transfected with GFP-tagged Rab43 (green) for 24 hours were stained  with antibodies to the 
Golgi marker TGN46 or the early-endosome marker EEA1 (red). DNA is stained blue in all 
panels. Bar indicates 10 µm in all panels. (F) HeLa cells treated for 48 hours with either 
control (-) or specific (+) siRNA duplexes were transfected for 24 hours with constructs for the 
corresponding GFP-tagged Rab as indicated in the figure. Cell extracts were western blotted 
for GFP to detect the expression of the Rabs. Blots were re-probed for tubulin as a loading 
control. 
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In summary, these observations support two important conclusions. Firstly, that RN-
tre specifically blocks Rab43 dependent trafficking of Shiga toxin to the trans-Golgi 
apparatus, and that EGF does not follow this pathway. Secondly, that RabGAP-5 
specifically blocks the Rab5 dependent trafficking of EGF through early endosomes, 
and that Shiga toxin does not follow this pathway. These two Rab GAPs and their 
target Rabs therefore define specific trafficking routes for Shiga toxin and EGF. 
3.3 Conclusion 
In this part of the work, 39 human TBC domain proteins and putative RabGAPs 
were tested for their ability to block the transport of STxB to the Golgi apparatus or 
the uptake of EGF into early endosomes. 
Before, the optimal conditions for both functional assays were established 
and validated. The two ligands showed different kinetics of early endocytic steps. 
Whereas EGF uptake was very rapid and the bulk of the ligand had reached the 
early endosome after 30 minutes, transport of STxB was slower and STxB was best 
visisble at the Golgi apparatus after 60 minutes at 37 °C. Consistent with published 
data (Mallard et al., 2002; White et al., 1999), the depletion of Rab6a/a’ and Rab6b 
by siRNA resulted in a partial block of STxB transport to the Golgi. However, the 
published Rab6 GAP TBC1D11/GAPCenA (Cuif et al., 1999) did not show any 
effect on the trafficking of STxB and could therefore not be confirmed as a GAP for 
Rab6. In contrast, TBC1D11/GAPCenA turned out to act as a GAP for Rab4 both, in 
extensive yeast-2-hybrid analysis and in biochemical assays. 
The screen for RabGAPs blocking the transport of STxB to the Golgi 
apparatus produced 6 positive candidates: EVI-5, RN-tre, TBC1D10A, TBC1D10B, 
TBC1D10C and TBC1D17. None of these proteins could redistribute the Rab6 
effector protein Bic-D1 from Golgi membranes, which hints to the fact that none acts 
on Rab6. In a side-by-side screen for TBC domain proteins blocking the endocytosis 
of EGF only RabGAP-5 proved positive. Interestingly, RabGAP-5 was specific for 
the EGF uptake route and had no effect on STxB trafficking. To further strengthen 
the results of the screenings with fluorescent STxB, all screen positives were tested 
in a cytotoxicity assay measuring the arrival of fully active Shiga-like 1 holotoxin in 
the ER and cytoplasm, where the toxin inhibits proteins synthesis of the host cell. In 
agreement with the fluorescent data, EVI-5, RN-tre and TBC1D17 were able to 
protect the cell significantly against intoxication by Shiga-like toxin 1, whereas 
RabGAP-5 could not. The effect of the TBC1D10 family was less clear. Biochemical 
analysis measuring the GAP activity of the screen positives with a representative set 
of human Rabs confirmed RabGAP-5 as a specific GAP for the Rab5 family (a-c) 
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and RN-tre as a specific GAP for the Golgi localised Rab43. In direct comparison, 
RabGAP-5 expression as well as Rab5 depletion by siRNA resulted in a block of 
EGF but not of STxB, whereas RN-tre expression as well as Rab43 depletion by 
siRNA blocked STxB transport but not EGF uptake. These two RabGAPs and their 
target Rabs therefore define specific trafficking routes for Shiga toxin and EGF. In 
summary, EGF trafficking through early endosomes is a Rab5 dependent pathway, 
which is not followed by Shiga toxin. Instead, the transport of Shiga toxin to the 
Golgi apparatus is dependent on Rab43. 
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4 Discussion 
4.1 The novel Rab6 binding protein PIST 
The Golgi localised GTPase Rab6 regulates the minus-end-directed transport of 
vesicles along microtubules. This is accomplished through the interaction of Rab6 
with the dynein-dynactin motor complex, either directly through the p150glued subunit 
of dynactin or indirectly through the coiled-coil proteins Bic-D1 and Bic-D2 (Matanis 
et al., 2002; Short et al., 2002). However, the nature of these Rab6 regulated 
transport vesicles and the exact mechanism of minus-end-directed movement is 
unclear. In order to achieve a better understanding of the molecular mechanisms 
underlying Rab6 function a screen for novel Rab6 effector proteins was carried out. 
This led to the identification of the coiled-coil and PDZ domain protein PIST as a 
Rab6 binding protein. 
4.1.1 PIST binds Rab6 with high affinity and specificity 
When tested against a representative set of Rab family members in their active 
state (QL mutants) in yeast two-hybrid PIST showed an interaction with Rab6 (a and 
b isoforms) only. This suggests that, within the family of Rab GTPases, PIST is a 
specific binding partner for Rab6. The use of Rab mutants, where the conserved 
glutamine of the G-domain (DxxGQ) is replaced with leucine (QL mutant) is thought 
to lock the Rab in its active state where GTP cannot be hydrolysed (Martinez et al., 
1994). As Rab effector proteins bind specifically to the active conformation of a Rab, 
Rab QL mutants are used to stabilise the Rab effector interaction. In a yeast two-
hybrid assay a stable interaction of the two fusion proteins (GAL4AD- and GAL4BD-
fusion) is essential for promoter activation and growth of the transformed yeast on 
quadruple drop-out medium (QDO). Short-lived interactions, such as enzyme-
substrate reactions are therefore likely to be difficult to detect with the yeast two-
hybrid system. Assuming that all QL mutants of the Rab GTPases used are 
efficiently locked in their active state and exhibit a similar behaviour towards effector 
protein binding in yeast two-hybrid, PIST interacts specifically with Rab6. 
 The PIST-Rab6 interaction is dependent on the active GTP-bound state of 
Rab6 as shown in GST–pulldown and –binding assays with recombinant Rab6. For 
both experiments bacterially expressed GST-tagged Rab6 was loaded either with 
GTP (wild-type and QL mutant) or GDP (TN mutant). Because Rab6 possesses a 
very low intrinsic rate of GTP-hydrolysis (Bergbrede et al., 2005), wild-type Rab6 is 
stable in its active GTP-bound state for the period of several days at 4 °C (Tim 
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Bergbrede, personal communication). Both, endogenous PIST from HeLa extract 
and recombinant full-length PIST bound Rab6 in its active state (wild-type and QL 
mutant) but not in its inactive conformation mimicked by the TN mutant. The fact 
that purified recombinant PIST binds Rab6 suggests that the interaction is direct and 
not mediated by an additional factor. 
Known Rab6 effectors like Bic-D1 and p150glued were used as controls for the 
efficiency of the pulldown reaction from HeLa cell extract and showed the same 
band pattern like PIST, namely binding of wild-type Rab6 and the QL mutant but not 
the TN mutant of Rab6. The signal for bound dynactin subunit p150glued appears to 
be very weak. This can be explained by the fact that the dynein-dynactin motor 
complex fulfils various functions within the cell (Habermann et al., 2001; Vaughan et 
al., 2002; Watson et al., 2005; Watson and Stephens, 2006) and only a small 
fraction of the complex interacts with Rab6 at the Golgi. Also the Bic-D1 signal in 
complex with wild-type Rab6 was not as strong as expected from a real effector 
protein. The affinity of the rabbit polyclonal Bic-D1 antibody (generated by Johannes 
Egerer, this laboratory) is obviously not sufficient for efficient detection of the 
antigen. The detection of unspecific, wrong sized bands in the pulldown reaction 
with Rab6T27N suggests that the Bic-D1 antibody cross-reacts with impurities in the 
protein preparation of Rab6T27N. 
Long coiled-coil proteins tend to aggregate in vitro, which lead to unspecific 
signals in binding assays. As a control for the specificity of PIST in Rab6 binding the 
Rab1 effector and coiled-coil protein p115 was probed together with PIST in the 
very same pulldown experiment. The lack of p115 binding, although present in the 
HeLa extract, provides evidence that the interaction of Rab6 with PIST is not based 
on general stickiness of coiled-coil proteins but is specific for PIST. 
4.1.2 PIST does not bind the Rho GTPase TC10 
PIST was originally identified as PDZ domain protein interacting specifically with 
TC10 (Neudauer et al., 2001). However, an interaction of PIST with the Rho family 
GTPase TC10 could not be observed in the course of this work, neither by yeast 
two-hybrid nor by direct binding assays with recombinant PIST. One reason for this 
discrepancy with published results could be the presence of an error in the TC10 
cDNA sequence used by Neudauer et al., 2001. When cloning the TC10 gene from 
a human cDNA library for this work, the original database entry turned out to contain 
an error. According to the expressed sequence tag database and the isolated 
clones, the TC10 mRNA encodes a protein 8 amino acids shorter at the N-terminus 
than published by Neudauer et al., 2001. The authors stated that PIST bound TC10 
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in yeast two-hybrid and with low affinity in in vitro binding assays, but that the two 
proteins could not be co-immunoprecipitated from cell extract. One caveat important 
when considering the work of Neudauer et al., 2001 is their use of a PIST fragment 
(amino acids 155-320) instead of the full-length protein. Based on the knowledge 
that proteins fragments can alter the behaviour towards interaction partners, the use 
of fragments without comparing to the full-length protein can be misleading. In this 
work full-length PIST showed no interaction with TC10 in yeast two-hybrid and in 
vitro binding assays. Due to the strong and specific interaction with Rab6, full-length 
PIST is regarded correctly folded both in yeast and purified from E. coli. 
Unfortunately there was no interaction partner of TC10 available to prove the activity 
of TC10 in both assays. However, since TC10 was expressed and purified in the 
same way as Rab6 and other GTPases successfully characterised in the laboratory, 
it is expected to behave in a similar manner and be a suitable substrate for in vitro 
binding assays. 
4.1.3 How is PIST localised to Golgi membranes? 
Immunofluorescence staining of HeLa cells with specific antibodies showed that 
PIST is a Golgi localised protein. The fact that PIST exhibits no structural features 
for direct membrane insertion or anchoring such as transmembrane helices or lipid 
modifications raises the question of how PIST is targeted to Golgi membranes. By 
the use of various deletion constructs of PIST the Golgi targeting region was 
mapped to the second coiled-coil domain of PIST. Because PIST was shown 
previously to form homodimers via the second coiled-coil domain (Neudauer et al., 
2001), the Golgi targeting of PIST fragments was examined in a PIST siRNA 
background where endogenous PIST was depleted from HeLa cells prior to trans-
fection with GFP-constructs. Importantly, also in cells depleted of endogenous PIST 
the second coiled-coil was sufficient to localise to Golgi membranes (PIST142-255). 
Yet, the Golgi signal was much stronger in cells expressing a fragment of PIST with 
both coiled-coil stretches (PIST1-255). This suggests that the Golgi localisation of 
PIST is dependent on the interaction of the second coiled-coil with Golgi resident 
proteins or lipids and that this interaction is stabilised by the N-terminal coiled-coil of 
the protein. 
Interestingly, there is good evidence that the interaction with Rab6 is 
dispensable for the Golgi localisation of PIST. First, yeast two-hybrid analysis as 
well as direct binding assays showed that the N-terminal coiled-coil region of PIST 
(PIST1-141) mediates the interaction with Rab6, whereas the fragment containing the 
second coiled-coil domain plus PDZ domain (PIST142-454) did not bind Rab6. 
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Unfortunately, the PIST deletion mutant containing the second coiled-coil alone 
(PIST142-255) was slightly toxic in yeast and could not be purified from E. coli, which 
makes a direct comparison of both coiled-coil domains in yeast two-hybrid and 
direct binding assays impossible. Nevertheless, further evidence for the Rab6 
independent localisation of PIST is provided by the fact that neither elevated nor 
decreased Rab6 levels affect the targeting of the endogenous PIST to the Golgi. 
While depletion of Rab6 by siRNA resulted in the loss of its effector protein Bic-D1 
from Golgi membranes, the localisation of PIST was unaltered in Rab6 depleted 
cells. One drawback of the Rab6 siRNA experiment is the poor quality of the Rab6 
polyclonal antibody. Rab6 cannot be detected efficiently on Western blot with this 
antibody and Rab6 protein levels might be decreased but not completely depleted. 
Furthermore, in this part of this work siRNA oligos targeting only Rab6a but not 
Rab6b were used. So, different effector proteins, like Bic-D1 and PIST, might exhibit 
different sensitivity to Rab6 isoforms and levels. Rab6b is reported to be expressed 
predominantly in brain (Opdam et al., 2000), but this might be a simplification as the 
nucleotide sequence encoding the Rab6b protein was cloned recently from a HeLa 
cell cDNA library (Shin-ichiro Yoshimura, unpublished results). All binding and 
pulldown reactions were performed using the Rab6a isoform, but PIST might bind 
stronger to Rab6b and be unaffected by altered Rab6a levels. The same problem 
accounts for the overexpression studies with Rab6a. PIST levels at the Golgi were 
unaltered irrespective which Rab6a mutant was expressed. One expects a Rab 
effector interaction to be titrated out by the overexpression of the inactive Rab TN 
mutant. Overexpression of Rab6T27N had no effect on PIST, but neither on Bic-D1. 
Therefore, this experiment was counted insignificant. Most likely, endogenous Rab6 
acts in a dominant active manner over the expression of the mutants and holds 
effector proteins like Bic-D1 in place. Taken together, these results suggest that 
Rab6 is not required for the localisation of its binding protein PIST. 
In search for other putative targeting factors for PIST at the Golgi the coiled-
coil protein Golgin160 was identified and could be confirmed as a binding partner for 
PIST by co-immunoprecipitation of endogenous proteins from cell extract and by 
yeast two-hybrid analysis. The Golgin160 binding region was mapped by yeast two-
hybrid to a region within PIST containing the second coiled-coil plus the sequence in 
front of the PDZ domain. The second coiled-coil alone (PIST142-255), which is 
sufficient for Golgi localisation of PIST, and the PDZ domain alone (PIST256-454) did 
not give a signal when tested against Golgin160 in the yeast-2-hybrid assay. 
Additionally, depletion of Golgin160 by siRNA resulted in fragmentation of the Golgi 
into mini stacks, but had no effects on the localisation of PIST to Golgi membranes. 
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These data suggest that Golgin160 is not the Golgi targeting factor for PIST. During 
the course of this work the interaction of PIST with Golgin160 was published by the 
Machamer lab (Hicks and Machamer, 2005). The authors found PIST in a yeast 
two-hybrid screen with the N-terminal non-coiled-coil head domain of Golgin160, 
which is important for targeting of Golgin160 to the cytoplasmic face of the Golgi 
apparatus (Hicks and Machamer, 2002). In agreement to the data presented in this 
work they mapped the Golgin160 binding region within PIST to the second coiled-
coil domain plus the sequence before the PDZ domain (Hicks and Machamer, 
2005). In addition, Hicks and Machamer, 2005 also showed that PIST can be co-
immunoprecipitated with Golgin160 from cell extract. Together, these independent 
but congruent data suggest that PIST is a binding partner of Golgin160 at the Golgi 
but is not dependent on Golgin160 for its localisation. 
 Another hint for the mechanism of Golgi localisation of PIST can be found in 
Charest et al., 2001. The authors show biochemical data on the interaction of PIST 
with the SNARE protein syntaxin 6. Syntaxin 6 was reported to be involved in 
vesicle fusion at multiple points in the endocytic and exocytic pathways between the 
TGN and the plasma membrane (Murray et al., 2005; Perera et al., 2003; Wendler 
and Tooze, 2001) and was suggested to regulate the plasma membrane delivery of 
protein and lipid components required for caveolar endocytosis (Choudhury et al., 
2005). Although the interaction of PIST with syntaxin 6 in GST-binding assays and 
immunoprecipitation was shown (Charest et al., 2001), data on the localisation of 
PIST and on the functional relationship between both proteins are missing. 
Unfortunately, no further studies dealing with PIST in relationship with syntaxin 6 
were published, and the issue of both, the Golgi localisation and the function of 
PIST remains elusive. 
4.1.4 What is the function of PIST in complex with Rab6? 
PIST is a ubiquitously expressed protein with two coiled-coil stretches and a PDZ 
domain (Neudauer et al., 2001), but its function is still unclear. The siRNA-mediated 
depletion of PIST from HeLa cells did not result in any apparent phenotype on Golgi 
structure or the localisation of its binding partners Rab6 and Golgin160 to Golgi 
membranes, which most likely excludes a major structural role for PIST at the Golgi. 
In comparison, other Golgi localised coiled-coil proteins such as Golgin84 are 
important for the maintenance of the stacked ribbon structure of the Golgi apparatus 
and upon their depletion the Golgi stack falls apart into single Golgi fragments (Barr 
and Short, 2003; Diao et al., 2003). Such a Golgi fragmentation phenotype is clearly 
not the case for the depletion of PIST from HeLa cells and neither for the 
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investigated tissue cells of PIST knock-out mice (Ito et al., 2004; Yao et al., 2002). 
PIST-/- mice are viable and show no obvious abnormalities except that male mice 
are infertile due to a defect in acrosome formation. The acrosome covers the 
anterior one third of the sperm head and contains hydrolytic enzymes needed for 
the binding of the sperm to the zona pellucida of the oocyte during fertilisation. In 
PIST-/- mice acrosome formation during spermiogenesis is blocked because Golgi-
derived proacrosomal vesicles fail to fuse with each other (Ito et al., 2004; Yao et 
al., 2002). Thus, PIST most likely plays a role in Golgi to plasma membrane 
transport of proacrosomal vesicles and therfore in acrosome formation. As the 
acrosome is a unique organelle in spermatids the question arises which role PIST 
plays in other cell types. 
In addition to its coiled-coil stretches PIST also contains a PDZ domain in the 
very C-terminus. PDZ domain proteins are known to fulfil the role as scaffold 
proteins in multisubunit protein complexes and to be essential players for various 
cell signalling processes such as cell polarisation (Harris and Lim, 2001; Nourry et 
al., 2003; Roh and Margolis, 2003). Several proteins have been identified as binding 
partners of the PIST PDZ domain (Cheng et al., 2002; Hassel et al., 2003; Ito et al., 
2006; Yao et al., 2001). Intriguingly, a number of these are transmembrane proteins 
including the plasma membrane chloride channel CFTR (Cheng et al., 2002). The 
plasma membrane expression of CFTR in COS-7 cells seems to be decreased by 
elevated PIST levels and the authors suggest that PIST down-regulates total and 
cell surface CFTR by targeting CFTR for degradation in the lysosome (Cheng et al., 
2002; Cheng et al., 2004; Cheng et al., 2005). This would mean that PIST acts as a 
specialised cargo receptor at the Golgi and directs Golgi-derived vesicles to the 
endocytic system or to the plasma membrane. The interaction of PIST with the 
SNARE syntaxin 6 (see above) would fit into this model. But how would Rab6 be 
involved? PIST is suggested to bind transmembrane cargo proteins via its PDZ 
domain. It localises to the Golgi via its C-terminal coiled-coil domain, possibly by 
interaction with syntaxin 6 or any other Golgi resident protein and binds Rab6 via its 
N-terminal coiled-coil domain. Rab6 has been implicated in microtubule-dependent 
transport by interaction with the dynein-dynactin motor complex (Matanis et al., 
2002; Short et al., 2002). Fitting all data together, one could speculate that Rab6 
regulates the transport of PIST-cargo loaded vesicles along microtubules. The fact 
that neither PIST nor Rab6 depletion in HeLa cells show any obvious effect on cell 
morphology or viability indicates a role of both proteins in specialised secretion or 
transport of certain molecules, or a role in transport to destinations within polarised 
cells such as apical and basolateral membrane that cannot be distinguished in the 
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HeLa cell model system. Another reason for the lack of phenotype after PIST 
depletion in HeLa cells could be the existence of functional redundant proteins in 
cell types other than spermatids. 
4.2 Rab GTPase activating proteins defining Shiga toxin and 
epidermal growth factor uptake 
Rab GTPases act as molecular switches and regulate membrane trafficking events. 
In their active GTP-bound state they recruit specific functional proteins, so called 
effectors, to target membranes. The active state of a Rab is terminated by 
interaction with its specific Rab GTPase-activating protein (GAP), which catalyses 
the GTP hydrolysis reaction and turns the Rab into the inactive GDP-bound state. 
There are over 60 Rab family GTPases encoded by the human genome, and at 
least 39 TBC-domain containing Rab GAPs. However, little is known about the 
function of the majority of these proteins. This is partly due to the enormous 
complexity of membrane trafficking systems, and the lack of suitable cell biological 
models for Rabs with functions in specific tissues. 
As a first step in unravelling this complex network, a cell biological screen for 
Rab GAPs that can influence the trafficking of Shiga toxin to the Golgi apparatus, or 
of EGF to early endosomes was performed. Furthermore, the target Rabs for some 
of these GAPs were identified using biochemical assays. The results suggest that 
while the trafficking of Shiga toxin from the cell surface to the Golgi is a multi-step 
process dependent on at least 6 different Rabs and Rab GAPs, EGF trafficking 
depends only on the action of Rab5 and RabGAP-5. 
4.2.1 A subset of human Rab GAPs influences Shiga toxin transport 
The retrograde transport of Shiga toxin from the cell surface via the Golgi to the ER 
is a multi-step process (Sandvig et al., 2002). Because each membrane trafficking 
step is regulated by a discrete set of Rabs (Zerial and McBride, 2001), it is likely that 
several Rabs are implicated in Shiga toxin trafficking. Yet, to date only Rab6 has 
been implicated in the retrograde transport of Shiga toxin (Girod et al., 1999; Mallard 
et al., 2002; White et al., 1999). To achieve a better understanding of the molecular 
mechanisms of retrograde trafficking pathways Rab GAPs were screened for their 
ability to interfere with the transport of Shiga toxin from the cell surface to the Golgi 
apparatus. 
Transient expression of a Rab GAP can be used to inactivate the 
endogenous pool of a Rab and in this way interfere with the process this Rab is 
involved in (Haas et al., 2005). Therefore, each of the 39 predicted human Rab 
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GAPs was expressed in HeLa cells and the transport of fluorescently labelled Shiga 
toxin B-subunit (STxB) was followed in theses cells. The time points chosen for 
fixation and immunofluorescent staining of the samples were 0 and 60 minutes. In 
control cells STxB had accumulated in the perinuclear Golgi region after 60 minutes 
at 37 °C. A lack of Golgi signal at this time point was counted as a “transport block” 
phenotype. It is extremely important to control the surface binding of STxB at t0 on 
ice before the uptake reaction is started by addition of warm growth medium. 
Otherwise, no conclusion can be drawn from cells without STxB signal at the Golgi 
after 60 minutes. The binding of STxB to HeLa cells of the stock used in the 
laboratory of Francis Barr was very reliable, that means a high percentage of cells 
expressed the Shiga toxin receptor Gb3 and this was stable over a high number of 
passages in cell culture. There are reports from other laboratories working with 
Shiga toxin that HeLa cells express Gb3 only sporadically in a certain percentage of 
cells and drift in sensitivity towards Shiga toxin by passage number (Robert 
Spooner, personal communication). This could be due to diversity between HeLa 
stocks, which has evolved over the many years of culturing this cell line, or due to 
different culture conditions such as the quality of the serum used. 
In the first round of screening, TBC domain proteins in their wild-type form were 
tested blindly according to their plasmid number, without any bias towards known 
Rab GAPs, for the signal of STxB in the perinuclear region after 60 minutes. Out of 
39 GAPs 9 candidates impaired the capability of STxB to reach the perinuclear 
region. In order to assure that the “transport block” phenotype on Shiga toxin 
trafficking was mediated by the catalytic activity of a Rab GAP on its target Rab and 
not by any other mechanism, positive candidates from the first round were re-tested 
as inactive point mutants. It was shown before that non-specific effects of RabGAP 
expression can easily be discriminated from the specific effects of Rab inactivation 
by use of an inactive point mutant in which the catalytic arginine residue is replaced 
by alanine (RA mutant) (Haas et al., 2005). During this second screening round only 
one GAP, TBC1D14 showed the same effect on STxB transport regardless of its 
wild-type or RA mutant state, and was therefore excluded from the list of positives.  
In the initial screen the blue channel was used for DAPI staining of the nuclei 
and relied on the detection of STxB in the perinuclear region, assuming it 
accumulated in Golgi membranes. This allowed a quick assessment of the general 
(nuclear) status of the cell and a rapid exclusion of non-phenotype GAPs. However, 
cells without a typical perinuclear Golgi structure such as dispersed Golgi fragments 
could be classed as false-positives in this way. Therefore, screen positives were 
tested again in Shiga toxin transport assays, this time with the Golgi matrix protein 
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GM130 stained in blue to check for Golgi morphology in GAP expressing cells. Co-
staining with GM130 revealed that in cells expressing TBC1D22A and TBC1D22B 
the Golgi stack was fragmented but STxB accumulated exactly in these Golgi 
fragments. This result suggests that TBC1D22A and TBC1D22B act on Rabs that 
play a role in maintaining Golgi structure but not in Shiga toxin transport. In contrast, 
in RN-tre expressing cells normal Golgi structure was disrupted as well but STxB 
had clearly not accumulated in these Golgi fragments. Taken together, after 
checking for catalytic activity dependence and Golgi morphology, 6 GAP candidates 
were counted positive in their ability to block the transport of STxB: RN-tre, EVI5, 
TBC1D10A-C and TBC1D17. 
To further validate the results obtained with the fluorescently labelled B-
subunit, the candidates were tested in another approach, measuring their ability to 
protect cells against the cytotoxic effects of fully active Shiga-like toxin 1. Once 
Shiga toxin reaches the ER, it gets translocated to the cytosol where it inhibits 
protein synthesis at the ribosome. Therefore, measuring protein synthesis is an 
indirect but very sensitive tool to measure the uptake and transport of the toxin 
within the cell (Spooner et al., 2004). Rab GAP expressing cells were incubated with 
various amounts of Shiga-like toxin 1 before the incorporation of [35S]-methionine 
was measured. The IC50 values of wild-type and RA mutant GAP expressing cells 
were used to calculate the fold protection shown by a wild-type GAP against Shiga-
like toxin 1. In agreement with the data obtained with fluorescently labelled STxB, 
RN-tre, EVI5 and TBC1D17 were able to protect cells against Shiga toxin between. 
The effect of the TBC1D10 family is not so clear as fold protection varies. One major 
caveat of the method is the transient expression of GAPs. The background of 
untransfected cells might artificially decrease the protective effect of a GAP. 
Although the transfection efficiency for each GAP was counted and used to correct 
the raw data obtained in the cytotoxicity assay, the exact ratio and behaviour of 
untransfected versus transfected cells in each single experiment remains unknown. 
Another issue is the nature of the block of Shiga toxin. In fluorescent analysis the 
detection threshold is relatively high, whereas cytotoxicity can be measured even 
with very low amounts of Shiga toxin reaching the cytoplasm. This means, a block in 
Shiga toxin transport would have to be 100 % in order to yield high protective 
values. Most likely, Shiga toxin is blocked from reaching the Golgi by the list of 
screen positive GAPs as observed by immunofluorescence studies, but not 
completely at molecular level as measured in the cytotoxicity assay. In combination, 
the issues of transfection efficiency and degree of block might decrease the real 
protective effect to the level of measured protection. However, multiple repetitions of 
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the experiment showed a clear trend towards RN-tre, EVI5 and TBC1D17 protecting 
cells against Shiga-like toxin 1. Importantly, RabGAP5, a GAP for Rab5 (Haas et al., 
2005) did not influence the transport of Shiga toxin, neither in fluorescent assays nor 
in cytotoxicity measurements. This suggests that endocytosis and retrograde 
transport of Shiga toxin is independent of Rab5. 
4.2.2 The role of Rab6 in the Shiga toxin trafficking pathway 
In previous studies, Rab6 has been implicated in Shiga toxin transport (Girod et al., 
1999; Mallard et al., 2002; White et al., 1999). This could be confirmed in this work 
using Rab6 siRNA. Shiga toxin transport to the Golgi was partially blocked in cells 
depleted of Rab6a and Rab6b. STxB was still detectable in the perinuclear region 
but compared to control cells greatly reduced. One reason for the incomplete block 
could be an inefficient depletion of Rab6 by siRNA. As the Rab6 antibody does not 
work in Western blotting endogenous protein levels could not be judged. Although 
the Rab6 effector Bic-D1 was lost from the Golgi in Rab6 depleted cells, low levels 
of either Rab6 isoform might be sufficient for the transport of Shiga toxin. Another 
theory could be an indirect role of Rab6 in Shiga toxin trafficking such as the 
delivery of cell surface components needed for efficient endocytosis of the toxin. In 
Rab6 depleted cells these components would inevitably be titrated out more or less 
rapidly according to their half-life. The issue of time span in different experimental 
setups could be essential for the effect on Shiga toxin trafficking. While a transiently 
expressed Rab GAP can act very rapidly in cells (within hours), the functional 
knock-down of a Rab by siRNA can take days. Furthermore, the expression of Rab 
GAPs is dominant whereas siRNA mediated depletion cannot be controlled for 
remaining functional pools of Rab below the detection threshold. Therefore, the 
identification of a Rab6 GAP could clarify the role of Rab6 in Shiga toxin trafficking. 
However, none of the Rab GAPs capable of blocking Shiga toxin transport was able 
to cause release of Bic-D1 from the Golgi to the cytoplasm. This indicates that they 
do not act on Rab6, because the Golgi localisation of Bic-D1 is Rab6 dependent. 
Furthermore, none of the tested GAPs was able to stimulate GTP-hydrolysis by 
Rab6 in biochemical assays. Why the Rab6 GAP was not found in the screen is 
unclear. There is evidence that some TBC-domain proteins form hetero-dimeric 
complexes (Pereira et al., 2001), and that this is necessary for their activity. If this is 
the case for the Rab6 GAP then it could have been missed in the current screen. 
 What is clear is that TBC1D11/GAPCenA, previously suggested to act on 
Rab6 (Cuif et al., 1999), is unlikely to be the GAP for Rab6. It displays robust 
biochemical activity towards Rab4 but not Rab6, and has none of the cell biological 
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properties expected for a Rab6 GAP. It cannot block Shiga toxin trafficking, or cause 
release of the Rab6 effector Bicaudal-D1 from the Golgi. Investigation of the 
interaction between TBC1D11/GAPCenA and the full set of Rabs in yeast two-
hybrid showed that regions outside of the minimal predicted catalytic-domain are 
required for specific Rab-binding. Strikingly, deletion of these regions relaxes the 
interaction specificity of the protein. Many previous studies have used truncated 
GAP domains rather than full-length proteins (Albert and Gallwitz, 1999; Pan et al., 
2006), and in the light of the data presented in this work this may be problematic 
since these proteins may have relaxed specificity and thus be able to accelerate 
GTP-hydrolysis on a broader spectrum of Rabs. 
Thus, it is clearly important to study the full-length proteins and not only 
truncated fragments corresponding to predicted domains. At the present time the 
identity of the Rab6 GAP remains mysterious and requires further investigation. 
4.2.3 Only RabGAP5 is able to block EGF uptake 
The TBC domain proteins RN-tre, EVI5, TBC1D10A-C and TBC1D17 were shown 
to influence the intracellular trafficking of Shiga toxin. The question remained 
whether these GAPs act specifically on the retrograde route of Shiga toxin to the 
Golgi apparatus or on general endocytic pathways such as receptor mediated 
endocytosis. Therefore, a second functional assay for the uptake of epidermal 
growth factor (EGF) and its receptor to early endosomes was used. Again, the full 
set of 39 human TBC domain proteins was screened blindly according to the 
plasmid number. The uptake of fluorescently labelled EGF was followed and time 
points for fixation and immunofluorescence analysis were chosen to be 0 and 30 
minutes. After 30 minutes EGF had reached the early endosomal compartment, 
marked by the early endosomal antigen 1 (EEA1) in control cells. The binding of 
EGF to the surface of HeLa cells was not as reliable as the binding of STxB. 
Dependent on the Rab GAP expressed the fraction of cells without bound EGF at t0 
was in the range of 5 to 40 %. Therefore, the number of cells without bound EGF at 
t0 and the number of cells with a block in endocytosis of EGF to early endosomes 
after 30 minutes were counted and compared side-by-side. From this direct 
comparison it became clear that only RabGAP-5 was able to block EGF uptake into 
early endosomes. In contrast, the GAPs inhibiting Shiga toxin trafficking to the Golgi 
did not affect the endocytosis of EGF and are therefore considered specific for the 
Shiga toxin route. 
There has been some controversy in the literature concerning the relative 
importance of RN-tre and RabGAP-5 as regulators for Rab5 and their involvement 
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in the uptake of endocytosed ligands (Haas et al., 2005; Lanzetti et al., 2000). 
However, the results presented in this work clearly show that although both these 
GAPs are involved in the trafficking of endocytosed ligands, they act on discrete 
trafficking pathways. One explanation for the differential sensitivity of EGF receptor 
trafficking to RN-tre could relate to the conditions and cell lines used. With low 
doses of EGF, the EGF receptor is almost entirely transported via the clathrin 
dependent pathway, while at higher or saturating doses it spills over into the clathrin 
independent pathway (Sigismund et al., 2005). Thus, with saturating amounts of 
EGF, RN-tre would be able to prevent transport of the pool of EGF receptor entering 
via the clathrin-independent pathway, however the data in this work on RN-tre and 
its target Rab suggest that this would be a Rab5-independent and Rab43-
dependent pathway. 
4.2.4 What are the target Rabs for the GAPs blocking Shiga toxin transport or 
EGF endocytosis? 
It has been suggested that Rab GAPs are not particularly specific towards their 
target Rab (Albert and Gallwitz, 1999; Pan et al., 2006). However, this is somewhat 
counter-intuitive since Rabs are argued to be important components acting at 
specific membrane trafficking steps and for specification of organelle identity 
(Munro, 2002; Pfeffer, 2001). Therefore one would expect their regulators to be 
equally specific. The data presented in this work support the idea that GAPs are 
likely to be specific towards particular target Rabs, or Rab subfamilies. First, Rab 
GAPs have highly specific effects on discrete membrane-trafficking pathways, 
consistent with the idea they act on specific Rabs in vivo. While RabGAP-5 is able 
to block the uptake of EGF into early endosomes, RN-tre, EVI5, TBC1D10A-C and 
TBC1D17 have been identified to play a role in the multi-step pathway of Shiga 
toxin. Furthermore, GAPs such as RabGAP-5, and RN-tre are highly active towards 
specific Rabs in biochemical assays, and depletion of the respective Rabs leads to 
the same effect observed with the expression of the GAP. 
 RN-tre, EVI5, TBC1D10B, TBC1D17 and RabGAP-5 were tested in 
biochemical assays for their ability to accelerate GTP hydrolysis by a specific Rab. 
A single Rab GAP was analysed at the same time together with a representative set 
of human Rabs, where each Rab subfamily was represented with at least one 
member. In this way experimental conditions and the activity state of the GAP were 
the same and GTP-hydrolysis rates could be compared directly within the set of 
Rabs. Only in the context with the full set of Rabs a single signal of hydrolysed GTP 
becomes meaningful. The results clearly show that RabGAP-5 acts specifically on 
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the Rab5a-c isoforms. This confirms previous data that RabGAP-5 is a GAP for 
Rab5 (Haas et al., 2005) and underlines the strong specificity of this GAP. Even 
very closely related Rabs such as Rab22a and Rab22b were not recognised by 
RabGAP-5 as a substrate. The Shiga toxin blocking GAP RN-tre showed specific 
activity towards Rab43. One might argue that also Rab35 is activated by RN-tre 
because its hydrolysis rate is approximately half of Rab43. However, Rab35 was 
found to be weakly activated by a number of GAPs tested. This suggests that 
Rab35 might be a false positive hit and also questions the significance of the very 
high hydrolysis rate of Rab35 by the GAP EVI5. Similarly, substrates for TBC1D10B 
and TBC1D17 could not be identified with certainty. The reason why the 
biochemical GTP-hydrolysis assay gave ambiguous results for EVI5, TBC1D10B 
and TBC1D17 could be linked to the activity of the recombinant GAP proteins. 
What is clear is that RabGAP-5 acts on Rab5a-c and RN-tre on Rab43 with high 
specificity. In order to validate the target Rabs for both GAPs in vivo Rab5 and 
Rab43 were tested in the functional assays STxB transport and EGF uptake. 
Consistent with the results observed with RabGAP-5 cells depleted of all three 
isoforms of Rab5 were not able to take up EGF into early endosomes but 
transported Shiga toxin to the Golgi apparatus. Cells depleted of Rab43 showed an 
inhibition of Shiga toxin transport, whereas endocytosis of EGF was normal. 
Taken together, these results suggest that RabGAP-5 is a specific GAP for 
Rab5 and controls the endocytosis of EGF, whereas RN-tre is a GAP for Rab43 and 
regulates the trafficking of Shiga toxin from the plasma membrane to the Golgi 
apparatus. Thus, different sets of Rab GAPs and their target Rabs control specific 
endocytic trafficking pathways. The approach used in this work, combining 
functional in vivo data with biochemical assays for target Rab identification should 
be useful for the study of other trafficking events, for trafficking between the ER and 
Golgi apparatus, or a wide variety of different regulated secretory events. 
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5 Material and Methods 
5.1 Material 
5.1.1 Reagents 
Reagents were obtained from Sigma-Aldrich (Seelze, Germany) or VWR 
(Darmstadt, Germany) unless stated in the text. 
5.1.2 Equipment 
A list of commonly used equipment and its suppliers is given in the table below. 
 
Equipment Description and manufacturer 
Benchtop centrifuge Eppendorf Centrifuge 5417C 
Benchtop refrigerated 
centrifuge 
Eppendorf Centrifuge 5417R 
Blotting machine BioRad Trans-blot SD 
Cell Culture Incubators Heraeus HeraCell 
Cell Culture Safety Hoods Heraeus HeraSafe 
Centrifuge Heraeus Multifuge 3 L-R 
Electroporation system BioRad MicroPulser 
Film Developer Kodak X-OMAT 2000 Processor 
Gel system BioRad Mini-PROTEAN 
Heating block/ mixer Eppendorf Thermomix Compact 
Incubators Heraeus Function Line 
Magentic stirrer IKA RET basic IKAMAG 
PCR machine Perkin Elmer Gene Amp 2400 
pH meter Beckman φ340pH/Temp meter 
Power pack BioRad Power Pack 200 and 300 
Scintillation counter Packard Tri-carb 2900TR 
Scintillation counter (96-well) Perkin Elmer Wallac Microbeta Trilux 
Shakers for bacterial and yeast 
culture 
Infors AG Multitron 
Grant Boekel BFR25 
Sonicator Bandelin Sonopuls 
SW28 rotor Beckman 
SW40 rotor Beckman 
Transilluminators UVP 2UV Transilluminator 
UVP Gel Documentation System 
Fujifilm LAS3000 
Ultracentrifuge Beckman Optima LE-80K 
UV/Visible Spectrophotometer Amersham-Pharmacia Ultrospec 300pro  
Vortex shaker IKA MS3 basic 
Waterbath Haake DC10 
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5.1.3 Solutions 
The composition of standard solutions not described in the respective methods 
chapter is given in the table below. Unless otherwise stated the solvent is water. 
 
Solution Composition 
DNA loading dye (6x) 0.25% (w/v) bromophenol blue 
40% (w/v) sucrose in TE 
L-Broth (LB) 10 g/l Bacto-tryptone 
5 g/l Bacto-yeast extract 
10 g/l NaCl 
LB-Agar LB plus 15 g/l Bacto-agar 
Milk-PBS (blocking buffer) 4% milk powder in PBS plus 0.2% (w/v) 
Tween-20 
PBS 8 g/l NaCl 
0.2 g/l KCl 
1.44 g/l Na2HPO4 
0.24 g/l KH2PO4 
(pH 7.4) 
Ponceau stain 0.2% Ponceau red in 1% acetic acid 
RIPA buffer 10 mM Tris-HCl pH 7.5 
150 mM NaCl 
1% (w/v) Triton-X 100 
0.1% (w/v) SDS 
1% (w/v) sodium deoxycholate 
SDS-PAGE lower buffer (4x) 181.72 g/l Tris base 
4 g/l SDS 
SDS-PAGE running buffer (10x) 30.2 g/l Tris base 
188 g/l glycine 
10 g/l SDS 
SDS-PAGE sample buffer (3x) For 100 ml: 
2.3 g Tris base 
9.0 g SDS 
30 ml glycerol 
Adjust pH to 6.8 with HCl, then adjust 
volume to 90 ml with dH2O 
50 mg bromophenol blue 
Add 10% ß-mercaptoethanol prior to use 
SDS-PAGE transfer buffer 1x SDS-PAGE running buffer 
10% methanol 
SDS-PAGE upper buffer (4x) 60.6 g/l Tris base 
4 g/l SDS 
TAE (50x) For 1 l: 
242.4 g Tris base 
57.2 ml glacial acetic acid 
50 mM EDTA pH 8.0 
TE 10 mM Tris-HCl pH 8.0 
1 mM EDTA 
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Solution Composition 
TNTE 10 mM Tris-HCl pH 7.5 
150 mM NaCl 
0.3% (w/v) Triton-X 100 
5 mM EDTA 
5.1.4 Plasmids 
The plasmids used in this thesis are listed in the table below and carry the pFB 
numbers of the plasmid stock in the Barr laboratory. 
 
Number Name Vector Insert and Notes 
pFB0789 pGBT9.Golgin160 pGBT9 Mouse Golgin160 fl, derived 
from pFB180 
pFB1162 pEGFP.C2.HumanTBC1D22a pEGFPC2 Human TBC1D22a fl, BamHI-
SalI, derived from pBS412 
pFB1468 pGBT9.Rab6aWT pGBT9 Human Rab6a, derived from 
pBS477 
pFB1469 pGBT9.Rab6aQ72L pGBT9 Human Rab6a Q72L GTP-
restricted mutant, derived from 
pBS478  
pFB1470 pGBT9.Rab6aT27N pGBT9 Human Rab6a T27N GDP-
restricted mutant, derived from 
pBS479 
pFB1471 pFAT2.Rab6aWT pFAT2 Human Rab6a, derived from 
pBS477 
pFB1471 pFAT2.Rab6aWT pFAT2 Human Rab6a, BamHI-SalI, 
derived from pBS477 
pFB1472 pFAT2.Rab6aQ72L pFAT2 Human Rab6a Q72L GTP-
restricted mutant, derived from 
pBS478 
pFB1473 pFAT2.Rab6aT27N pFAT2 Human Rab6a T27N GDP-
restricted mutant, derived from 
pBS479 
pFB1474 pEGFP.C2.Rab6aWT pEGFPC2 Human Rab6a, derived from 
pBS477 
pFB1476 pEGFP.C2.Rab6aT27N pEGFPC2 Human Rab6a T27N GDP-
restricted mutant, derived from 
pBS479 
pFB1706 pQE32.PIST pQE32 Human PIST fl, derived from 
pBS592 
pFB1709 pACT2.PIST pACT2 Human PIST fl, derived from 
pBS592 
pFB1710 pEGFP.C2.PIST pEGFPC2 Human PIST fl, derived from 
pBS592 
pFB1724 pFAT2.Rab33bwt pFAT2 Mouse Rab33b wt, BamHI-
SalI, plus STOP codon, derived 
from pBS609 
pFB1779 pFBT9.Rab33bQ92L pFBT9. Mouse Rab33b Q92L active 
mutant Gal4BD fusion from 
pFB1719 
pFB1799 pAct2.PIST1-255 pAct2 Human PIST aa 1-255, derived 
from pFB1794, 1st + 2nd CC 
pFB1800 pAct2 PIST142-454 pAct2 Human PIST aa 142-454, 
derived from pFB1795, 2nd CC 
+ PDZ 
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Number Name Vector Insert and Notes 
pFB1801 pAct2 PIST1-141 pAct2 Human PIST aa 1-141, derived 
from pFB1796, 1st CC 
pFB1802 pAct2 PIST142-255 pAct2 Human PIST aa 142-255, 
derived from pFB1797, 2nd CC 
pFB1803 pAct2 PIST256-454 pAct2 Human PIST aa 256-454, 
derived from pFB1798, PDZ 
pFB1809 pEGFP PIST1-255 pEGFPC2 Human PIST aa 1-255, derived 
from pFB1794, 1st + 2nd CC 
pFB1810 pEGFP PIST142-454 pEGFPC2 Human PIST aa 142-454, 
derived from pFB1795, 2nd CC 
+ PDZ 
pFB1811 pEGFP PIST1-141 pEGFPC2 Human PIST aa 1-141, derived 
from pFB1796, 1st CC 
pFB1812 pEGFP PIST142-255 pEGFPC2 Human PIST aa 142-255, 
derived from pFB1797, 2nd CC 
pFB1813 pEGFP PIST256-454 pEGFPC2 Human PIST aa 256-454, 
derived from pFB1798, PDZ 
PFB1824 pHIS PIST1-255 pQE32 Human PIST aa 1-255, derived 
from pFB1794, 1st + 2nd CC 
PFB1825 pHIS PIST142-454 pQE32 Human PIST aa 142-454, 
derived from pFB1795, 2nd CC 
+ PDZ 
PFB1826 pHIS PIST1-141 pQE32 Human PIST aa 1-141, derived 
from pFB1796, 1st CC 
PFB1827 pHIS PIST142-255 pQE32 Human PIST aa 142-255, 
derived from pFB1797, 2nd CC 
PFB1828 pHIS PIST256-454 pQE32 Human PIST aa 256-454, 
derived from pFB1798, PDZ 
pFB1842 pFBT9 Rab2 Q65L pFBT9. Human Rab2a Q65L GTP 
mutant, BamHI-SalI, derived 
from pFB1830 
pFB2116 pFAT2 Rab7likewt pFAT2 Human Rab7like, derived from 
pFB2000, BamHI, XhoI 
pFB2118 pFAT2 Rab8wt pFAT2 Human Rab8, derived from 
pFB1986, BamHI, XhoI 
pFB2120 pFAT2 Rab10wt pFAT2 Human Rab10, derived from 
pFB1987, BamHI, XhoI 
pFB2122 pFAT2 Rab30wt pFAT2 Human Rab30, derived from 
pFB1993, BamHI, XhoI 
pFB2298 pEGFPC2.TBC1D20 pEGFPC2 Human TBC1D20, BglII SalI, 
derived from pFB2264 
pFB2420 pFAT2.TC10 pFAT2 Human TC10, derived from 
pFB2411 
pFB2422 pFBT9.TC10 pFBT9 Human TC10, derived from 
pFB2411 
pFB2424 pFBT9.Rab1 Q70L pFBT9 Mouse Rab1 GTP restricted, 
derived from pBS574 
pFB2428 pFAT2.TC10Q67L pFAT2 Human TC10Q67L, GTP-
restricted, derived from 
pFB2426 
pFB2429 pFAT2.TC10S23N pFAT2 Human TC10S23N, GDP-
restricted, derived from 
pFB2427 
pFB2430 pFBT9.TC10Q67L pFBT9 Human TC10Q67L, GTP-
restricted, derived from 
pFB2426 
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Number Name Vector Insert and Notes 
pFB2431 pFBT9.TC10S23N pFBT9 Human TC10S23N, GDP-
restricted, derived from 
pFB2427 
pFB2434 pMalT.PISTfl pMalTEV Human PISTfl 
pFB2476 pACT2.TBC1D11/TBC1D11/GAPCenA pACT2 Human 
TBC1D11/TBC1D11/GAPCenA 
fl 
pFB2506 pEGFPC2.TBC1D13 pEGFP-C2 Human TBC1D13 fl 
pFB2508 pEGFPC2.TBC1D4 pEGFP-C2 Human TBC1D4 fl 
pFB2509 pEGFPC2.TBC1D20 R105A pEGFP-C2 Human TBC1D20 R105A 
pFB2512 pEGFPC2.TBC1D2 pEGFP-C2 Human TBC1D2 fl 
pFB2515 pEGFPC2.TBC1D3B/PRC 17 pEGFP-C2 Human TBC1D3B/PRC17 fl 
pFB2516 pEGFPC2.TBC1D22B pEGFP-C2 Human TBC1D22B fl 
pFB2521 pEGFPC2.TBC1D5 pEGFP-C2 Human TBC1D5 fl 
pFB2600 pFBT9.Rab1bQ67L pFBT9 Human Rab1bQ67L, GTP 
mutant, derived from pFB2366 
pFB2601 pFBT9.Rab2bQ65L pFBT9 Human Rab2bQ65L, GTP 
mutant, derived from pFB2368 
pFB2602 pFBT9.Rab3bQ81L pFBT9 Human Rab3bQ81L, GTP 
mutant, derived from pFB2369 
pFB2603 pFBT9.Rab4aQ72L pFBT9 Human Rab4aQ72L, GTP 
mutant, derived from pFB2582 
pFB2604 pFBT9.Rab5bQ79L pFBT9 Human Rab5bQ79L, GTP 
mutant, derived from pFB2370 
pFB2605 pFBT9.Rab6aQ72L pFBT9 Human Rab6aQ72L, GTP 
mutant, derived from pFB2371 
pFB2606 pFBT9.Rab8aQ67L pFBT9 Human Rab8aQ67L, GTP 
mutant, derived from pFB2372 
pFB2608 pFBT9.Rab9bQ66L pFBT9 Human Rab9bQ66L, GTP 
mutant, derived from pFB2374 
pFB2609 pFBT9.Rab10Q68L pFBT9 Human Rab10Q68L, GTP 
mutant, derived from pFB2375 
pFB2610 pFBT9.Rab11aQ70L pFBT9 Human Rab11aQ70L, GTP 
mutant, derived from pFB2376 
pFB2611 pFBT9.Rab13Q67L pFBT9 Human Rab13Q67L, GTP 
mutant, derived from pFB2377 
pFB2612 pFBT9.Rab14Q70L pFBT9 Human Rab14Q70L, GTP 
mutant, derived from pFB2378 
pFB2613 pFBT9.Rab18Q67L pFBT9 Human Rab18Q67L, GTP 
mutant, derived from pFB2591 
pFB2614 pFBT9.Rab23Q68L pFBT9 Human Rab23Q68L, GTP 
mutant, derived from pFB2380 
pFB2615 pFBT9.Rab27aQ78L pFBT9 Human Rab27aQ78L, GTP 
mutant, derived from pFB2383 
pFB2616 pFBT9.Rab27bQ78L pFBT9 Human Rab27bQ78L, GTP 
mutant, derived from pFB2384 
pFB2617 pFBT9.Rab30Q68L pFBT9 Human Rab30Q68L, GTP 
mutant, derived from pFB2595 
pFB2618 pFBT9.Rab31Q65L pFBT9 Human Rab31Q65L, GTP 
mutant, derived from pFB2386 
pFB2619 pFBT9.Rab35Q67L pFBT9 Human Rab35Q67L, GTP 
mutant, derived from pFB2388 
pFB2620 pFBT9.Rab40cQ73L pFBT9 Human Rab40cQ73L, GTP 
mutant, derived from pFB2599 
pFB2761 pFAT2.Human Rab4awt pFAT2 Human Rab4a wt, derived from 
pFB2305 
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pFB2762 pFAT2.Human Rab5bwt pFAT2 Human Rab5b wt, derived from 
pFB 2307 
pFB2773 pEGFP.C2.TBC1D11/GAPCenA pEGFP.C2 Human TBC1D11/GAPCenA fl 
pFB2780 pFBT9.Human Rab3aQ81L pFBT9 Human Rab3aQ81L, derived 
from pFB2753 
pFB2781 pFBT9.Human Rab33aQ95L pFBT9 Human Rab33aQ95L, derived 
from pFB2754 
pFB2782 pFBT9.Human Rab37Q82L pFBT9 Human Rab37Q82L, derived 
from pFB2755 
pFB2783 pFBT9.Human Rab39Q72L pFBT9 Human Rab39Q72L, derived 
from pFB2756 
pFB2824 pEGFP.C2.Rab6Q72L pEGFPC2 Human Rab6Q72L, GTP-
restricted, derived from 
Roberts Rabome clone 6.2 
pFB2861 pFBT9.Rab9aQ66L pFBT9 Human Rab9aQ66L, GTP-
locked, derived from pFB2585 
pFB2866  pEGFP.C2.RabGAP-5 pEGFP.C2 Human RabGAP-5 fl 
pFB2867 pCDN3.1mycA. RabGAP-5 pcDNA3.1mycA Human RabGAP-5 fl 
pFB2887 pMALTEVHis. RabGAP-5 pMALTEV-His Human RabGAP-5 fl wt 
pFB2911 pFBT9.Human Rab43Q77L pFBT9 Human Rab43Q77L, derived 
from pFB2767 
pFB2951 pCDNA3.1mycA.RabGAP-5 R165A pcDNA3.1mycA Human RabGAP-5 fl R165A 
mutant 
pFB2952 pACT2.TBC1D11/GAPCenA.aa1.723 pACT2 Human TBC1D11/GAPCenA 
aa1-723, without coiled-coil 
pFB2953 pACT2.TBC1D11/GAPCenA.aa724.998 pACT2 Human TBC1D11/GAPCenA 
aa724-998, Coiled-coil at C-
terminus 
pFB2954 pACT2.TBC1D11/GAPCenA.aa201.998 pACT2 Human 
TBC1D11/GAPCenA.aa 201-
998, without PTB Domain 
pFB2968 pFAT2.Rab31.Wt pFAT2 Human Rab31 WT 
pFB3009 pFBT9.Human Rab20Q61L pFBT9 Human Rab20 GTP mutant, 
derived from pFB2928 
pFB3016 pFAT2.Human Rab22awt pFAT2 Human Rab22a wt, GST+His-
tagged, derived from pFB2935 
pFB3026 pFAT2.Human Rab1bwt pFAT2 Human Rab1b wt, GST+His-
tagged, derived from pFB2301 
pFB3041 pCDNA3.1mycA.RN-tre.R150A pcDNA3.1mycA Human RN-tre FL R150A, 
derived from pFB3039 
pFB3042 pEGFPC2.RN-tre.R150A pEGFP-C2 Human RN-tre FL R150A, 
derived from pFB3039 
pFB3059 pCDNA3.1mycA.RN-tre.FL.WT pCDNA3.1mycA Human RN-tre WT FL from 
Testis 
pFB3056 pMALTEV.His.RN-tre.FL pMALTEV-His Human RN-tre WT FL 
pFB3060  pEGFPC2.RN-tre.FL.WT pEGFPC2 Human RN-tre WT FL from 
Testis 
pFB3086 pFAT2.Human Rab25wt pFAT2 Human Rab25wt, derived from 
pFB2319 
pFB3090 pFAT2.Rab5A.WT pFAT2 Human Rab5A derived from 
pFB2306 
pFB3093 pFAT2.Rab43.WT pFAT2 Human Rab43 WT 
pFB3116 pFBT9.Rab5A.QL pFBT9 Human Rab5A derived from 
pFB3112, GTP-lock 
pFB3123 pFBT9.Rab32.QL pFBT9 Human Rab32 derived from 
pFB2936, GTP-lock 
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pFB3176 pFAT2.Human Rab2bwt pFAT2 Human Rab2b wt, derived from 
pFB2303 
pFB3177 pFAT2.Human Rab3awt pFAT2 Human Rab3a wt, derived from 
pFB2686 
pFB3179 pFAT2.Human Rab9awt pFAT2 Human Rab9a wt, derived from 
pFB2310 
pFB3180 pFAT2.Human Rab9bwt pFAT2 Human Rab9b wt, derived from 
pFB2311 
pFB3181 pFAT2.Human Rab14wt pFAT2 Human Rab14 wt, derived from 
pFB2315 
pFB3182 pFAT2.Human Rab18wt pFAT2 Human Rab18 wt, derived from 
pFB2316 
pFB3183 pFAT2.Human Rab20wt pFAT2 Human Rab20 wt, derived from 
pFB2788 
pFB3184 pFAT2.Human Rab23wt pFAT2 Human Rab23 wt, derived from 
pFB2364 
pFB3185 pFAT2.Human Rab24wt pFAT2 Human Rab24 wt, derived from 
pFB2318 
pFB3186 pFAT2.Human Rab27awt pFAT2 Human Rab27a wt, derived 
from pFB2320 
pFB3188 pFAT2.Human Rab33awt pFAT2 Human Rab33a wt, derived 
from pFB2689 
pFB3189 pFAT2.Human Rab34wt pFAT2 Human Rab34 wt, derived from 
pFB2973 
pFB3190 pFAT2.Human Rab37wt pFAT2 Human Rab37 wt, derived from 
pFB2676 
pFB3191 pFAT2.Human Rab39wt pFAT2 Human Rab39 wt, derived from 
pFB2677 
pFB3195 pFAT2.Rab35.wt pFAT2 Human Rab35 wt 
pFB3196 pFAT2.Human Rab13.wt pFAT2 Human Rab13 wt 
pFB3204 pFBT9.Rab22a.QL pFBT9 Human Rab22a GTP Lock, 
derived from pFB2935 
pFB3209 pFAT2.Rab5C.WT pFAT2 Human Rab5C, from U2Os 
cDNA, WT 
pFB3246 pFBT9.Rab5C.QL pFBT9 Human Rab5C, from U2Os 
cDNA, Q80L GTP-Lock 
pFB3321 pFAT2.Human Rab21wt pFAT2 Human Rab21 wt, N-terminal 
His+GST-tag, derived from 
pFB3029 
pFB3325 pFAT2.Human Rab19bwt pFAT2 Human Rab19b wt, N-terminal 
His+GST-tag, derived from 
pFB 3319 
pFB3346 pFBT9.Human Rab19bQ79L pFBT9 Human Rab19b Q79L, GTP 
mutant, derived from pFB3343 
pFB3389 pFAT2.Rab6QL pFAT2 Human Rab6Q72L, GTP-
restricted, derived from 
pFB2583 
pFB3489 pEGFPC2.TBC1D14.fl.RA PEGFPC2. Human TBC1D14 fl R472A, 
BamHI BamHI, derived from 
pFB3487 
pFB3513 pFBT9.Rab34.Q111L pFBT9 Human Rab34 Q111L, derived 
from pFB3512 
pFB3514 pFBT9.Rab21.Q78L pFBT9. Human Rab21 Q78L, derived 
from pFB3513 
pFB3523 pFBT9.Rab28.Q72L pFBT9 Human Rab28 Q72L 
pFB3527 pFBT9.Rab38.Q69L pFBT9 Human Rab38 Q69L 
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pFB3554 pEGFPC2.AK074305 PEGFPC2. Human AK074305 FL WT 
derived from pFB3551 
pFB3558 pFAT2.Human Rab7wt pFAT2 Human Rab7 wt, derived from 
pFB3557 
pFB3590 pFAT2.Human Rab3d  pFAT2 Human Rab3d wt, derived from 
pFB3563 
pFB3687 pEGFPC2.TBC1D1 pEGFPC2 Human TBC1D1, derived form 
pFB3678 
pFB3706 pEGFPC2.TBC1D4 pEGFPC2 Human TBC1D4, derived 
frompFB3691 
pFB3732 pEGFPC2.EVI5 pEGFPC2 Human EVI5 derived from 
pFB3724 
pFB3733 pEGFPC2.EVI5RA pEGFPC2 Human EVI5RA derived from 
pFB3725 
pFB3812 pEGFPC2.EVI5-like.FL.WT pEGFPC2. Human EVI5-like FL, WT, 
derived from pFB3811 
pFB3820 pEGFPC2.USP6.FL.WT pEGFPC2. Human USP6 FL, WT, derived 
from pFB3819 
pFB3832 pEGFPC2.TBC1D10c.FL.WT pEGFPC2. Human TBC1D10c FL, WT, 
derived from pFB3831 
pFB3836 pEGFPC2.TBC1D10c.FL.RA pEGFPC2. Human TBC1D10c FL, R141A, 
derived from pFB3835 
pFB3840 pEGFPC2.TBC1D21.FL.WT pEGFPC2. Human TBC1D21 FL, WT, 
derived from pFB3839 
pFB3848 pEGFPC2.RUTBC1.FL.WT pEGFPC2. Human RUTBC1 FL, WT, 
derived from pFB3847 
pFB3856 pEGFPC2.RUTBC2.FL.WT pEGFPC2. Human RUTBC2 FL, WT, 
derived from pFB3855 
pFB4034 pEGFP.C2.Human Rab5bQ79A pEGFP-C2 Human Rab5b Q79A, N-
terminal GFP-tag, derived from 
pFB3948 
pFB4095  pEGFPC2.Paris1.FL.WT pEGFPC2. Human Paris1 FL WT, derived 
from pFB4094 
pFB4104 pEGFPC2.KIAA1171.FL.WT pEGFPC2. Human KIAA1171 FL WT, 
derived from pFB4103 
pFB4131 pEGFPC2.NP_060779.FL.WT pEGFPC2. Human NP_060779 FL WT, 
derived from pFB4130 
pFB4136 pEGFPC2.TBC1D18.FL.WT pEGFPC2. Human TBC1D18 FL, WT BclI 
SalI, derived from pFB2891 
pFB4141 pEGFPC2.TBC1D22b.FL.RA pEGFPC2. Human TBC1D22b FL R274A 
BamHI, SalI, derived from 
pFB3532 
pFB4143 pEGFPC2.TBC1D22a.FL.RA pEGFPC2. Human TBC1D22a FL R286A 
derived from pFB3530 
pFB4149 pEGFPC2.KIAA1055.FL.WT pEGFPC2. Human KIAA1055 FL WT, BglII 
BglII derived from pFB3541 
pFB4154 pEGFPC2.TBC1D10B.FL.WT pEGFPC2. Human TBC1D10B FL WT, 
derived from pFB4153 
pFB4333 GSTHis.Rab11bwt pFAT2 Human Rab11bwt 
pFB4362  pEGFPC2.RabGAP-5.FL.RA pEGFPC2 Human RabGAP-5 R165A 
inactive mutant, fl 
pFB4407 pFAT2.Rab6b wt pFAT2 Human Rab6b wt derived from 
pFB3565 
pFB4408 pEGFPC2.TBC1D7  pEGFPC2 Human TBC1D7 wt derived 
from pFB4309 
pFB4411 pEGFPC2.TBC1D8 pEGFPC2 Human TBC1D8 wt derived 
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from pFB3718 
pFB4412 pEGFPC2.TBC1D17 pEGFPC2 Human TBC1D17 wt derived 
from pFB3288 
pFB4414 pEGFPC2.TBC1D19 pEGFPC2 Human TBC1D19 wt  derived 
from  pFB3289 
pFB4417 pEGFPC2.TBC1D16 pEGFPC2 Human TBC1D16 wt derived 
from pFB3287 
pFB4420 pEGFPC2.KIAA0984 pEGFPC2 KIAA0984 wt BamHI-XhoI; 
derived from pFB3721 
pFB4423 pEGFPC2.TBC1D15 pEGFPC2 Human TBC1D15 wt derived 
from pFB3286 
pFB4427 pEGFPC2.KIAA0676 pEGFPC2 Human KIAA0676 wt derived 
from pFB3290 
pFB4430 pEGFP.C2.TBC1D10A fl wt pEGFPC2 Human TBC1D10A wt 
pFB4431 pEGFP.C2.TBC1D10A fl RA pEGFPC2 Human TBC1D10A RA 
pFB4433 pEGFP.C2.TBC1D17 fl RA pEGFPC2 Human TBC1D17 RA 
pFB4434 pEGFP.C2.KIAA0984 RA pEGFPC2 Human KIAA0984 
pFB4441 pMAL.TEV_His TBC1D17wt pMALTEV-His Human TBC1D17 wt FL 
pFB4555 pEGFPC2.TBC1D10b.Fl.RA pEGFPC2. Human TBC1D10b RA , 
derived from pFB4158. 
pFB4619 pFAT2.Human Rab12wt pFAT2 Human Rab12 wt, N-terminal 
GST+His6 tag, derived from 
pFB3583 
pFB4620 pFAT2.Human Rab15wt pFAT2 Human Rab15 wt, N-terminal 
GST+His6 tag, derived from 
pFB3569 
pFB4621 pFAT2.Human Rab17wt pFAT2 Human Rab17 wt, N-terminal 
GST+His6 tag, derived from 
pFB3498 
pFB4622 pFAT2.Human Rab20wt pFAT2 Human Rab20 wt, N-terminal 
GST+His6 tag, derived from 
pFB3760 
pFB4623 pFAT2.Human Rab28wt pFAT2 Human Rab28 wt, N-terminal 
GST+His6 tag, derived from 
pFB3520 
pFB4624 pFAT2.Human Rab32wt pFAT2 Human Rab32 wt, N-terminal 
GST+His6 tag, derived from 
pFB2936 
pFB4625 pFAT2.Human Rab36wt pFAT2 Human Rab36 wt, N-terminal 
GST+His6 tag, derived from 
pFB3573 
pFB4626 pFAT2.Human Rab38wt pFAT2 Human Rab38 wt, N-terminal 
GST+His6 tag, derived from 
pFB3524 
pFB4627 pFAT2.Human Rab40awt pFAT2 Human Rab40a wt, N-terminal 
GST+His6 tag, derived from 
pFB3571 
5.1.5 siRNA oligonucleotides 
siRNA oligonucleotides for siRNA-mediated depletion of specific mRNAs were 
generally designed to a target sequence of NN(N19)dTdT using the siDESIGN 
Center on the Dharmacon homepage (www.dharmacon.com) (Elbashir et al., 2002; 
Reynolds et al., 2004). The RNA oligonucleotides used in the course of this work 
are listed in the table below. 
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GL2 (Control)     CGUACGCGGAAUACUUCGAUU 
LaminA (Control)     CTGGACTTCCAGAAGAACATC 
Rab6A 3’UTR     GCUCACUGCUUUGGCCCCCUU 
PIST     CCCUGGUGCUAGUUGCAAAUU 
Golgin-160     GCAGCCUUCAUGCAGAUUCUU 
Rab5A #1, GCAAGCAAGUCCUAACAUUUU 
#2, UGACACUACAGUAAAGUUUUU 
#3, GGAAGAGGAGUAGACCUUAUU 
#4, AGAGUCCGCUGUUGGCAAAUU 
Rab5B #1, GGAGCGAUAUCACAGCUUAUU 
#2, GAAAGUCAAGCCUGGUAUUUU 
#3, CAACAAACGUAUGGUGGAGUU 
#4, AAGCUGCAAUCGUGGUUUAUU 
Rab5C #1, UCAUUGCACUCGCGGGUAAUU 
#2, GAACAAGAUCUGUCAAUUUUU 
#3, GCAAUGAACGUGAACGAAAUU 
#4, GCUAAGAAGCUUCCCAAGAUU 
Rab6A #1, GUGGAUUGAUGAUGUCAGAUU 
#2, CCAAAGAGCUGAAUGUUAUUU 
#3, GAGCAAAGCGUUGGAAAGAUU 
#4, GAAAGAGGAAGUGAUGUUAUU 
Rab6B #1, GCUGAUAAGAGGCAGAUAAUU 
#2, CAACAGACCUCUAAGUGGAUU 
#3, GAGUUAAGGUUCCAUAAUAUU 
#4, UCAGGAAAGUUGAGUGUAAUU 
Rab43 #1, GCGUCGACUUCACCAUGAAUU 
#2, GGAUUGAGGAUGUGAGGAAUU 
5.1.6 Antibodies 
The antibodies used in the course of this work are listed in the tables below, along 
with their typical dilutions used for western blotting and immunofluorescence. 
5.1.6.1 Primary antibodies 
Name Species Antigen Dilution 
for WB 
Dilution 
for IF 
Source 
9E10 Mouse c-myc 1:1000 1:1000 Cancer 
Research UK 
α−Bic-D1 Rabbit Human Bic-D1 
C-terminal 
fragment 
1:100 1:50 Barr laboratory 
α−EEA1 Mouse Human EEA1 1:50 1:50 BD Biosciences 
α−GFP Sheep His-GFP 1:2000 1:2000 Barr laboratory 
α−GM130 Mouse Human GM130 1:2000 1:2000 BD Biosciences 
α−GM130 Sheep His-rat GM130 1:1000 1:1000 Barr laboratory 
α−Golgin-
97 
Mouse Human golgin-97 nd 1:100 Molecular 
Probes 
α−Golgin-
97 
Sheep Human golgin-97 
aa 589-769 
1:500 1:500 Barr laboratory 
α−Golgin-
160 
Rabbit Human golgin-
160 
1:1000 1:1000 Barr laboratory 
Material and Methods 
 
103 
Name Species Antigen Dilution 
for WB 
Dilution 
for IF 
Source 
α−Histidine Mouse Hexahistidine 
epitope tag 
1:1000 - Dianova 
α−p115 Sheep Rat p115 aa 772-
959 
1:2000 1:2000 Barr laboratory 
α−p150glued Mouse Rat p150glued 1:100 1:100 BD Biosciences 
α−PIST Rabbit Human PIST full-
length 
1:1000 1:1000 Raised and 
purified during 
this work 
α−Rab6 (C-
19) 
Rabbit Human Rab6 C-
terminal peptide 
not 
working 
1:100 Santa Cruz 
Biotech 
α−TGN46 Sheep Human TGN46 1:2000 1:2000 Serotech 
α−Tubulin Mouse Tubulin 1:1000 1:1000 Sigma-Aldrich 
5.1.6.2 Secondary antibodies 
Name Species Antigen Dilution 
for WB 
Dilution 
for IF 
Source 
AMCA-α-
mouse 
Donkey Mouse 
IgG 
- 1:250 Jackson Laboratories 
Cy2-α-mouse Donkey Mouse 
IgG 
- 1:1000 Jackson Laboratories 
Cy3-α-mouse Donkey Mouse 
IgG 
- 1:1000 Jackson Laboratories 
HRP-α-mouse Sheep Mouse 
IgG 
1:2000 - Amersham-
Pharmacia 
AMCA-α-
mouse 
Donkey Mouse 
IgG 
- 1:250 Jackson Laboratories 
Cy2-α-rabbit Donkey Rabbit IgG - 1:1000 Jackson Laboratories 
Cy3-α-rabbit Donkey Rabbit IgG - 1:1000 Jackson Laboratories 
HRP-α-rabbit Donkey Rabbit IgG 1:2000 - Jackson Laboratories 
Cy2-α-sheep Donkey Sheep IgG - 1:1000 Jackson Laboratories 
Cy3-α-sheep Donkey Sheep IgG - 1:1000 Jackson Laboratories 
HRP-α-sheep Donkey Sheep IgG 1:10000 - Jackson Laboratories 
 
5.2 Bacterial Methods 
5.2.1 Growth and maintenance of E. coli 
Bacteria were grown at 37 °C in LB medium containing an appropriate antibiotic for 
selection (typically either 100 µg/ml ampicillin, 50 µg/ml kanamycin, or 34 µg/ml 
chloramphenicol). Short-term storage was on LB-agar plates plus antibiotic at 4 °C. 
5.2.2 Bacterial strains 
The following E. coli strains were used in the course of this work. 
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XL1-blue F’::Tn10 proA+B+ lacIq 
Δ(lacZ)M15/ recA1 endA1 
gyrA96 (NaIr) thi hsdR17 (rK-
mK+) glnV44 relA1 lac 
General cloning applications 
GM2163 F- ara-14 leuB6 fhuA31 lacY1 
tsx78 glnV44 galK2 galT22 
mcrA dcm-6 hisG4 rfbD1 
rpsL136 dam13::Tn9 xylA5 
mtl-1 thi-1 mcrB1 hsdR2 
Cloning of non-methylated 
DNA for digestion with Dam 
or Dcm-sensitive restriction 
enzymes 
BL21(DE3)* F- ompT gal [dcm] [lon] hsdSB 
rB- mB-; an E. coli B strain with 
DE3, a λ prophage carrying 
the T7 RNA polymerase gene 
Recombinant protein 
expression 
JM109* F’ traD36 proA+B+ lacIq 
Δ(lacZ)M15/ Δ(lac-proAB) 
glnV44 e14- gyrA96 recA1 
relA1 endA1 thi hsdR17 
Recombinant protein 
expression 
TOP10 F- mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 deoR araD139 
Δ(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG 
TA-cloning of PCR products 
 
*In most cases, BL21(DE3) and JM109 strains carrying the pRIL plasmid 
(Stratagene) were used for recombinant protein expression. This plasmid encodes 
the tRNA genes for rare arginine, isoleucine, and leucine codons and conveys 
chloramphenicol resistance. 
5.2.3 Preparation and transformation of chemically competent bacteria 
To prepare chemically competent E. coli, a single colony was picked from a fresh 
plate and used to inoculate 50 ml of LB (with selection, if necessary) and grown 
overnight at 37 °C with shaking. 1 ml of overnight culture was then used to inoculate 
100 ml of fresh LB and the cells were grown at 37 °C until an OD600 of 0.5. The 
culture was then chilled on ice for 15 minutes before being transferred to a sterile 
centrifuge tube and centrifuged at approximately 3000 x g for 10 minutes at 4 °C. 
The supernatant was discarded and the cell pellet resuspended in 0.4 total culture 
volume of TfbI (30 mM KOAc, 100 mM RbCl2, 10 mM CaCl2, 50 mM MnCl2, 
15% (v/v) glycerol, pH adjusted to 5.8 with dilute acetic acid). The cells were 
incubated on ice for 15 minutes and then pelleted as before. The cell pellet was then 
resuspended in 0.04 volume TfbII (10 mM MOPS, 75 mM CaCl2, 10 mM RbCl2, 
15 % (v/v) glycerol, pH adjusted to 6.5 with dilute NaOH). After storing on ice for 15 
minutes, the cells were aliquoted into 50 µl aliquots in sterile Eppendorfs, frozen in 
liquid nitrogen, and stored at – 80 °C until needed. 
For transformation, aliquots were thawed on ice before adding the DNA. In 
general, 5 µl of a ligation reaction was used for transformation of 50 µl competent 
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bacteria, or 1 µl of plasmid DNA (approx. 200 ng). Cells and DNA were mixed and 
left on ice for 15 minutes before being heat-shocked in a 42 °C water bath for 45 – 
90 seconds. Cells were placed back on ice for 1 minute before the addition of either 
250 µl (ligation transformation) or 1000 µl (plasmid transformation) LB. The cells 
were then allowed to recover for 30 – 60 minutes at 37 °C with shaking before being 
plated on LB-agar plates containing an appropriate selection antibiotic. All of a 
ligation transformation was plated while only 100 µl of a plasmid transformation was 
plated. Plates were then incubated overnight at 37 °C. 
5.2.4 Preparation and transformation of electrocompetent bacteria 
To prepare electrocompetent E. coli, a single colony was picked from a fresh plate 
and used to inoculate 5 ml of LB and grown overnight at 37 °C with shaking. 2.5 ml 
of the overnight culture was then used to inoculate 500 ml of fresh LB and grown at 
37 °C until an OD600 of between 0.5 and 0.6. The culture was then chilled on ice for 
15 minutes before being transferred to a sterile centrifuge tube and centrifuged at 
approximately 3000 x g for 10 minutes at 4 °C. The supernatant was removed and 
the cells resuspended in 10 ml sterile, ice-cold water. Centrifuge tubes were then 
filled with 500 ml ice-cold water and centrifuged as before. The supernatant was 
removed and the volume adjusted to 50 ml with ice-cold 10 % (v/v) glycerol before 
centrifuging as above. The cell pellet was resuspended in an equal volume of ice-
cold 10 % (v/v) glycerol and the cells were aliquoted into 40 µl aliquots in sterile 
Eppendorf tubes, frozen in liquid nitrogen, and stored at – 80 °C until needed. 
For electroporation, sterile 2 mm electroporation cuvettes were placed on ice 
to chill while cells were thawed on ice. 1-2 µl of yeast miniprep DNA or 1-10 ng 
plasmid DNA was added to the cuvette followed by 40 µl of electrocompetent cells. 
The cuvette was flicked to mix the DNA and cells and left on ice for 5 minutes. The 
electroporator was set to 2.5 kV, 25 µFarads. Cuvettes were dried with a tissue wipe 
and placed into the chamber and the cells electroporated (ideally, with a time 
constant of 4.7). 250 µl of LB medium was added to the cuvette immediately and the 
cells were transferred to a sterile Eppendorf tube and incubated at 37 °C for 1 hour 
before being plated on LB-agar plates containing an appropriate selective antibiotic 
and grown at 37 °C. 
5.2.5 Plasmid DNA preparation from bacteria 
Plasmid DNA was prepared using either miniprep or maxiprep kits (Qiagen, Hilden, 
Germany) according to the manufacturers instructions. Typically, minipreps were 
prepared from 1,5 ml, maxipreps from 150 ml of overnight cultures grown in LB 
containing selective antibiotic at 37 °C. 
5.2.6 Purification of 6xHis- and 6xHisGST-tagged proteins from bacteria 
A single colony was picked from a fresh plate of transformed E. coli and used to 
inoculate 25 ml of LB plus selective antibiotics and grown overnight at 37 °C with 
shaking. 10 ml of the overnight culture was then used to inoculate 1 l of fresh LB 
plus antibiotics and grown at 37 °C until an OD600 of 0.5 – 0.6 was reached. 
Depending upon the protein being expressed, cultures were shifted to 18 °C for 30 
minutes before being induced with 0.5 mM Isopropyl β-D-thiogalactoside (IPTG) 
from a 1 M stock or induced immediately at 37 °C. Cultures were then left for either 
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3 hours (37 °C) or overnight (18 °C). Bacteria were then harvested by centrifugation 
at 3000 x g for 15 minutes at 4 °C and cell pellets were frozen on dry ice for 20 
minutes. 
For protein purification, cell pellets were thawed by the addition of 20 ml lysis 
buffer per litre of original culture. Lysis buffer consisted of 0.5 mg/ml lysozyme and 
protease inhibitors added to IMAC5-TX (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 
5 mM imidazole, 0.1 % TX100). The cell pellet was resuspended and incubated at 
37 °C for 5 minutes or until the lysate became extremely viscous. The lysate was 
sonicated on ice using a Bandelin Sonopuls sonicator (Bandelin, Berlin, Germany) 
until the DNA was sheared and the lysate became much less viscous. The lysate 
was then centrifuged at 28000 rpm for 30 minutes at 4 °C in an SW28 rotor in a 
Beckman Optima LE-80K Ultracentrifuge (Beckman, USA) to pellet the cell debris. 
The cleared lysate supernatant was transferred into a clean falcon tube. 0.5 ml of 
Ni-NTA agarose (Qiagen) per litre of original culture, washed in IMAC5-TX, was 
added to the cleared lysate and the tube was rotated for 2 hours at 4 °C to allow 
protein binding to occur. The resin was then pelleted by centrifugation at 1000 x g 
for 5 minutes at 4 °C and washed in 2 x 30 ml of IMAC20-TX (20 mM Tris-HCl 
pH 8.0, 300 mM NaCl, 20 mM imidazole, 0.1 % TX100). The resin was then washed 
in a further 30 ml of IMAC20 without TX100 and bound protein was eluted by the 
addition of IMAC200 (20 mM Tris-HCl pH 8.0, 300 mM NaCl, 200 mM imidazole). 
The eluate was collected in 0.5 ml fractions. After SDS-PAGE analysis of 10 µl of 
these fractions, peak fractions containing recombinant protein were pooled and 
dialysed overnight at 4 °C into a suitable buffer (usually PBS). Protein concentration 
was then determined, before aliquoting and storage. 
5.2.7 Purification of MBP-tagged proteins from bacteria 
For purification of MBP-tagged proteins bacteria were grown as described in 5.2.6 
except that glucose was added to a final concentration of 0.2 % in order to prevent 
the up-regulation of amylase enzymes. After induction with 0.5 mM IPTG cultures 
were left shaking for 3 hours at 37 °C. Bacteria were then harvested by 
centrifugation at 3000 x g for 15 minutes at 4 °C and cell pellets were frozen on dry 
ice for 20 minutes. 
For protein purification, cell pellets were thawed by the addition of 20 ml lysis 
buffer per litre of original culture. Lysis buffer consisted of 0.5 mg/ml lysozyme 
added to TBS-TX (50 mM Tris-HCl pH7.5, 150 mM NaCl, 0.1 % TX100). The cell 
pellet was resuspended and incubated at 37 °C for 5 minutes or until the lysate 
became extremely viscous. The lysate was sonicated on ice using a Bandelin 
Sonopuls sonicator (Bandelin, Berlin, Germany) until the DNA was sheared and the 
lysate became much less viscous. The lysate was then centrifuged at 28000 rpm for 
30 minutes at 4 °C in an SW28 rotor in a Beckman Optima LE-80K Ultracentrifuge 
(Beckman, USA) to pellet the cell debris. The cleared lysate supernatant was 
transferred into a clean falcon tube. 1 ml of amylose resin (New England Biolabs, 
USA) per litre of original culture, washed in TBS-TX, was added to the cleared 
lysate and the tube was rotated for 4 hours at 4 °C to allow protein binding to occur. 
The resin was then pelleted by centrifugation at 1000 x g for 5 minutes at 4 °C and 
washed in 2 x 30 ml of TBS-TX and 1 x 30 ml TBS without TX100 (50 mM Tris-HCl 
pH7.5, 150 mM NaCl). Bound protein was then eluted by the addition of 20 mM free 
maltose in TBS. The eluate was collected in 1 ml fractions. After SDS-PAGE 
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analysis of 10 µl of these fractions, peak fractions containing recombinant protein 
were pooled and dialysed overnight at 4 °C into TBS containing 2 mM DTT. Protein 
concentration was then determined, before aliquoting and storage. 
5.3 DNA methods 
Standard DNA manipulations were performed essentially as described (Sambrook 
and Russel, 2001). Enzymes for DNA modification were obtained from New England 
Biolabs (Ipswich, MA, USA), Promega (Madison, WI, USA), or Invitrogen (Carlsbad, 
CA, USA) and used according to the suppliers instructions. 
5.3.1 "Shortway" cloning strategy 
As far as possible, a standard cloning strategy, referred to as the “Shortway” 
system, was used when generating constructs, in order to make all inserts 
compatible with a wide range of different vectors. This involved generating inserts 
with a BamHI, BglII, or BclI site at the 5’ end and a SalI or XhoI site at the 3’ end.  
The ATC of the BamHI/ BglII/ BclI site was designed to be in frame with the start 
codon of the insert i.e.  
GGG ATC CCC ATG (BamHI) 
GAG ATC TCC ATG (BglII) 
GTG ATC ACC ATG (BclI, dam sensitive) 
where the restriction site is underlined and the start codon is in italics. 
These restriction sites were added by PCR and the insert was TA-TOPO cloned into 
the vector pCRIITOPO (Invitrogen). Constructs were sequenced from pCRIITOPO 
and then subcloned into the following vectors: 
 
Yeast 2-hybrid bait vector pFBT9 (modified pGBT9 carrying a Kan resistance gene) 
Yeast 2-hybrid prey vector pFBT9 (pACT2) 
N-terminal 6xHis-tagging vectors (pQE32) 
N-terminal MBP-tagging vector (pMalTev6xHis) 
N-terminal 6xHisGST-tagging vector (pFAT2) 
N-terminal GFP-tagging vector (pEGFP-C2) 
C-terminal GFP-tagging vectors (pEGFP-N1, 2, or 3) 
N-terminal tagged mammalian expression vectors (pcDNA3.1/MycA or /Flag) 
 
If a sequence of interest was not clonable using this approach, alternative restriction 
sites were added to the 5’ and 3’ ends. 
5.3.2 Restriction digests and agarose gel electrophoresis of DNA 
Analytical restriction digests were carried out in a total volume of 20 µl using 0.5 µl 
of each enzyme in an appropriate buffer to digest approximately 500 ng of DNA. 
Digests were carried out for 2 hours at an appropriate temperature before being 
mixed with DNA loading buffer and loaded for electrophoresis onto a 1 % agarose 
gel (1 % (w/v) agarose dissolved in 1 x TAE containing 0.8 µg/ml ethidium bromide). 
The gel was run in 1 x TAE at a constant voltage of 80 V for approximately 50 
minutes and DNA was visualized on a UV transilluminator. 
Preparative restriction digests were performed similarly except that 2-3 µg 
DNA was used. Vector DNA was usually treated with alkaline phosphatase by the 
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addition of 1 µl enzyme to the digestion mix for 15 minutes immediately prior to 
loading on the gel. Following electrophoresis, appropriate bands were excised using 
a clean scalpel blade and purified using a gel extraction kit (Qiagen) according to 
the manufacturers instructions. 
5.3.3 Cloning digested DNA fragments 
Ligations were performed in a total volume of 20 µl using 1 µl of T4 DNA ligase 
(NEB) in 1x ligase buffer (NEB). 100 ng of vector DNA was used along with enough 
insert DNA to make a 3:1 molar ratio of insert:vector DNA. Ligations were incubated 
for 2 hours at room temperature before transformation of bacteria with 5 µl ligation 
product. 
5.3.4 mRNA isolation and cDNA synthesis 
Total RNA from HeLa cells was isolated using TRIZOL reagent (Invitrogen), which is 
a solution of phenol and guanidine isothiocyanate. Per 3.5 cm diameter dish of cells 
grown in a monolayer, 1 ml of TRIZOL reagent was added and pipetted up and 
down several times to homogenise the sample. After 5 minutes incubation at room 
temperature 200 µl of chloroform were added. The sample was mixed vigorously by 
hand for 15 seconds and incubated for 3 minutes at room temperature. 
Centrifugation at 10000 x g at 4 °C separated the sample into a lower organic phase 
and into an upper aqueous phase containing the RNA. This upper phase was 
transferred carefully to a new tube and mixed with 500 µl of isopropyl alcohol to 
precipitate the RNA. After an incubation of 10 minutes at room temperature, the 
RNA precipitate was pelleted by centrifugation at 10000 x g at 4 °C, the pellet was 
washed once with 75 % ethanol and centrifuged again at 7500 x g for 5 minutes at 
4 °C. Then, the RNA was briefly air-dried, redissolved in RNase-free water and 
quantified by UV-spectroscopy measuring A260 and A280. 
cDNA was generated by reverse transcription using the Advantage RT-for-
PCR kit from BD Clontech (Franklin Lakes, NJ, USA). For this, 1 µg of total RNA 
was diluted to 12.5 µl in RNase-free water and, together with 1 µl of the oligo(dT)18 
primer (20 pmol/µl), heated for 2 minutes at 70 °C. After rapid cooling on ice the 
following components were added to the mixture: 4 µl of 5 x reaction buffer (250 mM 
Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl2), 1 µl of dNTP mix (10 mM), 0.5 µl of 
RNase inhibitor and 1 µl of MMLV reverse transcriptase. The reaction was 
incubated for 1 hour at 42 °C, then heated for 5 minutes at 94 °C to stop the 
reaction and to destroy DNase activity and diluted with RNase-free water to 100 µl 
total volume. 
5.3.5 PCR and cloning of PCR products 
Oligonucleotides for PCR reactions were obtained from Metabion (Martinsried, 
Germany), or Qiagen (Hilden, Germany) and dissolved to 100 µM stocks in TE 
buffer. 
For all PCR reactions a GeneAmp PCR System 2400 thermocycler (Perkin-
Elmer, Waltham, MA, USA) was used. Reactions were carried out in a total volume 
of 50 µl and contained 1 x polymerase reaction buffer, 1.25 µM forward and reverse 
primers, 0.25 mM dNTPs, and 1 µl (2.5 U) Pfu turbo polymerase (Stratagene, La 
Jolla, CA, USA) or 1 µl (1 U) KOD hot start polymerase (Novagen, Madison, WI, 
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USA). As a template, either 10 ng plasmid DNA or 5 µl marathon-ready cDNA 
library (Clontech, Palo Alto, CA, USA) or HeLa cDNA library (see 5.3.4) was used. 
Typically, 25 cycles of denaturation at 94 °C for 15 seconds, annealing at 55 °C for 
30 seconds, and extension at 68 °C for 2 minutes per kb to be amplified, were used 
with an initial denaturation step of 2 minutes and a final extension step of 2 minutes 
per kb. PCR products were then analysed by agarose gel electrophoresis and, if 
required, bands were excised, gel extracted, and used for cloning. In the case of 
PCR cloning from cDNA libraries, a nested approach was generally used. A first 
round of PCR was performed as described above. The PCR product was then 
directly purified using a PCR nucleotide removal kit (Qiagen) according to the 
manufacturers instructions. 5 µl of the purified PCR product was then used in a 
second round of PCR using a set of primers designed internally to the primers used 
in the first round. This PCR product was then purified by agarose gel 
electrophoresis and used for cloning. 
Following gel extraction of PCR products, cloning was performed into the 
pCRIITOPO vector using the TA-TOPO cloning system (Invitrogen). Adenosine 
overhangs were added to the 3’ ends of the PCR product by incubation of the 
product with 1 µl Taq polymerase (Promega) at 72 °C for 30 minutes in the 
presence of polymerase buffer and 0.25 mM dNTPs in a total volume of 50 µl. 
2 µl of this mix was then added to a sterile Eppendorf along with 0.5 µl TA-TOPO 
cloning mix and incubated for 5 minutes at room temperature. This mix was then 
used for transformation of TOP10 bacteria. 
5.3.6 Site-directed mutagenesis 
Point mutagenesis was carried out using the Quickchange method. Forward and 
reverse mutagenic primers were designed to be 33 bases long with the codon to be 
altered in the middle, with 15 unchanged bases on either side. The quickchange 
reaction was then set up in a total volume of 50 µl with 1 x pfu polymerase buffer, 
1.25 µM forward and reverse primers, 0.25 µM dNTPs, 25 ng DNA template, and 
1 µl (2.5 U) pfu turbo polymerase. The following cycling parameters were then used: 
95 °C for 30 seconds followed by 18 cycles of 95 °C for 30 seconds, 53-55 °C for 30 
seconds, and 68 °C for 2 minutes per kb of plasmid. After cooling to 4 °C, 1 µl of the 
restriction enzyme DpnI was added to the reaction mix for 1 hour at 37 °C to digest 
methylated (parental) DNA. 5 µl of the reaction mix was used to transform XL1-blue 
bacteria. 
5.3.7 DNA sequencing 
All insert DNAs generated by PCR or mutagenesis, were sequenced commercially 
by Medigenomix (Martinsried, Germany), or in house at the Core Facility of the Max-
Planck-Institute. 
5.4 Protein methods 
5.4.1 SDS-PAGE and Coomassie staining 
Small (8 x 6.5 x 0.075 cm) SDS polyacrylamide gels were prepared as described 
(Sambrook and Russel, 2001). Samples were prepared in SDS-PAGE sample buffer 
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and boiled for 5 minutes. Gels were run in a BioRad Mini-PROTEAN 3 gel chamber 
(BioRad, Munich, Germany) in SDS-PAGE running buffer at 200 V, 30 mA. 
Protein gels were Coomassie stained by immersion in 0.01 % Coomassie 
Brilliant Blue R-250 in 50 % methanol, 10 % acetic acid for 20 minutes, with 
shaking. Gels were then destained in 20 % isopropanol, 20 % acetic acid. 
5.4.2 Tryptic digest for mass-spectrometry 
Sample preparation and analysis was carried out according to a protocol adapted 
from (Shevchenko et al., 1996). Coomassie stained bands from protein gels were 
excised with a clean scalpel, transferred to a Eppendorf Biopure tube and cut into 1 
mm cubes. The gel pieces were washed with 100 µl 50 mM NH4HCO3 for 10 
minutes at 22 °C, then shrunk in 100 µl acetonitrile for 10 minutes at 22 °C, all steps 
with shaking at 1000 rpm in an Eppendorf Thermomixer. This was repeated twice. 
Gel pieces were then dried in a vacuum centrifuge for 5 minutes at 35 °C. 10-15 µl 
of 10 mM DTT in 50 mM NH4HCO3 was added to the dried gel pieces and the 
mixture was incubated at 56 °C for 45 minutes. The gel pieces were returned to 
room temperature and overlaid with 10-15 µl 55 mM iodoacetamide in 50 mM 
NH4HCO3. The reaction was left for 30 minutes at room temperature in the dark. 
The supernatant was removed and replaced with 100 µl 50 mM NH4HCO3 and 
washed as above. The gel pieces were dried again for 5 minutes. 10-15 µl trypsin 
solution (12.5 ng/µl trypsin in 50 mM NH4HCO3; Sequencing-grade modified trypsin, 
Promega) was added to the dried gel cubes and left on ice for 30 minutes. 
Additional 50 mM NH4HCO3 (5-15 µl) was added to the mixture and the digest 
reaction was performed for 16 hours at 37°C. 
After that 2 µl 10% TFA were added to the digest. 1 µl of acidified sample 
was spotted onto the sample matrix (1-Cyano-4-hydroxycinnamic acid, Bruker 
Daltonik GmbH, Germany). The spot was washed once with 0.2% TFA. Mass 
spectrometry of the samples was performed by Dr. Roman Körner (MPI of 
Biochemistry, Department of Cell Biology, Martinsried, Germany) on a ReflexIII 
instrument (Bruker) MALDI TOF mass spectrometer, equipped with a Scout 384 Ion 
source. The spectra were processed with Xmass 5.1.1 software (Bruker). Proteins 
were identified using the database programs MASCOT 
(http://www.matrixscience.com) and ProFound (http://129.85.19.192/profound_bin/ 
WebProFound.exe). 
5.4.3 Western blotting 
Proteins run on SDS-gels were transferred to 45 µm Hybond-C Extra Nitrocellulose 
(Amersham-Pharmacia, UK) by semi-dry blotting in transfer buffer (1x SDS-PAGE 
running buffer plus 10 % methanol) using a Trans-Blot SD Transfer Cell (BioRad, 
Germany) at 15 V, 300 mA, for 45 minutes. Blots were then blocked in milk solution 
(4 % milk powder in PBS, plus 0.1 % Tween-20) for 1 hour before addition of the 
primary antibody. 
Blots were usually incubated with the primary antibody in milk solution for 1 
hour at room temperature before being washed 3 x 10 minutes in milk solution. 
Secondary antibodies linked to horseradish peroxidase were then also incubated 
with the blot for 1 hour before the blots were washed for a further 3 x 10 minutes in 
milk. Bound antibodies were then detected by chemiluminescence using ECL 
Western blot detection reagents (Amersham) according to the manufacturers 
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instructions, exposed to Kodak X-Omat XAR-5 film for an appropriate length of time 
and developed in a Kodak X-OMAT 2000 Processor. 
5.4.4 Determination of protein concentration 
Protein concentrations were determined using the BioRad Protein Assay kit, a 
modified version of the Bradford Assay. The dye reagent was diluted 1:5 in water 
and 1 ml 1x reagent was used per assay point. Different concentrations of bovine 
serum albumin (BSA) were used to construct a standard curve by addition to 1 ml 
aliquots of the dye reagent, mixing, and transfer to disposable cuvettes for 
measurement of the OD595 in an Ultrospec 3000 Pro spectrophotometer 
(Amersham-Pharmacia). Protein samples were measured in the same way and their 
concentration was calculated using the BSA standard curve. 
5.4.5 Protein precipitation with TCA 
When necessary proteins were precipitated using trichloroacetic acid (TCA) for 
loading on SDS-PAGE gels. Typically, protein samples were adjusted to 1 ml with 
water. Sodium deoxycholate was then added to a final concentration of 0.02 % and 
the sample vortexed. Next TCA was added to a final concentration of 12 %, the 
sample vortexed, and left on ice for 45 minutes. Precipitated proteins were then 
recovered by centrifugation at 20000 x g for 20 minutes at 4 °C. The supernatant 
was discarded and the pellet washed two times with ice-cold acetone before being 
centrifuged for a further 10 minutes. The supernatant was discarded and the pellet 
resuspended in an appropriate amount of 1.5x SDS-PAGE sample buffer with a 
small amount of 1 M Tris-HCl pH 8.0 added, as necessary, to adjust the pH of the 
sample. 
5.4.6 GST-Rab binding and pulldown assays 
For big scale pulldown assays from cell extract 500 µg GST-tagged Rab was bound 
to 50 µl glutathione sepharose 4B (Amersham) in a total volume of 1 ml in buffer 
NE100 (20 mM HEPES-NaOH pH 7.5, 100 mM NaCl, 10 mM EDTA, 0.1 % TX100) 
on a roller for 60 minutes at 4 °C. The beads were pelleted by centrifugation at 
600 g for 1 minute at 4 °C and washed three times with 1 ml buffer NE100 to 
remove bound nucleotide from the Rab. For the incubation with extract the loaded 
beads were resuspended in buffer NL100 (20 mM HEPES-NaOH pH 7.5, 100 mM 
NaCl, 5 mM MgCl2, 0.1 % TX100) and transferred to a 15 ml tube. 
In a total volume of 6 ml NL100 the beads were incubated for 60 minutes on 
a roller at 4 °C with 40 mg protein from RIPA lysed HeLa L cells or from rat liver 
cytosol. (Rat liver cytosol was prepared (Hino et al., 1978; Leelavathi, 1970) and 
provided by Ben Short.) To load the Rab with nucleotide GTP (for Rab6wt and 
Rab6Q72L) or GDP (for Rab6T27N) (both 100 mM frozen stock in NL100) was added 
to a final concentration of 5 mM. The beads were pelleted by centrifugation and 
washed three times with 1 ml NL100. Bound proteins were eluted in 500 µl buffer 
NE200 (20 mM HEPES-NaOH pH 7.5, 200 mM NaCl, 20 mM EDTA, 0.1 % TX100), 
rotating at 4 °C for 5 minutes. Eluted proteins were TCA precipitated (see 5.4.5) 
before being loaded on a SDS-gel. 
For small scale binding assays the same procedure was followed, except that only 
4 µg GST-Rab was bound to 15 µl glutathione sepharose 4B (Amersham) and 10 µg 
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His-tagged protein was added to a total volume of 400 µl buffer NL100. Bound 
protein was eluted directly in 1.5x SDS sample buffer and analysed on a 7.5 % 
SDS-gel. 
5.4.7 Antibody generation and purification 
A polyclonal α-PIST antibody was generated by immunisation of two rabbits with 
6xHis-tagged recombinant full-length PIST in collaboration with Charles River 
Laboratories, L'Arbresle Cedex, France. Rabbits were immunised initially subcuta-
neously with 250 µg antigen mixed with Freund’s complete adjuvant followed by four 
intramuscular boosts with 250 µg antigen mixed with Freund’s incomplete adjuvant. 
All test bleed and the final bleed out samples were tested on Western Blot for their 
ability to recognise recombinant antigen and endogenous PIST in cell extracts. PIST 
specific antibodies were purified from the bleed out of one rabbit via affinity 
chromatography. 
In order to exclude antibodies against the 6xHis-tag of the original antigen, 
MBP-tagged PIST full-length was coupled to Affigel-15 (BioRad). 4 ml of Affigel-15 
beads were washed once with water to remove the isopropanol storage solution and 
added to 4 ml protein solution of 1 mg/ml recombinant PIST in PBS. After 2 hours of 
incubation with rolling at 4 °C, the gel was pelleted for 2 minutes at 1000 x g and 
washed three times with 15 ml PBS, once with 15 ml of 0.2 M glycine pH 2.8 and 
again three times with 15 ml PBS. This removed any uncoupled protein and 
mimicked the conditions used to elute the antibody. For purification of the antibody 
15 ml serum was filtered to remove debris and was incubated with 1 ml of the 
affinity matrix (coupled to approx. 1 mg antigen) rolling for 90 minutes at 4 °C. After 
three washes with 15 ml PBS, bound antibodies were eluted using 0.2 M glycine 
pH 2.8 and collecting 1 ml fractions into Eppendorf tubes containing 200 ml 1M Tris-
HCl pH 8.0. Samples were immediately mixed to neutralise and stored on ice. After 
SDS-PAGE analysis antibody peak fractions were pooled, dialysed overnight 
against PBS, aliquoted and stored at – 80 °C or kept at 4 °C for immediate use. 
5.5 Yeast methods 
5.5.1 Strains, media and growth 
The S.cerevisiae strain PJ69-4A (James et al., 1996) was used for all two-hybrid 
experiments, the genotype of which is: 
MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1UAS-
GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2, MEL1 met2::GAL7-lacZ 
Yeast were grown in either YPDA or SC dropout media selecting for appropriate 
plasmids at 30 °C. Short-term storage was on agar plates at 4 °C. 
YPDA medium consisted of 20 g/l peptone (Difco/Becton-Dickinson), 10 g/l 
yeast extract (Difco), and 20 g/l glucose (plus 20 g/l Bacto-agar for YPDA-agar). The 
medium was then sterilised in an autoclave and, after cooling to approximately 
55 °C, 6 ml 0.2 % sterile filtered adenine hemisulphate was added. 
Synthetic complete (SC) dropout medium was prepared as follows: Amino 
acid base (-His/-Trp/-Leu/-Ura) was prepared by mixing 20 g alanine, arginine, 
asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, inositol, 
isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, 
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and valine with 5 g adenine and 2 g para-aminobenzoic acid. To prepare dropout 
mixes, 36.7 g of amino acid base was mixed with either 2 g histidine, 4 g leucine, 2 
g tryptophan, or 2 g uracil, as appropriate to form the correct dropout mix. SC 
dropout medium consisted of 6.7 g/l nitrogen base (without amino acids, Difco), 2 g/l 
appropriate dropout mix, 20 g/l glucose and pH adjusted to 7.5 (Hepes-NaOH) (plus 
20 g/l Bacto-agar for SC dropout agar). After autoclaving and cooling to 
approximately 55 °C, 6 ml 0.2 % sterile filtered adenine hemisulphate was added, 
unless dropout medium was also to be without adenine. 
5.5.2 Yeast transformation (frozen cell method) 
To prepare frozen competent yeast cells, several colonies were picked from a 
freshly grown plate and grown overnight in YPDA at 30 °C with shaking. The 
following morning, the overnight culture was diluted to an OD600 of 0.15 in fresh 
medium and grown at 30 °C to an OD600 of 0.5 – 0.6 (1.2 – 1.5 x 107 cells). The cells 
were then harvested at 3000 rpm for 2 minutes at room temperature in a Heraeus 
centrifuge. The cells were then washed in one half culture volume sterile water and 
spun as before. The cells were then resuspended in 1/8th culture volume of LiSorb 
(100 mM LiOAc, 10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 1 M sorbitol 
(molecular biology quality) filter sterilized). The resuspended pellet was incubated 
for 5 minutes at room temperature before being spun as before. The cell pellet was 
again resuspended in LiSorb (600 µl per 100 ml original culture). Single stranded 
carrier DNA was added (10 µl per 100 µl yeast of 10 mg/ml salmon sperm DNA 
(Gibco), heat-treated at 95 °C for 5 minutes). Cells were then aliquoted and frozen 
directly in a – 80 °C freezer where they were stored until use. 
To transform frozen competent yeast cells, the cells were thawed at room 
temperature. 25 µl cells were used per transformation. 0.5 µl plasmid DNA (approx. 
100 ng) was added to the cells, followed by 150 µl LiPEG (100 mM LiOAc, 10 mM 
Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 40 % PEG3350, filter sterilized). The cells 
were then vortexed and incubated for 20 minutes at room temperature. 17.5 µl 
DMSO was added and the cells were heat-shocked for 15 minutes in a 42 °C 
waterbath. The cells were then pelleted at 400 g in a microfuge, the supernatant 
removed, and the cells resuspended in 500 µl sterile water.  100 µl were the plated 
onto appropriate selective plates and grown at 30 °C. 
In the case of directed yeast two-hybrid experiments, transformed cells were 
originally grown on SC-Leu/-Trp plates to select for both the bait and prey plasmids. 
After 2 –3 days growth, colonies were picked and restreaked onto SC-Leu/-Trp and 
SC-Leu/-Trp/-His/-Ade plates to assess the two-hybrid interaction. 
5.5.3 Plasmid DNA minipreps from yeast cells 
To prepare plasmid DNA from yeast cells, a matchhead-sized ball of cells scraped 
from a fresh plate into 1 ml water, was pelleted at 400 g in a microfuge. The cell 
pellet was resuspended in 500 µl buffer S (10 mM K2HPO4 pH 7.2, 10 mM EDTA, 
50 mM β-mercaptoethanol (i.e. 100 µl per 25 ml added immediately prior to use), 
and 50 µg/ml zymolyase). The cells were then incubated at 37 °C for at least 1 hour. 
After that 100 µl lysis buffer (25 mM Tris-HCl pH 7.5, 25 mM EDTA, 2.5 % (w/v) 
SDS) was added, vortexed, and the lysate incubated at 65 °C for 30 minutes or 
longer until the mixture cleared. 166 µl 3 M KOAc pH 5.5 was then added to stop 
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the lysis reaction, tubes were inverted to mix, and incubated on ice for 10 minutes. 
They were then centrifuged at 20000 x g in a microfuge at 4 °C for 15 minutes and 
the supernatant was transferred to a clean Eppendorf tube. 800 µl cold ethanol was 
added, tubes were inverted to mix, and incubated on ice for 10 minutes before 
centrifugation as before for a further 10 minutes. The supernatant was removed and 
the pellet washed in 1 ml 70% ethanol. The pellet was allowed to air dry before 
resuspension in 40 µl sterile water. 
5.6 Mammalian cell methods 
5.6.1 Cell culture 
HeLa L cells were cultured at 37 °C and 5 % CO2 atmosphere in Dulbeccos 
Modified Eagle Medium (DMEM) containing 10 % fetal calf serum, 100 U/ml 
penicillin and 100 µg/ml streptomycin (GIBCO, Invitrogen) 
5.6.2 Immunofluorescence 
For immunofluorescence, cells were normally cultured on ethanol-flamed 15 mm 
coverslips in 6-well plates. For paraformaldehyde fixation, 3 % paraformaldehyde 
was prepared by dissolving 3 g paraformaldehyde in 100 ml PBS at 80 °C in a fume 
hood. 10 µl 1 M CaCl2 and 10 µl 1 M MgCl2 were added while stirring before the 
solution was allowed to cool to room temperature and pH adjusted to 7.4. The 
solution was then vacuum-filtered through a 0.45 µm filter and 15 ml aliquots were 
stored at – 20 °C. Coverslips were washed twice in 2 ml PBS and then fixed in 3% 
paraformaldehyde for 20 minutes. Coverslips were then washed once in 2 ml 
quench solution (50 mM NH4Cl in PBS made freshly prior to use) before incubation 
in a further 2 ml quench solution for 10 minutes. The coverslips were then washed in 
3 x 2ml PBS. If the cells were to be permeabilised, the coverslips were incubated for 
5 minutes in permeabilisation solution (0.2% TX100 in PBS) before washing in 3 x 
2ml PBS. 
For antibody labeling, primary antibodies were diluted appropriately in PBS. A strip 
of parafilm was placed on a flat surface and 50 µl drops of the antibody solution 
were placed on the strip. Coverslips with fixed cells were then transferred, cell face 
down, onto the antibody drops. The coverslips were then covered with a moist, dark 
chamber and left for 1 hour at room temperature. After this incubation they were 
washed in 3 x 2ml PBS. The same procedure was then followed for incubation with 
secondary antibodies conjugated to appropriate fluorophores. After washing in PBS 
for the final time, coverslips were mounted onto clean microscope slides by placing 
them, cell face down, onto a 10 µl drop of Moviol mounting medium (Prepared as 
follows: 2.4 g Moviol 4-88 added to 6 g analytical grade glycerol while stirring.  6 ml 
of ddH2O then added and the solution was left for 2 hours at room temperature. 
12 ml of 0.2 M Tris-HCl pH 8.5 was then added while stirring and the solution was 
mixed for 10 minutes at 50 °C. The Moviol solution was then clarified by 
centrifugation at 3000 x g for 15 minutes and stored at – 20 °C aliquoted into glass 
vials.). The mounting medium used usually contained 1 µg/ml DAPI stain. The 
coverslips were then left overnight at room temperature to allow the Moviol to dry. 
Images were collected using an Axioskop-2 with a 63x Plan Apochromat oil 
immersion objective of NA 1.4, standard filter sets (Carl Zeiss, Göttingen, Germany), 
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a 1300 by 1030 pixel cooled-CCD camera (model #CCD-1300-Y, Princeton 
Instruments, Trenton, NY) and Metavue software (Visitron Systems, Puchheim, 
Germany). Images were cropped in Adobe Photoshop 7.0 then sized and placed 
using Adobe Illustrator 10.0 (Adobe Systems, San Jose, CA). 
5.6.3 Cell extracts and immunoprecipitation 
In order to detach cells from the cell culture dishes, HeLa or Hek293T cells were 
treated with PBS containing 1 mM EDTA for 10 minutes at 37 °C, then gently 
pipetted off from the cell culture dishes into clean plastic vials and centrifuged for 5 
minutes at 400 g. Total cell extracts were prepared from cell pellets by addition of 
ice-cold lysis buffer (e.g. RIPA or TNTE, see 5.1.3) containing 1 tablet of complete 
mini protease inhibitor (Roche, Mannheim, Germany) per 10 ml solution and 
pipetting up and down several times. After 20 minutes incubation on ice the lysate 
was centrifuged at 20000 g at 4 °C. The supernatant was transferred to a clean 
Eppendorf and the protein concentration of the extract was determined as described 
in 5.4.4. 
For immunoprecipitation (IP) cell extracts were incubated with antibodies in 
an appropriate volume of lysis buffer. Small scale IPs for detection of proteins on 
Western blot were usually performed with cell extracts from one 10 cm dish and 
1 µg purified antibody in a total volume of 1 ml. After 1 hour incubation on a roller at 
4 °C the antibody-antigen complex was precipitated by adding 15 µl of either 
proteinA- (for rabbit polyclonal or mouse monoclonal antibodies) or proteinG-
sepharose (for sheep polyclonal antibodies) (both Amersham) and incubating for 
another 30 minutes while rolling at 4 °C. Then, the complex on beads was 
centrifuged at 400 g at 4 °C, washed three times with 1 ml lysis buffer and eluted 
with 1.5x SDS sample buffer. 
For big scale IPs, that means for detection of interacting proteins on CBB 
stained SDS-PAGE gels, cell extract of 20 x 15 cm dishes and 5 µg antibody was 
used in a total volume of 15 ml. In order to avoid a massive band of the antibody 
heavy chain (55 kDa) on the CBB stained gel the antibody was cross-linked to 
proteinA- or proteinG-sepharose using the bifunctional coupling reagent dimethyl 
pimelidate (DMP) before being used for IP reactions. The protocol followed is 
described in detail in (Harlow and Lane, 1998). In short, the antibody-sepharose 
complex was washed in 10 volumes of 0.2 M sodium borate pH 9.0 and centrifuged 
at 3000 g for 5 minutes. The antibody beads were resuspended in 10 volumes of 0.2 
M sodium borate pH 9.0 and solid DMP was added to a final concentration of 20 
mM. The slurry was incubated for 30 minutes at room temperature with gentle 
mixing, then the reaction was stopped by washing the beads once in 0.2 M 
ethanolamine pH 8.0, following incubation for 2 hours at room temperature in 0.2 M 
ethanolamine pH 8.0 with gentle mixing. After that beads were washed in PBS once, 
resuspended in PBS and used immediately or stored at 4 °C for further usage. 
5.6.4 Transient transfection of mammalian cells 
HeLa cells were transiently transfected with DNA constructs using the lipid-based 
transfection reagent FuGENE6 (Roche). The cells were seeded 24 hours before 
transfection to give 70% confluency at the start of transfection (approx. 70.000 to 
100.000 cells seeded per well of a 6-well plate). Usually, per single well of a 6-well 
plate 1 µg plasmid DNA was used in complex with 3 µl FuGene6 diluted in 100 µl 
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OptiMEM medium (Invitrogen). After gentle mixing and complex formation for 25 
minutes at room temperature the mixture was added drop-wise to the cells which 
were then incubated at 37 °C, 5 % CO2 in 2 ml DMEM until being processed for IP, 
Western blotting or immunofluorescence. 
5.6.5 RNA interference 
In order to selectively knockdown the expression levels of particular proteins, small 
interfering RNA duplexes (siRNAs) were transfected into cultured Hela cells. The 
protocol used was essentially that of (Elbashir et al., 2001). 21 nucleotide siRNA 
duplexes with a 2 nucleotide 3’ overhang were designed and produced by 
Dharmacon Inc (see 5.1.5). The lyophilised and already annealed siRNA duplexes 
were diluted to a stock solution of 100 µM and stored at – 80 °C. 
Hela cells were seeded 24 hours before transfection with the siRNA duplex 
(approx. 20.000 to 30.000 cells seeded per well of a 6-well plate for a 72 hours 
siRNA time course). For transfection, the lipid-based transfection reagent 
Oligofectamine (Invitrogen) was used. For the transfection of a single well of a 6-
well plate, the following amounts were used: 3 µl Oligofectamine and 3 µl of 20 µM 
siRNA duplex were added to 200 µl OptiMEM medium (Invitrogen) in a clean, 
RNAse-free Eppendorf tube. The mixture was mixed gently and left for 25 minutes 
at room temperature. The entire mixture was then added drop-wise to the cells 
which were then incubated at 37 °C, 5 % CO2 in 2 ml DMEM until being processed 
for Western blotting or immunofluorescence. 
 
 
5.7 Functional assays 
5.7.1 STxB purification and endocytosis 
Shiga toxin B-subunit (in vector pTrc99A, gift from Dr. Misumi, Fukuoka University 
School of Medicine, Fukuoka, Japan) was purified from periplasm of E. coli BL21. A 
single colony was picked from a fresh plate of transformed E. coli, used to inoculate 
25 ml of LB plus ampicillin and grown overnight at 30 °C with shaking. 1 ml of the 
overnight culture was then used to inoculate 1 l of fresh LB plus ampicillin, and 
grown at 30 °C until an OD600 of 0.5 – 0.6 was reached, before being induced with 
0.5 mM Isopropyl β-D-thiogalactoside (IPTG) from a 1 M stock for 14 hours. 
Bacteria were then harvested by centrifugation at 3000 x g for 15 minutes at 4 °C, 
washed once with ice-cold PBS and the cell pellet was resuspended in 20 ml ice 
cold 20 mM Tris-HCl pH 7,5, 150 mM NaCl. Polymixin B was added to a final 
concentration of 0.1 mg/ml and the suspension was incubated for 30 min on the 
roller at 4 °C. After sonication (2 x 10 s at 70 % intensity), the periplasm lysate was 
cleared by centrifugation at 13000 x g for 15 minutes at 4 °C. The supernatant was 
cleared again by centrifugation at 90000 x g for 35 minutes at 4 °C, then diluted to 
roughly 50 mM NaCl with 20 mM Tris-HCl pH 7,5 and loaded onto a 5 ml HiTrapQ 
anion exchange column (Amersham-Pharmacia). After washes with 20 ml 20 mM 
Tris-HCl pH 7,5, protein was eluted with 50 ml of a linear gradient from 0 mM to 
600 mM NaCl in 20 mM Tris-HCl pH 7,5 with a flow rate of 2 ml/min. 2.5 ml fractions 
were collected and analysed by SDS-PAGE. Fractions of interest were pooled 
Material and Methods 
 
117 
(which gave 15 ml of approx. 1 mg/ml protein) and concentrated in a centricon spin 
concentrator 10K (Millipore, Billerica, MA, USA) at 4 °C at 3000 x g to reach more or 
less 5 mg/ml total protein concentration. Then, 500 µl (approx. 2.5 mg) of this 
solution were loaded on a Superose 12 column (Amersham-Pharmacia) for gel 
filtraton in PBS with a flow rate of 0.15 ml/min. 1 ml fractions were collected and 
analysed by SDS-PAGE. 
 To label purified Shiga Toxin B-subunit on amine residues with an N-
hydroxysuccinimidyl ester of Cy3 dye one STxB peak fraction of approx. 1.1 mg/ml 
protein was added to one vial of Cy3 Mono-Reactive Dye Pack (GE Healthcare, 
Munich, Germany), mixed by gentle shaking and left at room temperature for 5 
minutes. The labelling reaction was stopped by addition of 100 µl 1M Tris-HCl 
pH 8.0 and everything passed through a PD10 desalting column (Amersham-
Pharmacia) in order to separate the labelled protein from excess, unconjugated dye. 
500 µl fractions in PBS were collected and the absorption at 280 nm and 552 nm 
wavelength was measured in a spectrophotometer for each fraction. The two 
fractions with highest protein concentration (fraction 8 and 9) were pooled and molar 
concentrations of dye and protein were calculated using the molar extincition 
coefficient of 150000 M-1cm-1 at 552 nm for the Cy3 dye and 170000 M-1cm-1 at 280 
nm for the pentameric Shiga toxin B-subunit. The calculation was corrected for the 
absorbance of the dye at 280 nm, which is approximately 8 % of the absorbance at 
552 nm. Finally, this lead to a stoichiometry of 5 Cy3 dye molecules per pentamer of 
STxB and a protein concentration of 0.7 mg/ml in 1 ml solution. 
For uptake assays, HeLa cells plated on glass coverslips at a density of 
70000 cells/ well of a 6-well plate and, as indicated in the figures transfected for 24 
hours with DNA plasmids, were washed three-times in ice cold PBS, and placed on 
40 µl drops of uptake medium (DME, 2% (w/v) bovine serum albumin, 20 mM 
HEPES-NaOH pH 7.5) and 0.7 µg/ml Cy3-STxB on an ice cold metal plate covered 
in Parafilm (Pechiney Plastic Packaging, Menasha, WI). After 30 minutes incubation 
the coverslips were washed three-times in ice cold PBS to remove excess ligand. 
One coverslip was fixed to give the total bound ligand, while the remaining 
coverslips were transferred to a 6-well plate containing pre-warmed growth medium 
and incubated at 37 °C and 5 % CO2. At the time points indicated in the figures 
coverslips were fixed and processed for immune fluorescence microscopy (see 
5.6.2). 
5.7.2 Shiga-like toxin 1 cytotoxicity assay 
Cytotoxicity was defined as a decrease in the ability of cells to incorporate [35S]-
methionine into acid-precipitable material after Shiga-like toxin 1 treatment using an 
established method (Spooner et al., 2004). HeLa cells were plated at a density of 
150.000 cells/well in a 6-well plate and, the next day, transiently transfected with 
either wild-type or RA-mutant RabGAPs for 10 hours using FuGene6 like described 
in 5.6.4. Then, the cells were detached from the dish using PBS containing 1 mM 
EDTA, re-plated in 96-well plates at a density of 15.000 cells/well and left for 
another 14 hours. After washing with PBS, cells were incubated for 1 hour with 100 
µl DMEM/FCS containing serial 2-fold dilutions from 50 ng/ml to 0.05 ng/ml of 
Shiga-like toxin 1. Subsequently, cells were washed with PBS and incubated in PBS 
containing 50 µCi/ml [35S]-methionine for 30 minutes. Labelled proteins were 
precipitated with three washes in 5 % (w/v) trichloroacetic acid, the wells were 
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washed twice with PBS, then 50 µl of scintillation fluid were added, and the amount 
of radiolabel incorporated was determined in a Wallac MicroBeta Trilux counter 
(Perkin-Elmer). For each condition, the concentration giving 50 % inhibition (IC50) for 
Shiga-like toxin 1 was calculated from the toxin titration. 
5.7.3 EGF uptake assay 
EGF coupled to Alexa Fluor 488 or Alex Fluor 555 (40x stock, 200 µg/ml) (Molecular 
Probes, Invitrogen) were stored as stock solutions in PBS at – 20 °C. For uptake 
assays, HeLa cells plated on glass coverslips at a density of 70.000 cells/ well of a 
6-well plate were washed three times with serum-free growth medium 36 hours after 
plating, and then incubated in serum free growth medium for 12 to 14 hours at 37 °C 
and 5 % CO2. Coverslips were then washed three-times in ice cold PBS, and placed 
on 40 µl drops of uptake medium (DME, 2% (w/v) bovine serum albumin, 20 mM 
HEPES-NaOH pH 7.5) and 5 µg/ml EGF on an ice cold metal plate covered in 
Parafilm (Pechiney Plastic Packaging, Menasha, WI). After 30 minutes incubation 
the coverslips were washed three-times in ice cold PBS to remove excess ligand. 
One coverslip was fixed to give the total bound ligand, while the remaining 
coverslips were transferred to a 6-well plate containing pre-warmed growth medium 
and incubated at 37 °C and 5 % CO2. At the time points indicated in the figures 
coverslips were fixed and processed for immune fluorescence microscopy (see 
5.6.2). 
For combined EGF and STxB assays, both ligands were mixed and bound 
simultaneously to the cell surface, and then the standard procedure was followed. 
5.7.4 GTP-hydrolysis assay 
To measure GTP-hydrolysis of a Rab together with a certain GAP Rab proteins 
were loaded with [γ-32P]GTP and incubated with the GAP. GTP hydrolysis was 
measured counting free inorganic phosphate [γ-32P] in the supernatant of GAP and 
control reactions after charcoal extraction. 
Before, GTP-binding was measured using a nitrocellulose filter-binding assay (Du 
and Novick, 2001). To monitor Rab GTP loading 10 µl of 10x assay buffer (500 mM 
Hepes-NaOH pH 6.8, 10 mg/ml BSA, 10 mM DTT), 73 µl ddH2O, 5 µl 10 mM EDTA 
pH 8.0, 5 µl 1 mM GTP, 2 µl of [γ-32P]GTP (Amersham, PB10244, 10 mCi/ml; 5000 
Ci/mmol) and 100 pmoles Rab protein, diluted with 1x assay buffer to 5 µl, were 
mixed on ice and then incubated in a 30 °C water bath. Every 5 minutes, a 20 µl 
aliquot of the loading mixture was taken and pipetted immediately onto a 
nitrocellulose filter sitting on top of a vacuum flask. The filter was washed twice with 
assay buffer (without BSA) and then dried on Whatman paper, before being 
transferred to a scintillation vial containing 4 ml of Ultima Gold scintillation liquid 
(Perkin-Elmer) and scintillation counted. 
For the GTP-hydrolysis reaction together with the GAP, Rab proteins were 
loaded with GTP in the same reaction mix (10 µl of 10x assay buffer, 73 µl ddH2O, 5 
µl 10 mM EDTA pH 8.0, 5 µl 1 mM GTP, 2 µl of [γ-32P]GTP (Amersham, PB10244, 
10 mCi/ml; 5000 Ci/mmol) and 100 pmoles Rab protein, diluted with 1x assay buffer 
to 5 µl). After 15 minutes incubation at 30 °C in a waterbath the reaction mix with the 
loaded Rab was split into two and kept on ice. A 2.5 µl aliquot of the assay mix was 
scintillation counted to measure the specific activity in cpm/pmole GTP. GAP 
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reactions were started by the addition of 0.5 pmoles of the RabGAP to one vial (+ 
GAP) and assay buffer to the other vial (- GAP). Reactions were then incubated at 
30 °C for 60 minutes, then stopped on ice. 5 µl samples were taken in duplicate. 
These aliquots were immediately added to 795 µl of ice cold 5% (w/v) activated 
charcoal slurry in 50 mM NaH2PO4, vortexed to mix thoroughly and left on ice for 1 
h. Then the samples were centrifuged for 5 minutes at 16100 g in a benchtop 
microfuge to pellet the charcoal. A 400 µl aliquot of the supernatant was transferred 
into a scintillation vial containing 4 ml of Ultima Gold scintillation liquid (Perkin-
Elmer) and scintillation counted. 
The amount of GTP hydrolysed in each reaction was calculated from the 
specific activity of the reaction mixture. First, the measured specific activity from the 
2.5 µl aliquot (cpm/ 2,5 µl) was multiplied by 40 to get the specific activity for the full 
assay (100 µl). This value was then divided by the amount of total GTP in the 
reaction mixture (5000 pmol) to get the specific activity in cpm/pmole GTP. The 
double counted cpm values from the 5 µl aliquots taken from each reaction after 60 
minutes incubation were averaged and then multiplied by 2 (factor for 400 µl out of 
800 µl charcoal mix) and by 20 (factor for 5 µl out of 100 µl total reaction mix). To 
calculate how much GTP in pmole was hydrolysed, the corrected cpm activity 
values were divided by the specific activity per pmole GTP (cpm/pmole). For 
comparison in the diagram the amount of hydrolysed GTP of the minus GAP 
reactions were substracted from the plus GAP reactions and plotted as pmol 
hydrolysed GTP/ hour. 
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Abbreviations 
CC   coiled-coil 
CGN   cis Golgi network 
EEA1   early endosomal antigen 1 
EGF   epidermal growth factor 
EGFR   EGF receptor 
ER   endoplasmic reticulum 
ERGIC  ER-to-Golgi intermediate compartment 
ESCRT  endosomal sorting complex required for transport 
GAP   GTPase-activating protein 
Gb3   globotriasoyl ceramide 
GDF   GDI displacement factor 
GDI   GDP dissociation inhibitor 
GDP   guanosine diphosphate 
GEF   guanine nucleotide exchange factor 
GPI   glycosylphosphatidylinositol 
GTP   guanosine triphosphate 
GTPase  guanosine triphosphatase 
IC50   inhibitory concentration required for 50 % inhibition 
NSF   N-ethylmaleimide sensitive fusion protein 
MPR   mannose 6-phosphate receptor 
MVB   multivesicular body 
QDO   quadrupel drop-out 
siRNA   small interfering RNA 
SNARE  soluble NSF attachment receptor 
STxB   Shiga toxin B-subunit 
TfR   transferrin receptor 
TGN   trans Golgi network 
VTC   vesicular tubular cluster 
Y2H   yeast two-hybrid 
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